BEGIN:VCALENDAR
PRODID:-//Google Inc//Google Calendar 70.9054//EN
VERSION:2.0
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:PDUFA
X-WR-TIMEZONE:America/Los_Angeles
X-WR-CALDESC:
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180531
DTSTAMP:20171003T193836Z
UID:1h56pllphrmun5m51urhtqat2c@google.com
CREATED:20171003T130003Z
DESCRIPTION:2018-05-31 In connection with its determination that Kitov s ap
 plication is sufficiently complete to permit a substantive review\, the FDA
 \, under the Prescription Drug User Fee Act (PDUFA)\, has set a target date
  of May 31\, 2018 to complete its review. http://www.sec.gov/Archives/edgar
 /data/1614744/000121390017010169/f6k100217_kitovpharma.htm
LAST-MODIFIED:20171003T130003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:KTOV Kitov Pharmaceuticals Holdings Ltd PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180126
DTSTAMP:20171003T193836Z
UID:85k97qp89e4paamud01vjoaf34@google.com
CREATED:20170926T130002Z
DESCRIPTION:2018-01-26 The PDUFA (Prescription Drug User Fee Act) goal date
  for completion of the FDA review of the Linhaliq NDA is January 26\, 2018.
  http://www.businesswire.com/news/home/20170925005309/en/Aradigm-Announces-
 FDA-Acceptance-NDA-Linhaliq-Priority
LAST-MODIFIED:20170926T130003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ARDM ARADIGM CORPORATION PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180228
DTSTAMP:20171003T193836Z
UID:nsrnsk5aa0j03ec9msd408deic@google.com
CREATED:20170913T130017Z
DESCRIPTION:2018-02-28 The PDUFA (Prescription Drug User Fee Act) goal date
  for completion of the FDA s review of the SCILEX NDA is set for February 2
 8\, 2018\, which is the standard six-month review period for a class 2 resp
 onse. http://www.sec.gov/Archives/edgar/data/850261/000114420417047543/v474
 996_ex99-1.htm
LAST-MODIFIED:20170913T130017Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SRNE Sorrento Therapeutics Inc PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180223
DTSTAMP:20171003T193836Z
UID:bsq5hpg7i765k6kg7f0r8534ao@google.com
CREATED:20170913T130010Z
DESCRIPTION:2018-02-23 FDA Has Assigned a PDUFA Action Date of February 23\
 , 2018 http://www.globenewswire.com/news-release/2017/09/12/1117889/0/en/Ke
 mPharm-Announces-FDRR-Process-Completion-and-Resubmission-of-the-Apadaz-NDA
 .html
LAST-MODIFIED:20170913T130010Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:KMPH KemPharm PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180630
DTSTAMP:20171003T193836Z
UID:u1llnln002f1nt1ipnhpevkng0@google.com
CREATED:20170913T130003Z
DESCRIPTION:2018-06-30 The FDA set a target action date under the Prescript
 ion Drug User Fee Act (PDUFA) of June 30\, 2018 for both applications. http
 ://www.sec.gov/Archives/edgar/data/1100412/000114420417047589/v475008_ex99-
 1.htm
LAST-MODIFIED:20170913T130003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ARRY ARRAY BIOPHARMA INC PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180107
DTSTAMP:20171003T193836Z
UID:4ka64v1fqjtaipn9crkinrrhjo@google.com
CREATED:20170912T130004Z
DESCRIPTION:2018-01-07 In May 2017\, the company announced that the U.S. Fo
 od and Drug Administration (FDA) had set a PDUFA target action date of Janu
 ary 7\, 2018 for the companys New Drug Application (NDA). http://www.busine
 sswire.com/news/home/20170909005029/en/Intersect-ENT-Announces-Presentation
 -Meta-Analysis-Randomized-Studies
LAST-MODIFIED:20170912T130004Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:XENT INTERSECT ENT\, INC. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180217
DTSTAMP:20171003T193836Z
UID:ffaonnghqopbk4cbm6kd873fuo@google.com
CREATED:20170901T130010Z
DESCRIPTION:2018-02-17 The PDUFA (Prescription Drug User Fee Act) goal date
  for completion of the FDA s review of the Vitaros NDA is set for February 
 17\, 2018\, which is the standard six month review period for NDA resubmiss
 ions. http://www.sec.gov/Archives/edgar/data/1017491/000101749117000096/a8-
 kaugust302017.htm
LAST-MODIFIED:20170901T130010Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:APRI APRICUS BIOSCIENCES INC PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180202
DTSTAMP:20171003T193836Z
UID:uk1f4jpvo2jbu10olou34mmbf8@google.com
CREATED:20170901T130003Z
DESCRIPTION:2018-02-02 The FDA has indicated a six-month review timeline an
 d established a Prescription Drug User Fee Act (PDUFA) target action date o
 f February 2\, 2018. http://www.globenewswire.com/news-release/2017/08/31/1
 106075/0/en/AMAG-Announces-U-S-FDA-Filing-Acceptance-and-Six-Month-Review-o
 f-Feraheme-ferumoxytol-for-the-Treatment-of-All-Adult-Patients-With-Iron-De
 ficiency-Anemia.html
LAST-MODIFIED:20170901T130003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AMAG AMAG Pharmaceuticals\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180430
DTSTAMP:20171003T193836Z
UID:5nh8767ehil62c8i1ue5ohehao@google.com
CREATED:20170831T130003Z
DESCRIPTION:2018-04-30 FDA Sets PDUFA Target Action Date of April 30\, 2018
  http://www.prnewswire.com/news-releases/long-term-analysis-of-phase-3-head
 -to-head-study-confirms-kyprolis-carfilzomib-regimen-extends-overall-surviv
 al-in-patients-with-relapsed-multiple-myeloma-300511801.html
LAST-MODIFIED:20170831T130004Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AMGN Amgen PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180228
DTSTAMP:20171003T193836Z
UID:onpg4b0regncgud46r4fu265bg@google.com
CREATED:20170830T130003Z
DESCRIPTION:2018-02-28 The PDUFA action date is February 28\, 2018. http://
 www.prnewswire.com/news-releases/fda-accepts-biomarins-pegvaliase-biologics
 -license-application-bla-and-grants-priority-review-designation-300511063.h
 tml
LAST-MODIFIED:20170830T130003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:BMRN BioMarin Pharmaceutical Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180228
DTSTAMP:20171003T193836Z
UID:k2ndvis6epsvdcaa4ndba37jko@google.com
CREATED:20170829T130023Z
DESCRIPTION:2018-02-28 The review classification for the application is Pri
 ority\, and the user fee goal date under the Prescription Drug User Fee Act
  (PDUFA) is February 28\, 2018. http://www.businesswire.com/news/home/20170
 828005271/en/La-Jolla-Pharmaceutical-Company-Announces-U.S.-FDA
LAST-MODIFIED:20170829T130023Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:LJPC LA JOLLA PHARMACEUTICAL COMPANY PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20171129
DTSTAMP:20171003T193836Z
UID:irbm4paa4nb4akv2j05c4f9jpk@google.com
CREATED:20170829T130016Z
DESCRIPTION:2017-11-29 The FDA has set a target action date of November 29\
 , 2017 under the Prescription Drug User Fee Act (PDUFA). http://www.sec.gov
 /Archives/edgar/data/882095/000110465917053806/a17-21015_1ex99d1.htm
LAST-MODIFIED:20170829T130017Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:GILD GILEAD SCIENCES INC PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180126
DTSTAMP:20171003T193836Z
UID:d1m39j4qent0vhc4v1djr0p31k@google.com
CREATED:20170829T130010Z
DESCRIPTION:2018-01-26 The Agency provided a new Prescription Drug User Fee
  Act (PDUFA) date of January 26\, 2018. http://www.sec.gov/Archives/edgar/d
 ata/1611787/000095010317008227/dp79897_ex9901.htm
LAST-MODIFIED:20170829T130010Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AAAP Advanced Accelerator Applications S A PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170828
DTSTAMP:20171003T193836Z
UID:1f393292idrpsauhi2i15iuetk@google.com
CREATED:20170829T130003Z
DESCRIPTION:2017-08-28 Description 99.1 Press Release dated August 28\, 201
 7 titled Advanced Accelerator Applications Announces New Prescription Drug 
 User Fee Act (PDUFA) date of January 26\, 2018\, for Lutetium Lu 177 Dotata
 te (Lutathera ) http://www.sec.gov/Archives/edgar/data/1611787/000095010317
 008227/dp79897_6k.htm
LAST-MODIFIED:20170829T130004Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AAAP Advanced Accelerator Applications S A PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20171216
DTSTAMP:20171003T193836Z
UID:qtkhvp3ct9avfln4bebbfknfvk@google.com
CREATED:20170821T130002Z
DESCRIPTION:2017-12-16 -PDUFA Action Date is December 16\, 2017- http://www
 .businesswire.com/news/home/20170816005171/en/FDA-Accepts-Supplemental-Biol
 ogics-License-Application-Grants
LAST-MODIFIED:20170821T130003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SGEN SEATTLE GENETICS\, INC. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180208
DTSTAMP:20171003T193836Z
UID:quru6jen40pf0bopnpcdqu6be8@google.com
CREATED:20170815T130002Z
DESCRIPTION:2018-02-08 The FDA has assigned a new Prescription Drug User Fe
 e Act ( PDUFA ) goal date of February 8\, 2018. http://www.sec.gov/Archives
 /edgar/data/1535955/000114420417042629/v473147_ex99-1.htm
LAST-MODIFIED:20170815T130003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:LPCN Lipocine Inc PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20171230
DTSTAMP:20171003T193836Z
UID:q7ko99823211q5hib6o802s348@google.com
CREATED:20170811T130003Z
DESCRIPTION:2017-12-30 Macrilen NDA filed at end of Q2\; FDA granted a PDUF
 A date of December 30\, 2017 http://www.businesswire.com/news/home/20170810
 006242/en/Aeterna-Zentaris-Reports-Quarter-2017-Financial-Operating
LAST-MODIFIED:20170811T130003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AEZS AETERNA ZENTARIS INC. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170829
DTSTAMP:20171003T193836Z
UID:rs45pardprf193k0jnvisrak0c@google.com
CREATED:20170810T130009Z
DESCRIPTION:2017-08-29 The PDUFA action date for meropenem-vaborbactam is A
 ugust 29\, 2017. http://www.sec.gov/Archives/edgar/data/1113481/00011134811
 7000027/pressreleaseq22017.htm
LAST-MODIFIED:20170810T130010Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:MDCO MEDICINES CO DE PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20171112
DTSTAMP:20171003T193836Z
UID:u07osvto1ocr8ebemtt4qbtn2s@google.com
CREATED:20170810T130003Z
DESCRIPTION:2017-11-12 The FDA set a Prescription Drug User Fee Act (PDUFA)
  goal date of November 12\, 2017 for a decision on the Companys NDA for CIN
 VANTI. http://www.businesswire.com/news/home/20170809005980/en/Heron-Therap
 eutics-Reports-Financial-Results-Months-Ended
LAST-MODIFIED:20170810T130003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:HRTX HERON THERAPEUTICS\, INC. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180302
DTSTAMP:20171003T193836Z
UID:ihb4kfqr2de33rgc9tgm4gh1l4@google.com
CREATED:20170804T130018Z
DESCRIPTION:2018-03-02 The Company has filed a Supplemental New Drug Applic
 ation (sNDA) for OTIPRIO in acute otitis externa (AOE) with the United Stat
 es Food and Drug Administration (FDA) and has been assigned a Prescription 
 Drug User Fee Act (PDUFA) action date of March 2\, 2018. http://www.sec.gov
 /Archives/edgar/data/1493566/000156459017015330/R7.htm
LAST-MODIFIED:20170804T130018Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:OTIC OTONOMY INC PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20171110
DTSTAMP:20171003T193836Z
UID:jibpkajr8revk77o5uu036c77k@google.com
CREATED:20170804T130011Z
DESCRIPTION:2017-11-10 This will provide the FDA and Dynavax up to three mo
 nths to agree on the post-marketing study prior to an updated PDUFA date (e
 xpected to be no later than November 10\, 2017). http://www.marketwired.com
 /press-release/dynavax-provides-us-regulatory-update-on-heplisav-b-followin
 g-fda-advisory-committee-nasdaq-dvax-2228958.htm
LAST-MODIFIED:20170804T130012Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:DVAX Dynavax Technologies PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20171226
DTSTAMP:20171003T193836Z
UID:nhcvoae26jjqljmn1slbt1qasc@google.com
CREATED:20170804T130003Z
DESCRIPTION:2017-12-26 Agile reported that the Prescription Drug User Fee A
 ct (PDUFA) goal date for this NDA is December 26\, 2017. http://www.sec.gov
 /Archives/edgar/data/1594337/000155837017005857/ex-99d1.htm
LAST-MODIFIED:20170804T130003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:CORI Corium International Inc PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20171202
DTSTAMP:20171003T193836Z
UID:budsqpj3smkk11muansl7mr30o@google.com
CREATED:20170728T130010Z
DESCRIPTION:2017-12-02 The FDA has set a Prescription Drug User Fee Act (PD
 UFA) action date of Dec. 2\, 2017. http://www.prnewswire.com/news-releases/
 fda-grants-priority-review-for-amgens-supplemental-biologics-license-applic
 ation-for-repatha-evolocumab-to-include-data-on-reducing-risk-of-cardiovasc
 ular-events-300495792.html
LAST-MODIFIED:20170728T130010Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AMGN Amgen PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20171226
DTSTAMP:20171003T193836Z
UID:cfndr067trs594b6ocv8sdlcd4@google.com
CREATED:20170728T130003Z
DESCRIPTION:2017-12-26 The FDA stated that it considers the resubmission to
  be a complete response to the CRL and established December 26\, 2017 as th
 e Prescription Drug User Fee Act (PDUFA) goal date. http://www.globenewswir
 e.com/news-release/2017/07/27/1063744/0/en/Agile-Therapeutics-Announces-FDA
 -Acceptance-of-the-NDA-Resubmission-of-Twirla.html
LAST-MODIFIED:20170728T130003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AGRX Agile Therapeutics\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180517
DTSTAMP:20171003T193836Z
UID:51juk3iufot9hlgbqdn8jbajko@google.com
CREATED:20170721T130003Z
DESCRIPTION:2018-05-17 The FDA has set a Prescription Drug User Fee Act (PD
 UFA) target action date of May 17\, 2018. http://www.prnewswire.com/news-re
 leases/fda-accepts-biologics-license-application-for-aimovig-erenumab-30049
 1861.html
LAST-MODIFIED:20170721T130003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AMGN Amgen PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180112
DTSTAMP:20171003T193836Z
UID:vpar51pshl0vq4h5bvad9tvffc@google.com
CREATED:20170718T130003Z
DESCRIPTION:2018-01-12 FDA grants Priority Review with Prescription Drug Us
 er Fee Act (PDUFA) date of Jan. 12\, 2018 http://www.globenewswire.com/news
 -release/2017/07/17/1047326/0/en/Spark-Therapeutics-Biologics-License-Appli
 cation-for-Investigational-Voretigene-Neparvovec-Accepted-for-Filing-by-FDA
 .html
LAST-MODIFIED:20170718T130003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ONCE Spark Therapeutics\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20171014
DTSTAMP:20171003T193836Z
UID:ojs4d4a9j7gek139rd0v2p0f4c@google.com
CREATED:20170706T130003Z
DESCRIPTION:2017-10-14 Pending notification of the acceptance by the FDA of
  the Supplemental NDA\, the Company has been advised that the PDUFA goal da
 te is October 14\, 2017. http://www.sec.gov/Archives/edgar/data/914475/0001
 19312517221423/d367364d8k.htm
LAST-MODIFIED:20170706T130003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:NBIX NEUROCRINE BIOSCIENCES INC PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180214
DTSTAMP:20171003T193836Z
UID:copbpummnckif7gf0bedhrd07g@google.com
CREATED:20170628T130002Z
DESCRIPTION:2018-02-14 The agency has established a Prescription Drug User 
 Fee Act (PDUFA) target action date of February 14\, 2018. http://www.globen
 ewswire.com/news-release/2017/06/26/1028946/0/en/AMAG-Announces-U-S-FDA-Fil
 ing-Acceptance-of-Supplemental-New-Drug-Application-for-Makena-hydroxyproge
 sterone-caproate-injection-Subcutaneous-Auto-Injector.html
LAST-MODIFIED:20170628T130003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AMAG AMAG Pharmaceuticals\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170827
DTSTAMP:20171003T193836Z
UID:gstvip153pmd4va1na6g9ciavk@google.com
CREATED:20170622T130045Z
DESCRIPTION:2017-08-27 The FDA has set a Prescription Drug User Fee Act (PD
 UFA) target action date of August 27\, 2017 for avelumab in this indication
 . http://www.businesswire.com/news/home/20170502005770/en/PFIZER-REPORTS-FI
 RST-QUARTER-2017-RESULTS
LAST-MODIFIED:20170622T130045Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:PFE PFIZER INC. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170723
DTSTAMP:20171003T193836Z
UID:idcorkn7817aerkfkttqt2j6hs@google.com
CREATED:20170622T130026Z
DESCRIPTION:2017-07-23 -PDUFA Date of July 23\, 2017- http://www.businesswi
 re.com/news/home/20170327005232/en/FDA-Grants-Priority-Review-Eagle-Pharmac
 euticals%E2%80%99-Ryanodex
LAST-MODIFIED:20170622T130026Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:EGRX EAGLE PHARMACEUTICALS PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170605
DTSTAMP:20171003T193836Z
UID:sjp84efkn3spe11aali90akkr8@google.com
CREATED:20170622T130011Z
DESCRIPTION:2017-06-05 A supplemental New Drug Application (sNDA) for the t
 wo-month dosing option of ARISTADA is currently under review with the U.S. 
 Food and Drug Administration (FDA) and has been assigned a Prescription Dru
 g User Fee Act (PDUFA) action date of June 5\, 2017. http://www.businesswir
 e.com/news/home/20170320005167/en/Alkermes-Present-Data-Two-Month-Dosing-Op
 tion-ARISTADA%C2%AE
LAST-MODIFIED:20170622T130011Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ALKS ALKERMES PLC PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20171224
DTSTAMP:20171003T193836Z
UID:u0ae6du42tprb8s9a2ga392tn4@google.com
CREATED:20170622T130003Z
DESCRIPTION:2017-12-24 The PDUFA target action date for the completion of t
 he FDAs review of the NDA is December 24\, 2017. http://www.globenewswire.c
 om/news-release/2017/05/09/981376/0/en/FDA-Accepts-Aclaris-Therapeutics-New
 -Drug-Application-for-Topical-Treatment-of-Seborrheic-Keratosis-a-Common-Sk
 in-Condition.html
LAST-MODIFIED:20170622T130003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ACRS Aclaris Therapeutics\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170609
DTSTAMP:20171003T193836Z
UID:t5914o6brseodpci08vk50a9u4@google.com
CREATED:20170621T212638Z
DESCRIPTION:2017-06-09 The PDUFA action date for this Priority Review has b
 een extended to June 9\, 2017. http://www.businesswire.com/news/home/201705
 02005767/en/Merck-Announces-First-Quarter-2017-Financial-Results
LAST-MODIFIED:20170621T212638Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:MRK MERCK PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170707
DTSTAMP:20171003T193836Z
UID:4rom1mh3v7r3q8oekjpsgaref4@google.com
CREATED:20170621T212631Z
DESCRIPTION:2017-07-07 In November 2016\, Emmaus announced that the U.S. Fo
 od and Drug Administration (FDA) set a Prescription Drug User Fee Act (PDUF
 A) date of July 7\, 2017 for a decision on Emmaus New Drug Application (NDA
 ) for its flagship product\, an orally-administered pharmaceutical grade L-
 glutamine (PGLG) product for the treatment of SCD. http://www.businesswire.
 com/news/home/20170123005698/en/Generex-Announces-Deal-Acquire-Controlling-
 Equity-Interest
LAST-MODIFIED:20170621T212631Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:GNBT GENEREX BIOTECHNOLOGY CORPORATION PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20171023
DTSTAMP:20171003T193836Z
UID:1t460mpbde451pe9cqe9r6rskg@google.com
CREATED:20170621T212618Z
DESCRIPTION:2017-10-23 The FDA set a Prescription Drug User Fee Act (PDUFA)
  date of October 23\, 2017. http://www.businesswire.com/news/home/201703080
 05390/en/FDA-Accepts-sBLA-Filing-Soliris%C2%AE-Eculizumab-Potential
LAST-MODIFIED:20170621T212618Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ALXN ALEXION PHARMACEUTICALS\, INC. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180417
DTSTAMP:20171003T193836Z
UID:ht8adf9blhd8sjlc1fghe0mvf8@google.com
CREATED:20170620T130023Z
DESCRIPTION:2018-04-17 Rigel expects the action date for the FDA to complet
 e its review will be April 17\, 2018\, under the Prescription Drug User Fee
  Act (PDUFA). http://www.prnewswire.com/news-releases/fda-accepts-rigels-ne
 w-drug-application-for-tavalisse-fostamatinib-disodium-for-the-treatment-of
 -chronic-itp-300475653.html
LAST-MODIFIED:20170620T130023Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:RIGL Rigel Pharmaceuticals\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170922
DTSTAMP:20171003T193836Z
UID:ar5h0mlctakea8rqj09v35kcus@google.com
CREATED:20170620T130016Z
DESCRIPTION:2017-09-22 The FDA granted Priority Review with a PDUFA\, or ta
 rget action\, date of Sept. 22\, 2017. http://www.businesswire.com/news/hom
 e/20170523005508/en/FDA-Grants-Priority-Review-Merck%E2%80%99s-Supplemental
 -Biologics
LAST-MODIFIED:20170620T130016Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:MRK MERCK PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20171129
DTSTAMP:20171003T193836Z
UID:fhpf2ha1g6etjo6sa2fbkdbagg@google.com
CREATED:20170620T130010Z
DESCRIPTION:2017-11-29 Prescription Drug User Fee Act (PDUFA) Set for Novem
 ber 29\, 2017 http://www.businesswire.com/news/home/20170526005397/en/Kite-
 Receives-U.S.-Food-Drug-Administration-Priority
LAST-MODIFIED:20170620T130010Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:KITE KITE PHARMA\, INC. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180203
DTSTAMP:20171003T193836Z
UID:ho5t4i90edpdfhfo4bcob0raos@google.com
CREATED:20170620T130003Z
DESCRIPTION:2018-02-03 FDA Sets PDUFA Target Action Date of Feb. 3\, 2018 h
 ttp://www.prnewswire.com/news-releases/fda-accepts-amgens-supplemental-biol
 ogics-license-application-to-expand-indication-for-xgeva-denosumab-to-inclu
 de-multiple-myeloma-patients-300475662.html
LAST-MODIFIED:20170620T130003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AMGN Amgen PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180124
DTSTAMP:20171003T193836Z
UID:a5l8c9d028ur7dicskjpta0hlc@google.com
CREATED:20170608T130003Z
DESCRIPTION:2018-01-24 The Prescription Drug User Fee Act (PDUFA) date is J
 anuary 24\, 2018. http://www.sec.gov/Archives/edgar/data/1347613/0001104659
 17037832/a17-14878_1ex99d1.htm
LAST-MODIFIED:20170608T130003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SGYP SYNERGY PHARMACEUTICALS INC PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20171025
DTSTAMP:20171003T193836Z
UID:k8fqjstn3e86pmpnlqbaqskg60@google.com
CREATED:20170605T130003Z
DESCRIPTION:2017-10-25 VARUBI® IV PDUFA date is October 25\, 2017 http://ww
 w.globenewswire.com/news-release/2017/06/03/1007926/0/en/TESARO-Provides-Bu
 siness-and-Pipeline-Update-at-ASCO-Investor-Briefing.html
LAST-MODIFIED:20170605T130003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:TSRO TESARO\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20171116
DTSTAMP:20171003T193836Z
UID:hbb81tqnfilkaoliet4hcle41k@google.com
CREATED:20170524T130003Z
DESCRIPTION:2017-11-16 The Prescription Drug User Fee Act (PDUFA) goal date
  for a decision is November 16\, 2017 and an opinion from the Committee for
  Medicinal Products for Human Use (CHMP) is expected in the first half of 2
 018.  rhGUS is an enzyme replacement therapy for the treatment of MPS VII. 
 http://www.globenewswire.com/news-release/2017/05/23/995136/0/en/Ultragenyx
 -Announces-Recombinant-Human-Beta-Glucuronidase-Biologics-License-Applicati
 on-and-Marketing-Authorization-Application-Filed-and-Accepted-for-Review-FD
 A-Grants-Priority-Re.html
LAST-MODIFIED:20170524T130003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:RARE Ultragenyx Pharmaceutical Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180228
DTSTAMP:20171003T193836Z
UID:e31m9cg144un376uqk1butim5c@google.com
CREATED:20170516T130004Z
DESCRIPTION:2018-02-28 The February 28\, 2018 PDUFA date and the advisory c
 ommittee plans are consistent with our previously disclosed expectations. T
 he FDA has set the PDUFA goal date for the completion of the FDA s review o
 f the Rhopressa TM NDA for February 28\, 2018. http://www.sec.gov/Archives/
 edgar/data/1337553/000119312517169518/d382069dex991.htm
LAST-MODIFIED:20170516T130004Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AERI AERIE PHARMACEUTICALS INC PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20171227
DTSTAMP:20171003T193836Z
UID:75i96djbu6kcmjftrg69nraon0@google.com
CREATED:20170509T130003Z
DESCRIPTION:2017-12-27 PDUFA date set for December 27\, 2017 http://www.prn
 ewswire.com/news-releases/bausch--lomb-announces-pdufa-date-for-new-otc-red
 ness-reliever-brimonidine-tartrate-ophthalmic-solution-0025-300453630.html
LAST-MODIFIED:20170509T130003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:VRX Valeant Pharmaceuticals International\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170830
DTSTAMP:20171003T193836Z
UID:go1lnt4eqb9svhcmh48ughpfic@google.com
CREATED:20170505T130003Z
DESCRIPTION:2017-08-30 A New Drug Application (NDA) was filed with the U.S.
  Food and Drug Administration (FDA) for IDHIFA® (enasidenib) in relapsed an
 d/or refractory (R/R) acute myeloid leukemia (AML) with an isocitrate dehyd
 rogenase 2 (IDH2) mutation\; the NDA was granted Priority Review and has be
 en given a Prescription Drug User Fee Act (PDUFA) action date of August 30\
 , 2017. http://www.globenewswire.com/news-release/2017/05/04/978484/0/en/Ag
 ios-Reports-First-Quarter-2017-Financial-Results.html
LAST-MODIFIED:20170505T130003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AGIO Agios Pharmaceuticals PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170522
DTSTAMP:20171003T193836Z
UID:7733akd4p927gm8vh7hupeqebs@google.com
CREATED:20170501T130010Z
DESCRIPTION:2017-05-22 Per the Prescription Drug User Fee Act (PDUFA)\, the
  new target action date is May 22\, 2017. http://www.sec.gov/Archives/edgar
 /data/1121404/000119312517145587/d383471dex993.htm
LAST-MODIFIED:20170501T130010Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SNY Sanofi PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170522
DTSTAMP:20171003T193836Z
UID:030muklctqlf0hr9g9utp2usbk@google.com
CREATED:20170501T130002Z
DESCRIPTION:2017-05-22 Per the Prescription Drug User Fee Act (PDUFA)\, the
  new target action date is May 22\, 2017. http://www.prnewswire.com/news-re
 leases/regeneron-and-sanofi-announce-kevzara-sarilumab-biologics-license-ap
 plication-resubmission-accepted-for-review-by-us-fda-300447685.html
LAST-MODIFIED:20170501T130003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:REGN Regeneron Pharmaceuticals\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170814
DTSTAMP:20171003T193836Z
UID:p344kjg6oqkls7f2fq12277cj0@google.com
CREATED:20170330T130018Z
DESCRIPTION:2017-08-14 The Prescription Drug User Fee Act (PDUFA) target ac
 tion date is Aug. 14\, 2017. http://www.prnewswire.com/news-releases/fda-gr
 ants-priority-review-for-amgens-blincyto-blinatumomab-supplemental-biologic
 s-license-application-300431405.html
LAST-MODIFIED:20170330T130018Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AMGN Amgen PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170824
DTSTAMP:20171003T193836Z
UID:7mf0kccnttd64k11hoju0lrcu4@google.com
CREATED:20170321T130011Z
DESCRIPTION:2017-08-24 PDUFA date set for August 24\, 2017 http://www.prnew
 swire.com/news-releases/bausch--lomb-and-nicox-announce-pdufa-date-for-nove
 l-glaucoma-candidate-latanoprostene-bunod-300426306.html
LAST-MODIFIED:20170321T130011Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:VRX Valeant Pharmaceuticals International\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20171106
DTSTAMP:20171003T193836Z
UID:3i7isjlhkei871h7jvdjic03pk@google.com
CREATED:20170321T130003Z
DESCRIPTION:2017-11-06 A supplemental new drug application is under review 
 by the U.S. FDA\, with a Prescription Drug User Fee Act (PDUFA) target acti
 on date of November 6\, 2017 for completion. http://www.globenewswire.com/n
 ews-release/2017/03/20/942122/0/en/Keryx-Announces-the-Largest-Medicare-Par
 t-D-Plan-Sponsor-Added-Auryxia-to-its-Medicare-Part-D-Plan-Formularies.html
LAST-MODIFIED:20170321T130003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:KERX Keryx Biopharmaceuticals\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170915
DTSTAMP:20171003T193836Z
UID:iikkmdckdospb51g3avefuusng@google.com
CREATED:20170316T130002Z
DESCRIPTION:2017-09-15 The Prescription Drug User Fee Act (PDUFA) goal date
  is June 19\, 2017. The PDUFA date for this product candidate is September 
 15\, 2017. http://www.sec.gov/Archives/edgar/data/1467652/00011046591701624
 7/a17-8249_1ex99d1.htm
LAST-MODIFIED:20170316T130003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:NEOS Neos Therapeutics Inc PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170619
DTSTAMP:20171003T193836Z
UID:oo6fuf138djvc3b95vo2cvko4o@google.com
CREATED:20170315T130016Z
DESCRIPTION:2017-06-19 The Prescription Drug User Fee Act (PDUFA) goal date
  is June 19\, 2017. The PDUFA date for this product candidate is September 
 15\, 2017. http://www.sec.gov/Archives/edgar/data/1467652/00011046591701624
 7/a17-8249_1ex99d1.htm
LAST-MODIFIED:20170315T130016Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:NEOS Neos Therapeutics Inc PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20171030
DTSTAMP:20171003T193836Z
UID:oq0dluabbr5lmjcfmuio015ci8@google.com
CREATED:20170315T130010Z
DESCRIPTION:2017-10-30 NDA for Pemetrexed Injection for non-small cell lung
  cancer and mesothelioma accepted for filing\; PDUFA target date of October
  30\, 2017\; http://www.businesswire.com/news/home/20170301005537/en/Eagle-
 Pharmaceuticals-Reports-Fourth-Quarter-Full-Year
LAST-MODIFIED:20170315T130010Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:EGRX EAGLE PHARMACEUTICALS\, INC. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170830
DTSTAMP:20171003T193836Z
UID:fhh6on5b89uf23nai0bsce8l3o@google.com
CREATED:20170315T130002Z
DESCRIPTION:2017-08-30 PDUFA date set for Aug. 30\, 2017 http://www.busines
 swire.com/news/home/20170301005785/en/FDA-Accepts-Drug-Application-Grants-P
 riority-Review
LAST-MODIFIED:20170315T130002Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:CELG CELGENE CORPORATION PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170630
DTSTAMP:20171003T193836Z
UID:s53slm6qbbqc4nm1bim7tp2mkg@google.com
CREATED:20170313T130010Z
DESCRIPTION:2017-06-30 In a notice received from the FDA last evening\, the
  Prescription Drug User Fee Act (PDUFA) date for Abaloparatide-SC  has been
  extended to June 30\, 2017. http://www.globenewswire.com/news-release/2017
 /03/10/934380/0/en/Radius-Health-Receives-Notification-of-PDUFA-Extension-f
 or-Abaloparatide-SC.html
LAST-MODIFIED:20170313T130010Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:RDUS Radius Health Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170719
DTSTAMP:20171003T193836Z
UID:nb40t1ehqcpsi70ohvvhm9bn50@google.com
CREATED:20170313T130002Z
DESCRIPTION:2017-07-19 Exhibit 99.1 Ocular Therapeutix Reports Fourth Quart
 er and Full Year 2016 Financial Results PDUFA Target Action Date of July 19
 \, 2017 for the DEXTENZA NDA for the Treatment of Ocular Pain Occurring Aft
 er Ophthalmic Surgery Enrollment Continues in the First Phase 3 Clinical Tr
 ial with http://www.sec.gov/Archives/edgar/data/1393434/000110465917015632/
 a17-7843_1ex99d1.htm
LAST-MODIFIED:20170313T130002Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:OCUL OCULAR THERAPEUTIX INC PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20171024
DTSTAMP:20171003T193836Z
UID:fvb3clrpbsj4vpk94ago46q3a8@google.com
CREATED:20170307T140003Z
DESCRIPTION:2017-10-24 - FDA has assigned a PDUFA date of October 24\, 2017
  - http://www.prnewswire.com/news-releases/ptc-therapeutics-announces-fda-a
 cknowledgment-of-new-drug-application-filing-for-translarna-for-the-treatme
 nt-of-nonsense-mutation-duchenne-muscular-dystrophy-300418256.html
LAST-MODIFIED:20170307T140004Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:PTCT PTC Therapeutics\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170830
DTSTAMP:20171003T193836Z
UID:7cqt2gdanmcounggh2fc26sbe4@google.com
CREATED:20170301T140011Z
DESCRIPTION:2017-08-30 The FDA has assigned a Prescription Drug User Fee Ac
 t (PDUFA) goal date of August 30\, 2017. Teva is committed to advancing new
  therapeutic options for patients with neurological and movement disorders.
  http://www.sec.gov/Archives/edgar/data/818686/000130901417000162/exhibit1.
 htm
LAST-MODIFIED:20170301T140011Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20171020
DTSTAMP:20171003T193836Z
UID:14fgdgbf7ss1dddl4omeq436s4@google.com
CREATED:20170228T140011Z
DESCRIPTION:2017-10-20 The FDA has assigned a Prescription Drug User Fee Ac
 t (PDUFA) date of October 20\, 2017\, ten months from the official NDA subm
 ission. http://www.globenewswire.com/news-release/2017/02/27/927935/0/en/An
 tares-Pharma-Announces-FDA-Acceptance-of-New-Drug-Application-for-Quickshot
 -Testosterone.html
LAST-MODIFIED:20170228T140011Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ATRS Antares Pharma Inc PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20171012
DTSTAMP:20171003T193836Z
UID:ts9oc4b2emrofl45kr6cscg0l8@google.com
CREATED:20170228T140003Z
DESCRIPTION:2017-10-12 The FDA has also set a Prescription Drug User Fee Ac
 t (PDUFA) date of October 12\, 2017. http://www.prnewswire.com/news-release
 s/acelrx-pharmaceuticals-new-drug-application-for-dsuvia-accepted-for-filin
 g-with-pdufa-date-of-october-12-2017-300413748.html
LAST-MODIFIED:20170228T140003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ACRX AcelRx Pharmaceuticals\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170216
DTEND;VALUE=DATE:20170217
DTSTAMP:20171003T193836Z
UID:45vqevadd7fpqtfgod0n2mvi8c@google.com
CREATED:20160126T140008Z
DESCRIPTION:2016-11-16 The FDA has assigned a Prescription Drug User Fee Ac
 t (PDUFA) action date of November 16\, 2016. http://www.prnewswire.com/news
 -releases/valeant-announces-fda-acceptance-of-bla-submission-for-brodalumab
 -in-moderate-to-severe-plaque-psoriasis-300208845.html\n\nDelayed until Feb
  16\, 2017\nhttp://otp.investis.com/clients/us/valeant_pharmaceuticals1/SEC
 /sec-show.aspx?Type=html&FilingId=11677635&Cik=0000885590
LAST-MODIFIED:20170219T210411Z
LOCATION:
SEQUENCE:1
STATUS:CONFIRMED
SUMMARY:VRX Valeant Pharmaceuticals International\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170614
DTSTAMP:20171003T193836Z
UID:mj7sudeduhp9peffphlud65bqc@google.com
CREATED:20170213T140003Z
DESCRIPTION:2017-06-14 The PDUFA\, or target action\, date for both applica
 tions is June 14\, 2017. http://www.businesswire.com/news/home/201702030052
 88/en/FDA-Accepts-sBLAs-Merck%E2%80%99s-KEYTRUDA%C2%AE-pembrolizumab-Locall
 y
LAST-MODIFIED:20170213T140003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:MRK MERCK PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20171006
DTSTAMP:20171003T193836Z
UID:l2gbvg60r4tnscknar2n9nn7vs@google.com
CREATED:20170208T140003Z
DESCRIPTION:2017-10-06 Assigns PDUFA date of October 6\, 2017 http://www.gl
 obenewswire.com/news-release/2017/02/07/914606/0/en/Flexion-Therapeutics-An
 nounces-New-Drug-Application-for-Zilretta-FX006-Accepted-by-U-S-Food-and-Dr
 ug-Administration.html
LAST-MODIFIED:20170208T140003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:FLXN Flexion Therapeutics PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170510
DTSTAMP:20171003T193836Z
UID:qhbadnmttnnitniqsfdhvd928o@google.com
CREATED:20170203T140022Z
DESCRIPTION:2017-05-10 The PDUFA action date is May 10\, 2017. http://www.s
 ec.gov/Archives/edgar/data/310158/000141057817000034/a17-3583_1ex99d1.htm
LAST-MODIFIED:20170203T140022Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:MRK Merck Co Inc PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170925
DTSTAMP:20171003T193836Z
UID:755lqcmu6h314j6h2o2bdoiiqg@google.com
CREATED:20170203T140010Z
DESCRIPTION:2017-09-25 The FDA has determined that the Company s applicatio
 n is sufficiently complete to permit a substantive review\, and has set a t
 arget action date under the Prescription Drug User Fee Act ( PDUFA ) of Sep
 tember 25\, 2017. http://www.sec.gov/Archives/edgar/data/1474835/0001654954
 17000719/pressrelease_intellipharm.htm
LAST-MODIFIED:20170203T140010Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:IPCI Intellipharmaceutics International Inc PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170209
DTSTAMP:20171003T193836Z
UID:82kf2ag5qumskqv6cmdu89alb0@google.com
CREATED:20170203T140003Z
DESCRIPTION:2017-02-09 FDA has set a Feb. 9\, 2017\, PDUFA target action da
 te for the review of Parsabiv for the treatment of secondary hyperparathyro
 idism (sHPT) in adult patients with chronic kidney disease (CKD) on hemodia
 lysis. http://www.prnewswire.com/news-releases/amgen-reports-fourth-quarter
 -and-full-year-2016-financial-results-300401566.html
LAST-MODIFIED:20170203T140003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AMGN Amgen PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170620
DTSTAMP:20171003T193836Z
UID:i7ak9l3uj7g7hs61cdrubm411c@google.com
CREATED:20170120T140002Z
DESCRIPTION:2017-06-20 The FDA is expected to provide a decision on or arou
 nd June 20\, 2017\, the designated Prescription Drug User Fee Act (PDUFA) a
 ction date. http://www.prnewswire.com/news-releases/us-fda-acknowledges-rec
 eipt-of-shires-new-drug-application-for-shp465-for-adhd-611177175.html
LAST-MODIFIED:20170120T140003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SHPG Shire plc PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170824
DTSTAMP:20171003T193836Z
UID:k5bgbm1bbbpabp7j63g0vq92ng@google.com
CREATED:20170109T140003Z
DESCRIPTION:2017-08-24 -- PDUFA Action Date Set for August 24\, 2017 -- htt
 p://www.globenewswire.com/news-release/2017/01/09/904182/0/en/Adamas-Outlin
 es-Key-2017-Priorities-and-Highlights-2016-Achievements.html
LAST-MODIFIED:20170109T140003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ADMS Adamas Pharmaceuticals\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170624
DTSTAMP:20171003T193836Z
UID:13o63p3f3fbl0f3k209ma48lpk@google.com
CREATED:20161226T140003Z
DESCRIPTION:2017-06-24 The application for betrixaban\, an FDA-designated F
 ast Track investigational drug\, was deemed sufficiently complete to permit
  a substantive review and has been given a Prescription Drug User Fee Act (
 PDUFA) action date of June 24\, 2017.   http://www.globenewswire.com/news-r
 elease/2016/12/23/901631/0/en/Portola-Pharmaceuticals-Announces-FDA-Accepts
 -New-Drug-Application-for-Priority-Review-and-EMA-Validates-Marketing-Autho
 rization-Application-for-Oral-Factor-Xa-Inhibitor-Anticoagul.html
LAST-MODIFIED:20161226T140003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:PTLA Portola Pharmaceuticals\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170630
DTSTAMP:20171003T193836Z
UID:qpeiq07aroge692u5a12qejnik@google.com
CREATED:20161221T140002Z
DESCRIPTION:2017-06-30 Niraparib New Drug Application accepted for review b
 y FDA with a PDUFA goal date of June 30\, 2017 http://www.globenewswire.com
 /news-release/2016/12/20/899156/0/en/Tesaro-Announces-Priority-Review-Desig
 nation-for-Niraparib-NDA.html
LAST-MODIFIED:20161221T140003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:TSRO TESARO\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170315
DTSTAMP:20171003T193836Z
UID:2ngsjbpb5kntl2alr6at53h1g0@google.com
CREATED:20161220T140003Z
DESCRIPTION:2017-03-15 The FDA granted Priority Review with a PDUFA\, or ta
 rget action\, date of March 15\, 2017. http://www.businesswire.com/news/hom
 e/20161201005463/en/FDA-Grants-Priority-Review-Supplemental-Biologics-Licen
 se
LAST-MODIFIED:20161220T140003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:MRK MERCK PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170829
DTSTAMP:20171003T193836Z
UID:nm59j8elhv36iv7g13u2mhj3ps@google.com
CREATED:20161108T153329Z
DESCRIPTION:2017-08-29 The FDA has assigned a Prescription Drug User Fee Ac
 t (PDUFA) goal date of August 29\, 2017\, for completion of the review of t
 he BLA. http://www.sec.gov/Archives/edgar/data/1567529/000117891316006772/e
 xhibit_99-1.htm
LAST-MODIFIED:20161108T153329Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:KMDA KAMADA LTD PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170429
DTSTAMP:20171003T193836Z
UID:n9frdo9ucr0l66q1g2uqar5dfg@google.com
CREATED:20161101T130003Z
DESCRIPTION:2017-04-29 The FDA granted ARIAD s request for Priority Review 
 and has set an action date of April 29\, 2017 under the Prescription Drug U
 ser Fee Act (PDUFA). http://www.sec.gov/Archives/edgar/data/884731/00011575
 2316007121/a51450187ex99_1.htm
LAST-MODIFIED:20161101T130003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ARIA ARIAD PHARMACEUTICALS INC PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170224
DTSTAMP:20171003T193836Z
UID:8k9hnnonhtkvnfaiti6hc1scd8@google.com
CREATED:20161028T130003Z
DESCRIPTION:2017-02-24 The sNDA was granted Priority Review and the Prescri
 ption Drug User Fee Act (PDUFA) date for the submission is February 24\, 20
 17. http://www.sec.gov/Archives/edgar/data/816284/000110465916152369/a16-20
 497_1ex99d1.htm
LAST-MODIFIED:20161028T130003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:CELG CELGENE CORP DE PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170527
DTSTAMP:20171003T193836Z
UID:ocjmlb1p1qd3u130estbbtumc8@google.com
CREATED:20161026T130002Z
DESCRIPTION:2017-05-27 The FDA granted a PDUFA action date of May 27\, 2017
 . http://www.sec.gov/Archives/edgar/data/310158/000110465916151769/a16-2029
 9_1ex99d1.htm
LAST-MODIFIED:20161026T130003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:MRK Merck Co Inc PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170411
DTSTAMP:20171003T193836Z
UID:21ngh3hq53ov4tn694f32t4s34@google.com
CREATED:20161012T130003Z
DESCRIPTION:2017-04-11 The INGREZZA application has been given a Prescripti
 on Drug User Fee Act (PDUFA) target action date of April 11\, 2017. http://
 www.sec.gov/Archives/edgar/data/914475/000119312516734878/d270263d8k.htm
LAST-MODIFIED:20161012T130003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:NBIX NEUROCRINE BIOSCIENCES INC PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170329
DTSTAMP:20171003T193836Z
UID:eel8vkivjt1dpkjhl2jstrfv4k@google.com
CREATED:20161006T130003Z
DESCRIPTION:2017-03-29 The application has been given a Prescription Drug U
 ser Fee Act (PDUFA) target action date of March 29\, 2017. http://www.sec.g
 ov/Archives/edgar/data/1121404/000119312516731229/d245195dex994.htm
LAST-MODIFIED:20161006T130003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SNY Sanofi PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170329
DTSTAMP:20171003T193836Z
UID:50p29imcnqia70jdhhtrbnr5ig@google.com
CREATED:20160927T130011Z
DESCRIPTION:2017-03-29 The application has been given a Prescription Drug U
 ser Fee Act (PDUFA) target action date of March 29\, 2017. http://www.prnew
 swire.com/news-releases/regeneron-and-sanofi-announce-dupilumab-biologics-l
 icense-application-accepted-for-priority-review-by-us-fda-300333529.html
LAST-MODIFIED:20160927T130011Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:REGN Regeneron Pharmaceuticals\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170719
DTSTAMP:20171003T193836Z
UID:r202tsi8tekqmkrausrch0tshg@google.com
CREATED:20160927T130003Z
DESCRIPTION:2017-07-19 The FDA has set a Prescription Drug User Fee Act (PD
 UFA) target action date of July 19\, 2017\, for romosozumab. http://www.prn
 ewswire.com/news-releases/amgen-and-ucb-announce-us-fda-acceptance-of-biolo
 gics-license-application-for-romosozumab-300334171.html
LAST-MODIFIED:20160927T130003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AMGN Amgen PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170507
DTSTAMP:20171003T193836Z
UID:3vcjjbou5mneuhd67mks08qf40@google.com
CREATED:20160920T130003Z
DESCRIPTION:2017-05-07 Exhibit 99.1 FOR IMMEDIATE RELEASE TherapeuticsMD An
 nounces FDA Acceptance of New Drug Application (NDA) and Prescription Drug 
 User Fee Act (PDUFA) Date for Yuvvexy (TX-004HR) - PDUFA target action date
  of May 7\, 2017 - BOCA RATON\, Florida\, Sept. 19\, 2016 TherapeuticsMD\, 
 http://www.sec.gov/Archives/edgar/data/25743/000138713116007014/ex99-1.htm
LAST-MODIFIED:20160920T130003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:TXMD TherapeuticsMD Inc PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170228
DTSTAMP:20171003T193836Z
UID:earfq5j13msfhsiqqroi91d9gk@google.com
CREATED:20160915T130003Z
DESCRIPTION:2017-02-28 PDUFA Goal Date Extended to February 28\, 2017 http:
 //www.prnewswire.com/news-releases/fda-extends-pdufa-date-for-telotristat-e
 tiprate-for-the-treatment-of-carcinoid-syndrome-300328376.html
LAST-MODIFIED:20160915T130003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:LXRX Lexicon Pharmaceuticals\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170427
DTSTAMP:20171003T193836Z
UID:r53jgt601qb1u3e3h7gblqd5hc@google.com
CREATED:20160907T130003Z
DESCRIPTION:2017-04-27 Additional Data Submitted to BLA following FDA Reque
 st\, PDUFA Action Date Extended to April 27\, 2017 http://www.globenewswire
 .com/news-release/2016/09/06/869879/0/en/BioMarin-Announces-Update-to-Brine
 ura-Cerliponase-Alfa-Program-for-Treatment-of-CLN2-Disease-a-Form-of-Batten
 -Disease.html
LAST-MODIFIED:20160907T130003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:BMRN BioMarin Pharmaceutical Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170223
DTSTAMP:20171003T193836Z
UID:rap8arapg9hs0sckvl2usndnls@google.com
CREATED:20160824T130002Z
DESCRIPTION:2017-02-23 Assigns PDUFA Date of February 23\, 2017 http://www.
 businesswire.com/news/home/20160823006191/en/FDA-Accepts-Clovis-Oncology%E2
 %80%99s-Drug-Application-Rucaparib
LAST-MODIFIED:20160824T130002Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:CLVS CLOVIS ONCOLOGY\, INC. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20161113
DTSTAMP:20171003T193836Z
UID:69dupviit533h0h651sa495jb8@google.com
CREATED:20160802T130002Z
DESCRIPTION:2016-11-13 The company recently filed for approval of this manu
 facturer with the U.S. Food and Drug Administration (FDA) and the FDA has a
 ssigned a Prescription Drug User Fee Act (PDUFA) action date of November 13
 \, 2016. http://www.sec.gov/Archives/edgar/data/1114220/000119312516665668/
 d126609dex991.htm
LAST-MODIFIED:20160802T130003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:KERX Keryx Biopharmaceuticals\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20161228
DTSTAMP:20171003T193836Z
UID:u8e330pina1955c8g2jti2uspg@google.com
CREATED:20160706T130011Z
DESCRIPTION:2016-12-28 PDUFA Dates of December 27 and 28\, 2016 http://glob
 enewswire.com/news-release/2016/07/05/853594/0/en/Cempra-Announces-FDA-Acce
 ptance-of-Solithera-New-Drug-Applications-in-the-Treatment-of-Community-Acq
 uired-Bacterial-Pneumonia.html
LAST-MODIFIED:20160706T130011Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:CEMP Cempra\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20161227
DTSTAMP:20171003T193836Z
UID:ofgj89sfj956k2bkfgcgmeph5c@google.com
CREATED:20160706T130003Z
DESCRIPTION:2016-12-27 PDUFA Dates of December 27 and 28\, 2016 http://glob
 enewswire.com/news-release/2016/07/05/853594/0/en/Cempra-Announces-FDA-Acce
 ptance-of-Solithera-New-Drug-Applications-in-the-Treatment-of-Community-Acq
 uired-Bacterial-Pneumonia.html
LAST-MODIFIED:20160706T130004Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:CEMP Cempra\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20161228
DTSTAMP:20171003T193836Z
UID:lpvlpt7ftkt1386vgmftbnjl6o@google.com
CREATED:20160628T130003Z
DESCRIPTION:2016-12-28 The Prescription Drug User Fee Act (PDUFA) target ac
 tion date is December 28\, 2016. http://www.globenewswire.com/news-release/
 2016/06/27/851476/0/en/Advanced-Accelerator-Applications-Announces-FDA-Prio
 rity-Review-for-Lutathera.html
LAST-MODIFIED:20160628T130003Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AAAP Advanced Accelerator Applications PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160815
DTSTAMP:20171003T193836Z
UID:8mbm7jivarem0b5dlodbqm6fv0@google.com
CREATED:20160620T130003Z
DESCRIPTION:2016-08-15 FDA has set a Prescription Drug User Fee Act (PDUFA)
  target action date of August 15\, 2016. http://www.globenewswire.com/news-
 release/2016/06/17/849403/0/en/FDA-Accepts-Emergent-BioSolutions-Supplement
 al-Biologics-License-Application-for-Large-Scale-Manufacturing-of-BioThrax-
 in-Building-55.html
LAST-MODIFIED:20160620T130006Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:EBS Emergent BioSolutions Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170111
DTSTAMP:20171003T193836Z
UID:sgqueq47079s8sco10bnth9jac@google.com
CREATED:20160606T130003Z
DESCRIPTION:2017-01-11 Rolapitant IV NDA accepted for review by FDA\; PDUFA
  date is January 11\, 2017 http://www.globenewswire.com/news-release/2016/0
 6/04/846113/0/en/TESARO-Provides-Pipeline-Update-at-ASCO-Investor-Briefing.
 html
LAST-MODIFIED:20160606T130004Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:TSRO TESARO\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160930
DTSTAMP:20171003T193836Z
UID:da2m73cd7mh85aob98ontch474@google.com
CREATED:20160601T130010Z
DESCRIPTION:2016-09-30 The FDA granted Vertex's request for Priority Review
  of this sNDA\, and a target review date of September 30\, 2016 was set und
 er the Prescription Drug User Fee Act (PDUFA). http://www.businesswire.com/
 news/home/20160531005756/en/U.S.-FDA-Accepts-Priority-Review-Supplemental-D
 rug
LAST-MODIFIED:20160601T130010Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:VRTX VERTEX PHARMACEUTICALS INCORPORATED PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170107
DTSTAMP:20171003T193836Z
UID:5f9frjvgfrunr9o12dct9nv8o0@google.com
CREATED:20160517T130005Z
DESCRIPTION:2017-01-07 The Prescription Drug User Fee Act (PDUFA) goal date
  for the completion of the FDA’s review is January 7\, 2017. http://www.sec
 .gov/Archives/edgar/data/78003/000119312516591095/d178752dex991.htm
LAST-MODIFIED:20160517T130005Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:PFE PFIZER INC. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160809
DTSTAMP:20171003T193836Z
UID:4dcssmqsqlisfg05siq22qodto@google.com
CREATED:20160506T130016Z
DESCRIPTION:2016-08-09 The FDA granted Priority Review with a PDUFA action 
 date of Aug. 9\, 2016\; the sBLA will be reviewed under the FDA’s Accelerat
 ed Approval program. http://www.businesswire.com/news/home/20160505005707/e
 n/Merck-Announces-First-Quarter-2016-Financial-Results
LAST-MODIFIED:20160506T130016Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:MRK MERCK PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160609
DTSTAMP:20171003T193836Z
UID:on3445jobfven2sbq2mp3li504@google.com
CREATED:20160506T130007Z
DESCRIPTION:2016-06-09 The Antimicrobial Drugs Advisory Committee of the FD
 A has scheduled a meeting on June 9\, 2016 to discuss the BLA for ZINPLAVA 
 (bezlotoxumab)\, an investigational antitoxin for the prevention of Clostri
 dium difficile (C. difficile) infection recurrence\, which was accepted by 
 the FDA for Priority Review with a PDUFA action date of July 23\, 2016. htt
 p://www.businesswire.com/news/home/20160505005707/en/Merck-Announces-First-
 Quarter-2016-Financial-Results
LAST-MODIFIED:20160506T130007Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:MRK MERCK PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160901
DTSTAMP:20171003T193836Z
UID:q8cedgvucdoib3bfk51ath9pb0@google.com
CREATED:20160504T130009Z
DESCRIPTION:2016-09-01 The Prescription Drug User Fee Act (PDUFA) target ac
 tion date is Sept. 1\, 2016. http://www.prnewswire.com/news-releases/fda-gr
 ants-priority-review-for-amgens-supplemental-biologics-license-application-
 for-blincyto-blinatumomab-300262144.html
LAST-MODIFIED:20160504T130010Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AMGN Amgen PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20161022
DTSTAMP:20171003T193836Z
UID:247m10irftqisruiqkgcvltgs8@google.com
CREATED:20160428T130032Z
DESCRIPTION:2016-10-22 A six month review period has been assigned for the 
 resubmitted NDA\, and the new Prescription Drug User Fee Act (PDUFA) date w
 ill be October 22\, 2016. http://www.businesswire.com/news/home/20160427006
 350/en/FDA-Accepts-Resubmission-Drug-Application-RAYALDEE%C2%AE
LAST-MODIFIED:20160428T130032Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:OPK OPKO HEALTH\, INC. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20161215
DTSTAMP:20171003T193836Z
UID:vj67qnbit8ml6oc3sa4mbq87mc@google.com
CREATED:20160428T130023Z
DESCRIPTION:2016-12-15 In a notice received from the FDA\, the Prescription
  Drug User Fee Act (PDUFA) action date for HEPLISAV-B has been extended by 
 three months to December 15\, 2016.  http://www.sec.gov/Archives/edgar/data
 /1029142/000156459016016758/dvax-ex991_6.htm
LAST-MODIFIED:20160428T130023Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:DVAX Dynavax Technologies PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170129
DTSTAMP:20171003T193836Z
UID:gtnhn2p7jndo24h5s85ogssero@google.com
CREATED:20160420T130009Z
DESCRIPTION:2017-01-29 PDUFA target action date of January 29\, 2017 http:/
 /www.sec.gov/Archives/edgar/data/1347613/000110465916112406/a16-8681_1ex99d
 1.htm
LAST-MODIFIED:20160420T130009Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SGYP SYNERGY PHARMACEUTICALS INC. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20161111
DTSTAMP:20171003T193836Z
UID:amu2mjcurg01896p5erfd49i60@google.com
CREATED:20160418T130010Z
DESCRIPTION:2016-11-11 Based on the results of Studies 108 and 110\, Gilead
  submitted a New Drug Application to the U.S. Food and Drug Administration 
 (FDA) for TAF and the FDA has set a target review date under the Prescripti
 on Drug User Fee Act (PDUFA) of November 11\, 2016. http://www.businesswire
 .com/news/home/20160415005142/en/Gilead-Announces-Full-48-Week-Results-Phas
 e-3
LAST-MODIFIED:20160418T130011Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:GILD GILEAD SCIENCES\, INC. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160925
DTSTAMP:20171003T193836Z
UID:47064tqilam8b8idi6riu8j450@google.com
CREATED:20160415T130010Z
DESCRIPTION:2016-09-25 Exhibit 99.1 DURECT Announces FDA Acceptance of REMO
 XY NDA\, PDUFA Date of September 25\, 2016 CUPERTINO\, CA\, April 12\, 2016
  /PRNewswire / DURECT Corporation (Nasdaq: DRRX) today announced its licens
 ee\, Pain Therapeutics (Nasdaq: PTIE)\, has been informed by the U.S. Food 
 and Drug http://www.sec.gov/Archives/edgar/data/1082038/000119312516540580/
 d178008dex991.htm
LAST-MODIFIED:20160415T130010Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:DRRX DURECT CORP PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160925
DTSTAMP:20171003T193836Z
UID:ppn9c85tsfung7kvlphiet93r0@google.com
CREATED:20160413T130021Z
DESCRIPTION:2016-09-25 FDA Accepts REMOXY NDA for Review\, Sets PDUFA Date 
 of September 25\, 2016 http://www.sec.gov/Archives/edgar/data/1069530/00011
 7184316009127/exh_991.htm
LAST-MODIFIED:20160413T130021Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:PTIE Pain Therapeutics\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160604
DTSTAMP:20171003T193836Z
UID:dehhm1daeiqqcobf99rf7uupl0@google.com
CREATED:20160413T130008Z
DESCRIPTION:2016-06-04 Our Epinephrine Pre-filled Syringe (“PFS”) has an FD
 A agency action date (PDUFA date) of June 4\, 2016. http://www.sec.gov/Arch
 ives/edgar/data/887247/000138713116004941/ex99-1.htm
LAST-MODIFIED:20160413T130009Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ADMP Adamis Pharmaceuticals Corporation PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160719
DTSTAMP:20171003T193836Z
UID:uboq6cvcvrene25kir90ph07m0@google.com
CREATED:20160406T130010Z
DESCRIPTION:2016-07-19 -New PDUFA date set for July 19\, 2016- http://www.p
 rnewswire.com/news-releases/valeant-and-progenics-announce-pdufa-date-exten
 sion-for-oral-relistor-300245266.html
LAST-MODIFIED:20160406T130010Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:PGNX Progenics Pharmaceuticals PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160719
DTSTAMP:20171003T193836Z
UID:lcrnfq730f6vlr8vr2191llo04@google.com
CREATED:20160405T130009Z
DESCRIPTION:2016-07-19 -New PDUFA date set for July 19\, 2016- http://www.p
 rnewswire.com/news-releases/valeant-and-progenics-announce-pdufa-date-exten
 sion-for-oral-relistor-300245266.html
LAST-MODIFIED:20160405T130010Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:VRX Valeant Pharmaceuticals International\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160914
DTSTAMP:20171003T193836Z
UID:ndj7n038p40tecqb8cqlmojvcg@google.com
CREATED:20160330T130007Z
DESCRIPTION:2016-09-14 The FDA Prescription Drug User Fee Act ("PDUFA") goa
 l date for a decision is September 14\, 2016. http://www.prnewswire.com/new
 s-releases/aralez-announces-fda-acceptance-of-new-drug-application-for-yosp
 rala-300241774.html
LAST-MODIFIED:20160330T130008Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ARLZ Aralez Pharmaceuticals Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160701
DTSTAMP:20171003T193836Z
UID:e6isg2vrrnkr3um4vi4u9mtf38@google.com
CREATED:20160323T130026Z
DESCRIPTION:2016-07-01 Forward-Looking Statements This press release contai
 ns forward-looking statements including related to our PDUFA action (goal) 
 date of July 1\, 2016. http://www.sec.gov/Archives/edgar/data/1516479/00014
 3774916028208/ex99-1.htm
LAST-MODIFIED:20160323T130026Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:INSY Insys Therapeutics Inc PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170107
DTSTAMP:20171003T193836Z
UID:hp8mnmipcb7253qqd07n0ooll8@google.com
CREATED:20160323T130012Z
DESCRIPTION:2017-01-07 The Prescription Drug User Fee Act (PDUFA) goal date
  for the completion of the FDA’s review is January 7\, 2017. http://www.bus
 inesswire.com/news/home/20160322005577/en/Anacor-Pharmaceuticals-Announces-
 FDA-Acceptance-NDA-Crisaborole
LAST-MODIFIED:20160323T130012Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ANAC ANACOR PHARMACEUTICALS\, INC. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160426
DTSTAMP:20171003T193836Z
UID:8hu2qph3appc6cthmsu7fmi0j4@google.com
CREATED:20160321T130011Z
DESCRIPTION:2016-04-26 The FDA has set a Prescription Drug User Fee Act\, o
 r PDUFA\, goal date of April 26\, 2016. http://www.sec.gov/Archives/edgar/d
 ata/1267565/000155837016004252/R10.htm
LAST-MODIFIED:20160321T130011Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:COLL COLLEGIUM PHARMACEUTICAL INC PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160714
DTSTAMP:20171003T193836Z
UID:63fhsg0l1hjtoom4vl6qkc7bkk@google.com
CREATED:20160318T130008Z
DESCRIPTION:2016-07-14 The FDA has set a target action date under the Presc
 ription Drug User Fee Act (“PDUFA”) of July 14\, 2016. http://www.globenews
 wire.com/news-release/2016/03/17/820781/0/en/Elite-Announces-U-S-FDA-Priori
 ty-Review-Designation-for-SequestOx-NDA.html
LAST-MODIFIED:20160318T130008Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ELTP Elite Pharmaceuticals\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20161105
DTSTAMP:20171003T193836Z
UID:21hnm65os0q1jg8vchu32ti32g@google.com
CREATED:20160314T130013Z
DESCRIPTION:2016-11-05 The FDA has set a Prescription Drug User Fee Act (PD
 UFA) target action date of Nov. 5\, 2016\, for the ENBREL sBLA application.
  http://www.prnewswire.com/news-releases/fda-accepts-amgens-supplemental-bi
 ologics-license-application-for-the-expanded-use-of-enbrel-etanercept-to-tr
 eat-pediatric-patients-with-chronic-severe-plaque-psoriasis-300234327.html
LAST-MODIFIED:20160314T130013Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AMGN Amgen PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160509
DTSTAMP:20171003T193836Z
UID:kldo72akdkkni5fntppfrqu5lc@google.com
CREATED:20160310T140013Z
DESCRIPTION:2016-05-09 Within days\, the company resubmitted the NDA and re
 ceived a PDUFA date of May 9\, 2016. The FDA accepted the NDA and has given
  Spectrum a PDUFA date of December 11\, 2016. http://www.sec.gov/Archives/e
 dgar/data/831547/000083154716000053/exhibit991q42015.htm
LAST-MODIFIED:20160310T140013Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SPPI SPECTRUM PHARMACEUTICALS INC PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20170103
DTSTAMP:20171003T193836Z
UID:35nc7djcij34901fhi6f7q32jo@google.com
CREATED:20160308T140013Z
DESCRIPTION:2017-01-03 The FDA provided a PDUFA (Prescription Drug User Fee
  Act) goal date of January 3\, 2017. http://www.sec.gov/Archives/edgar/data
 /887359/000110465916102832/a16-5902_1ex99d1.htm
LAST-MODIFIED:20160308T140013Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:VCEL Vericel Corp PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20161014
DTSTAMP:20171003T193836Z
UID:t4cs4d5aic5bm7ckc7bolimdbs@google.com
CREATED:20160301T140009Z
DESCRIPTION:2016-10-14 The FDA Prescription Drug User Fee Act (PDUFA) goal 
 date for a decision is October 14\, 2016. http://www.prnewswire.com/news-re
 leases/egalet-announces-fda-acceptance-of-new-drug-application-for-arymo-er
 -morphine-sulfate-extended-release-tablets-300227415.html
LAST-MODIFIED:20160301T140009Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:EGLT Egalet Corporation PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160601
DTSTAMP:20171003T193836Z
UID:5lq5997kmdl95vvfq8s49pf0h4@google.com
CREATED:20160226T140007Z
DESCRIPTION:2016-06-01 The PDUFA date has been extended by the standard ext
 ension period of three months from 1 March 2016 to the new goal date of 1 J
 une 2016. Due to the timing of this submission\, the FDA extended the PDUFA
  date to allow additional time for review of the English translated documen
 ts. http://www.sec.gov/Archives/edgar/data/1611787/000095010316011371/dp637
 30_6k.htm
LAST-MODIFIED:20160226T140008Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AAAP Advanced Accelerator Applications S A PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160407
DTSTAMP:20171003T193836Z
UID:37uohkd715eotskcvr9bbplns8@google.com
CREATED:20160224T140010Z
DESCRIPTION:2016-04-07 In April 2015\, Gilead filed a New Drug Application 
 (NDA) with the U.S. Food and Drug Administration (FDA) for two fixed-dose c
 ombinations of F/TAF (200/10 mg and 200/25 mg)\, and the FDA has set a targ
 et review date under the Prescription Drug User Fee Act (PDUFA) of April 7\
 , 2016. http://www.businesswire.com/news/home/20160223006478/en/Gilead-Anno
 unces-Results-Study-Evaluate-Switching-FTAF-Based
LAST-MODIFIED:20160224T140011Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:GILD GILEAD SCIENCES\, INC. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160527
DTEND;VALUE=DATE:20160528
DTSTAMP:20171003T193836Z
UID:d7pid39im42ko8567fue5n9pgo@google.com
CREATED:20160104T140012Z
DESCRIPTION:Extended to May 27\, 2016\nhttp://www.marketwired.com/press-rel
 ease/titan-pharmaceuticals-announces-notification-fda-action-date-extension
 -probuphine-nasdaq-ttnp-2098472.htm\n\n2016-02-27 An agency action date has
  been set for Feb. 27\, 2016. http://www.marketwired.com/press-release/tita
 n-pharmaceuticals-braeburn-pharmaceuticals-announce-date-fda-advisory-commi
 ttee-nasdaq-ttnp-2080538.htm
LAST-MODIFIED:20160223T162025Z
LOCATION:
SEQUENCE:1
STATUS:CONFIRMED
SUMMARY:TTNP Titan Pharmaceuticals\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20161022
DTSTAMP:20171003T193836Z
UID:5o978tjebmen5lntqmmulm67c8@google.com
CREATED:20160223T140011Z
DESCRIPTION:2016-10-22 The Prescription Drug User Fee Act (PDUFA) goal date
  for a decision by the FDA is October 22\, 2016. http://www.prnewswire.com/
 news-releases/fda-accepts-for-review-supplemental-new-drug-application-for-
 xtandi-enzalutamide-capsules-in-metastatic-castration-resistant-prostate-ca
 ncer-with-data-from-head-to-head-studies-of-enzalutamide-versus-bicalutamid
 e-300223864.html
LAST-MODIFIED:20160223T161447Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:MDVN Medivation PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20161211
DTSTAMP:20171003T193836Z
UID:hte19chcq89jkmuq1ome6q6k7o@google.com
CREATED:20160222T140014Z
DESCRIPTION:2016-12-11 The FDA has set a target action date under the Presc
 ription Drug User Fee Act (PDUFA) of December 11\, 2016. http://www.busines
 swire.com/news/home/20160219005209/en/Spectrum-Pharmaceuticals-Announces-FD
 A%E2%80%99s-Acceptance-NDA-Filing
LAST-MODIFIED:20160222T140015Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SPPI SPECTRUM PHARMACEUTICALS PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160609
DTSTAMP:20171003T193836Z
UID:nuvbsrsb70uc2vud0mgf276qfc@google.com
CREATED:20160211T140011Z
DESCRIPTION:2016-06-09 In addition\, the FDA has set a target action date u
 nder the Prescription Drug User Fee Act (PDUFA) of June 9\, 2016. http://ww
 w.sec.gov/Archives/edgar/data/1434647/000156459016012558/kmph-ex991_6.htm
LAST-MODIFIED:20160211T140012Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:KMPH KEMPHARM INC PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160526
DTSTAMP:20171003T193836Z
UID:v2r208791s20lbumuis84f6krc@google.com
CREATED:20160209T140023Z
DESCRIPTION:2016-05-26 PDUFA goal date extended by standard extension perio
 d of three months to May 26\, 2016 http://www.businesswire.com/news/home/20
 160208005533/en/Sarepta-Therapeutics-Receives-Notification-PDUFA-Extension-
 Eteplirsen
LAST-MODIFIED:20160209T140023Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SRPT SAREPTA THERAPEUTICS\, INC. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160722
DTSTAMP:20171003T193836Z
UID:bfa5kl8q084qh6cjn18u0s0ots@google.com
CREATED:20160205T135947Z
DESCRIPTION:2016-07-22 The FDA determined that the submission is a complete
  response and has assigned a 6-month review period for the NDA and a Prescr
 iption Drug User Fee Act (PDUFA) goal date of July 22\, 2016. http://www.pr
 newswire.com/news-releases/us-fda-acknowledges-receipt-of-resubmission-of-s
 hires-new-drug-application-for-lifitegrast-for-dry-eye-disease-in-adults-56
 7715061.html
LAST-MODIFIED:20160205T135947Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SHPG Shire plc PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160622
DTSTAMP:20171003T193836Z
UID:r8ad5n034ga0177qtgf7rd9a3s@google.com
CREATED:20160129T140015Z
DESCRIPTION:2016-06-22 The FDA granted Priority Review to the filing and as
 signed a Prescription Drug User Fee Act action date of June 22\, 2016. http
 ://www.businesswire.com/news/home/20160128005475/en/Exelixis-Announces-U.S.
 -FDA-Deems-Drug-Application
LAST-MODIFIED:20160129T140015Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:EXEL EXELIXIS\, INC. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160723
DTSTAMP:20171003T193836Z
UID:sdq2ggr9t1olq0m94a2fgsitm0@google.com
CREATED:20160128T140009Z
DESCRIPTION:2016-07-23 The FDA granted Priority Review for bezlotoxumab\, w
 ith a Prescription Drug User Fee Act (PDUFA) action date of July 23\, 2016.
  http://www.businesswire.com/news/home/20160127005220/en/Merck-Announces-FD
 A-Acceptance-Biologics-License-Application
LAST-MODIFIED:20160128T140010Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:MRK MERCK PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20161030
DTSTAMP:20171003T193836Z
UID:na3qba7h588oip7lnk58l8c5tc@google.com
CREATED:20160111T140020Z
DESCRIPTION:2016-10-30 Per the Prescription Drug User Fee Act (PDUFA)\, the
  target action date is October 30\, 2016. http://www.prnewswire.com/news-re
 leases/regeneron-and-sanofi-announce-sarilumab-biologics-license-applicatio
 n-accepted-for-review-by-us-fda-300201389.html
LAST-MODIFIED:20160111T154643Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SNY Sanofi PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160207
DTSTAMP:20171003T193836Z
UID:k4ehp9bud26isori5qof3d33sg@google.com
CREATED:20160111T140029Z
DESCRIPTION:2016-02-07 The FDA granted Vertex's request for Priority Review
  of this sNDA\, and a target review date of February 7\, 2016 was set under
  the Prescription Drug User Fee Act (PDUFA) for the FDA's decision on the s
 NDA. http://www.businesswire.com/news/home/20160110005035/en/Vertex-Outline
 s-2016-Business-Priorities-Support-Discovery
LAST-MODIFIED:20160111T140029Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:VRTX VERTEX PHARMACEUTICALS INCORPORATED PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160817
DTSTAMP:20171003T193836Z
UID:k4v033v3lfq28hidjnmm10nab4@google.com
CREATED:20160111T140012Z
DESCRIPTION:2016-08-17 Completed a BLA submission\, which is awaiting accep
 tance for filing\; the FDA assigned a PDUFA date of August 17\, 2016 under 
 an Accelerated Approval pathway. http://www.globenewswire.com/news-release/
 2016/01/08/800508/0/en/Portola-Pharmaceuticals-to-Webcast-Corporate-Update-
 on-January-12-2016.html
LAST-MODIFIED:20160111T140012Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:PTLA Portola Pharmaceuticals\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20161030
DTSTAMP:20171003T193836Z
UID:tvqtqaiqbebv09mju2kkls8mtg@google.com
CREATED:20160108T140013Z
DESCRIPTION:2016-10-30 Per the Prescription Drug User Fee Act (PDUFA)\, the
  target action date is October 30\, 2016. http://www.prnewswire.com/news-re
 leases/regeneron-and-sanofi-announce-sarilumab-biologics-license-applicatio
 n-accepted-for-review-by-us-fda-300201389.html
LAST-MODIFIED:20160108T140013Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:REGN Regeneron Pharmaceuticals\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160529
DTEND;VALUE=DATE:20160530
DTSTAMP:20171003T193836Z
UID:7be46nla98ldua6e1k2jutt630@google.com
CREATED:20150901T140029Z
DESCRIPTION:2016-05-29 To provide time for a full review of the submission\
 , the original PDUFA date of February 29\, 2016 has been extended by three 
 months\, resulting in a new PDUFA date of May 29\, 2016. https://globenewsw
 ire.com/news-release/2015/12/17/796641/0/en/FDA-Extends-PDUFA-Date-for-Obet
 icholic-Acid-for-the-Treatment-of-PBC.html
LAST-MODIFIED:20160103T160605Z
LOCATION:
SEQUENCE:1
STATUS:CONFIRMED
SUMMARY:ICPT Intercept Pharmaceuticals\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160710
DTSTAMP:20171003T193836Z
UID:ern4du4fdjekf1a2q2cbd1kbco@google.com
CREATED:20151217T140007Z
DESCRIPTION:2016-07-10 WINNIPEG\, Dec. 2\, 2015 /PRNewswire/ - Medicure Inc
 . ("Medicure" or the "Company") (TSXV:MPH\, OTC:MCUJF)\, a specialty pharma
 ceutical company\, today announced that the U.S. Food and Drug Administrati
 on ("FDA") has assigned a Prescription Drug User Fee Act ("PDUFA")  action 
 date of July 10\, 2016\, for completing its review of the AGGRASTAT (tirofi
 ban HCl) supplemental New Drug Application ("sNDA") submitted by the Compan
 y. http://www.prnewswire.com/news-releases/medicure-announces-pdufa-action-
 date-for-new-aggrastat-indication-560008761.html
LAST-MODIFIED:20151217T140007Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:MCUJF Medicure Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160628
DTSTAMP:20171003T193836Z
UID:tafgn1poqj1kbqnea25821uke8@google.com
CREATED:20151216T140009Z
DESCRIPTION:2016-06-28 PDUFA goal date extended by three months to June 28\
 , 2016 http://www.businesswire.com/news/home/20151215006801/en/Clovis-Oncol
 ogy-Receives-Notification-PDUFA-Extension-Rociletinib
LAST-MODIFIED:20151216T140010Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:CLVS CLOVIS ONCOLOGY\, INC. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160724
DTSTAMP:20171003T193836Z
UID:5iu2g0amk38cjc94gllq5t0ig4@google.com
CREATED:20151212T180817Z
DESCRIPTION:2016-07-24 PDUFA target action date of July 24\, 2016 http://ww
 w.businesswire.com/news/home/20151209005645/en/Ocular-Therapeutix%E2%84%A2-
 Announces-FDA-Acceptance-NDA-Filing
LAST-MODIFIED:20151212T180817Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:OCUL OCULAR THERAPEUTIX\, INC. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160628
DTSTAMP:20171003T193836Z
UID:6jon1dc1pd4rla15c8bvbdsjvg@google.com
CREATED:20151113T140007Z
DESCRIPTION:2016-06-28 The FDA has assigned a Prescription Drug User Fee Ac
 t ("PDUFA") action date of June 28\, 2016\, for completion of the review of
  the NDA for LPCN 1021. http://www.sec.gov/Archives/edgar/data/1535955/0001
 14420415064691/v424540_ex99-1.htm
LAST-MODIFIED:20151113T140008Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:LPCN Lipocine Inc PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20151226
DTSTAMP:20171003T193836Z
UID:oq69nhavqtl06a5afbs0dcfd8o@google.com
CREATED:20151112T140008Z
DESCRIPTION:2015-12-26 Entered into an exclusive U.S. licensing agreement w
 ith Teikoku Pharma USA Inc. to market\, sell and distribute Docetaxel Injec
 tion Concentrate\, Non-Alcohol Formula\, an investigational product intende
 d for the treatment of breast cancer\, non-small cell lung cancer\, prostat
 e cancer\, gastric adenocarcinoma\, and head and neck cancer (PDUFA Date: D
 ecember 26\, 2015)\; http://www.businesswire.com/news/home/20151111005640/e
 n/Eagle-Pharmaceuticals-Reports-Quarter-2015-Results
LAST-MODIFIED:20151112T140008Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:EGRX EAGLE PHARMACEUTICALS\, INC. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160122
DTSTAMP:20171003T193836Z
UID:mjehmkgb1ub0h61lvnteci10hs@google.com
CREATED:20151110T140011Z
DESCRIPTION:2016-01-22 The PDUFA date for this submission was stated by Amg
 en to be January 22\, 20161. http://www.businesswire.com/news/home/20151109
 006635/en/Ligand-Reports-Quarter-2015-Financial-Results
LAST-MODIFIED:20151110T140011Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:LGND LIGAND PHARMACEUTICALS INCORPORATED PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160824
DTSTAMP:20171003T193836Z
UID:c3b8pcg8t660cg5es79f759cus@google.com
CREATED:20151109T140008Z
DESCRIPTION:2016-08-24 The FDA has set a Prescription Drug User Fee Act (PD
 UFA) target action date of Aug. 24\, 2016\, for the etelcalcetide applicati
 on. http://www.prnewswire.com/news-releases/fda-accepts-amgens-new-drug-app
 lication-for-novel-intravenous-calcimimetic-etelcalcetide-300174208.html
LAST-MODIFIED:20151109T140009Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AMGN Amgen PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160416
DTSTAMP:20171003T193836Z
UID:p54in9mb7nfikcjtcoclg5arqk@google.com
CREATED:20151106T140007Z
DESCRIPTION:2016-04-16 The Prescription Drug User Fee Act date for the subm
 ission is April 16\, 2016. http://www.businesswire.com/news/home/2015110500
 5805/en/Celgene-Reports-Quarter-2015-Operating-Financial-Results
LAST-MODIFIED:20151106T140007Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:CELG CELGENE CORPORATION PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160501
DTSTAMP:20171003T193836Z
UID:h6buriplqhn4c10egsv9dsouv8@google.com
CREATED:20151103T140005Z
DESCRIPTION:2016-05-01 PDUFA Date Set for May 1\, 2016 http://www.businessw
 ire.com/news/home/20151102005516/en/ACADIA-Pharmaceuticals-Announces-FDA-Pr
 iority-Review-NUPLAZID%E2%84%A2
LAST-MODIFIED:20151103T140006Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ACAD ACADIA PHARMACEUTICALS INC. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160710
DTSTAMP:20171003T193836Z
UID:obnh7a2r2gs9qofie0t0i3mcfo@google.com
CREATED:20151029T130010Z
DESCRIPTION:2016-07-10 A supplemental Biologics License Application for a m
 onthly administration single-dosing option was submitted to FDA and has rec
 eived a Prescription Drug User Fee Act target action date of July 10\, 2016
 . http://www.prnewswire.com/news-releases/amgens-third-quarter-2015-revenue
 s-increased-14-percent-to-57-billion-and-adjusted-earnings-per-share-eps-in
 creased-18-percent-to-272-300168138.html
LAST-MODIFIED:20151029T130010Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AMGN Amgen PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20151224
DTSTAMP:20171003T193836Z
UID:4gh160m75f6skf92e7rt1si5vk@google.com
CREATED:20151028T130022Z
DESCRIPTION:2015-12-24 Additionally\, the FDA extended the PDUFA action dat
 e for a separate sBLA for KEYTRUDA for the treatment of patients with ipili
 mumab-refractory advanced melanoma to Dec. 24\, 2015. http://www.businesswi
 re.com/news/home/20151027005850/en/Merck-Announces-Third-Quarter-2015-Finan
 cial-Results
LAST-MODIFIED:20151028T130022Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:MRK MERCK PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160227
DTSTAMP:20171003T193836Z
UID:3vkr1boq6rvph9movsrgd6gcfo@google.com
CREATED:20151028T130012Z
DESCRIPTION:2016-02-27 The FDA has assigned priority review to Telesta's BL
 A with a review (PDUFA) date of February 27\, 2016. http://www.prnewswire.c
 om/news-releases/telesta-therapeutics-and-ipsen-announce-exclusive-license-
 agreement-for-mcna1-for-the-treatment-of-non-muscle-invasive-bladder-cancer
 -in-major-ex-united-states-territories-537834831.html
LAST-MODIFIED:20151028T130012Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:BNHLF Telesta Therapeutics Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20151229
DTSTAMP:20171003T193836Z
UID:275sh24t2q0l6k51d806g9did4@google.com
CREATED:20151026T130023Z
DESCRIPTION:2015-12-29 The Prescription Drug User Fee Act (PDUFA) target go
 al date for lesinurad is December 29\, 2015. http://www.businesswire.com/ne
 ws/home/20151023006000/en/FDA-Advisory-Committee-Recommends-Approval-Lesinu
 rad-Gout
LAST-MODIFIED:20151026T130023Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AZN ASTRAZENECA PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160721
DTSTAMP:20171003T193836Z
UID:u3r23c4k3pf3mo0c5ghfn7gjd8@google.com
CREATED:20151015T130044Z
DESCRIPTION:2016-07-21 The FDA has set an action date of July 21\, 2016 to 
 complete its review\, as per the Prescription Drug User Fee Act (PDUFA). ht
 tp://www.prnewswire.com/news-releases/bausch--lomb-and-nicox-announce-fda-a
 cceptance-of-new-drug-application-for-novel-glaucoma-candidate-vesneo-latan
 oprostene-bunod-300146826.html
LAST-MODIFIED:20151015T130045Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:VRX Valeant Pharmaceuticals International\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160527
DTSTAMP:20171003T193836Z
UID:14siicuiiu0pr036ugs29996lo@google.com
CREATED:20151015T130036Z
DESCRIPTION:2016-05-27 The FDA has set a user fee goal date under the Presc
 ription Drug User Fee Act of May 27\, 2016\, which is the target date for t
 he FDA to complete its review of the sNDA. http://www.prnewswire.com/news-r
 eleases/vanda-announces-fda-has-accepted-for-review-the-fanapt-supplemental
 -new-drug-application-for-maintenance-treatment-of-schizophrenia-in-adults-
 300142878.html
LAST-MODIFIED:20151015T130036Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:VNDA Vanda Pharmaceuticals Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20151025
DTSTAMP:20171003T193836Z
UID:rrkftoci30b2djj4h3k3qdca04@google.com
CREATED:20151015T130027Z
DESCRIPTION:2015-10-25 The FDA has set an action date of October 25\, 2015\
 , based on the Prescription Drug User Fee Act V. http://www.prnewswire.com/
 news-releases/shire-delivers-strong-revenue-growth-and-cash-generation-20-i
 ncrease-in-non-gaap-earnings-per-ads-501800781.html
LAST-MODIFIED:20151015T130027Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SHPG Shire plc PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20151111
DTSTAMP:20171003T193836Z
UID:qld5lhcgskdpohj0sqih1irqs4@google.com
CREATED:20151015T130018Z
DESCRIPTION:2015-11-11 In the United States\, the Prescription Drug User Fe
 e Act action date is November 11\, 2015. http://www.businesswire.com/news/h
 ome/20151005006803/en/Exelixis-Announces-Positive-Survival-Results-Phase-3
LAST-MODIFIED:20151015T130018Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:EXEL EXELIXIS\, INC. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160206
DTSTAMP:20171003T193836Z
UID:3b42934p5aqn04kl7tqdnsl508@google.com
CREATED:20151008T130018Z
DESCRIPTION:2016-02-06 The FDA granted Vertex’s request for Priority Review
  of this sNDA\, and a target review date of February 6\, 2016 was set under
  the Prescription Drug User Fee Act (PDUFA) for the FDA's decision on the s
 NDA. http://www.businesswire.com/news/home/20151007006509/en/Supplemental-D
 rug-Application-KALYDECO%C2%AE-ivacaftor-People-Cystic
LAST-MODIFIED:20151008T130018Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:VRTX VERTEX PHARMACEUTICALS INCORPORATED PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160331
DTSTAMP:20171003T193836Z
UID:v2e74lfr33qf8vneeesehevp2g@google.com
CREATED:20151001T130021Z
DESCRIPTION:2016-03-31 Based on timelines established by the Prescription D
 rug User Fee Act (PDUFA)\, FDA review of the NDA is expected to be complete
 d by March 31\, 2016.  http://www.prnewswire.com/news-releases/jazz-pharmac
 euticals-announces-us-fda-acceptance-for-filing-with-priority-review-of-nda
 -for-defibrotide-for-hepatic-veno-occlusive-disease-300151412.html
LAST-MODIFIED:20151001T130021Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:JAZZ Jazz Pharmaceuticals plc PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160117
DTSTAMP:20171003T193836Z
UID:6pqqam0bjn6541d0tmo2rsqj1o@google.com
CREATED:20150921T130050Z
DESCRIPTION:2016-01-17 The FDA has assigned a Prescription Drug User Fee Ac
 t (PDUFA) goal date of January 17\, 2016. http://www.sec.gov/Archives/edgar
 /data/818033/000129993315001364/exhibit1.htm
LAST-MODIFIED:20150921T130050Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:HRTX HERON THERAPEUTICS INC DE PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160122
DTSTAMP:20171003T193836Z
UID:n1j4424od0ts6mlqjat9e8k1ok@google.com
CREATED:20150921T130029Z
DESCRIPTION:2016-01-22 The Prescription Drug User Fee Act (PDUFA) target ac
 tion date is Jan. 22\, 2016. http://www.prnewswire.com/news-releases/fda-gr
 ants-priority-review-for-amgens-supplemental-new-drug-application-for-expan
 ded-labeling-of-kyprolis-carfilzomib-in-relapsed-multiple-myeloma-300145710
 .html
LAST-MODIFIED:20150921T130030Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AMGN Amgen PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160430
DTSTAMP:20171003T193836Z
UID:tpoosuo7nnvuko2so0rf926fl4@google.com
CREATED:20150910T130019Z
DESCRIPTION:2016-04-30 LYON\, FRANCE--(Marketwired - Sep 9\, 2015) - Flamel
  Technologies (NASDAQ: FLML) today announced that it has received a Prescri
 ption Drug User Fee Act (PDUFA) date of April 30\, 2016 from the U.S. Food 
 and Drug Administration (FDA) for its third New Drug Application (NDA). htt
 p://www.marketwired.com/press-release/flamel-technologies-announces-fda-acc
 eptance-of-third-nda-filing-nasdaq-flml-2053779.htm
LAST-MODIFIED:20150910T130019Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:FLML Flamel Technologies PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20151208
DTSTAMP:20171003T193836Z
UID:i1o3da4h1l0i4o4kgce2vo1nfg@google.com
CREATED:20150907T130018Z
DESCRIPTION:2015-12-08 The previously disclosed September 8\, 2015 PDUFA da
 te has been extended by the standard extension period of three months. http
 ://www.businesswire.com/news/home/20150904005097/en/Alexion-Receives-Notifi
 cation-PDUFA-Date-Extension-Kanuma%E2%84%A2
LAST-MODIFIED:20150907T130018Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ALXN ALEXION PHARMACEUTICALS\, INC. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20151208
DTEND;VALUE=DATE:20151209
DTSTAMP:20171003T193836Z
UID:mcq3e0p0im1a282cj30udu3bh4@google.com
CREATED:20150224T150009Z
DESCRIPTION:2015-09-08 The FDA established a target action date of Septembe
 r 8\, 2015 under the Prescription Drug User Fee Act (PDUFA).  http://www.pr
 newswire.com/news-releases/fda-accepts-bla-filing-for-synagevas-kanuma-sebe
 lipase-alfa-grants-priority-review-and-assigns-pdufa-date-300039456.html
LAST-MODIFIED:20150905T190951Z
LOCATION:
SEQUENCE:1
STATUS:CONFIRMED
SUMMARY:GEVA Synageva BioPharma Corp. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160127
DTSTAMP:20171003T193836Z
UID:9vlvh3um3etiuvg540pt0ijbk4@google.com
CREATED:20150904T140025Z
DESCRIPTION:2016-01-27 Received FDA acknowledgement of the resubmission of 
 the new drug application (NDA) for NT-0202\, the Company’s Amphetamine XR o
 rally disintegrating tablet (ODT)\, with a Prescription Drug User Fee Act (
 PDUFA) goal date of January 27\, 2016. http://www.businesswire.com/news/hom
 e/20150903005294/en/Neos-Therapeutics-Announces-Quarter-2015-Financial-Resu
 lts
LAST-MODIFIED:20150904T140025Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:NEOS NEOS THERAPEUTICS\, INC. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20151109
DTSTAMP:20171003T193836Z
UID:f80r8kkfl8uhanm7ak4f0gkeo8@google.com
CREATED:20150904T140017Z
DESCRIPTION:2015-11-09 This is the Company s second upcoming PDUFA goal dat
 e as the PDUFA goal date for its Methylphenidate extended-release orally di
 sintegrating tablet (now provisionally called Cotempla XR-ODT ) is November
  9\, 2015. http://www.sec.gov/Archives/edgar/data/1467652/00011046591506340
 9/a15-18967_1ex99d1.htm
LAST-MODIFIED:20150904T140017Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:NEOS Neos Therapeutics Inc PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160415
DTSTAMP:20171003T193836Z
UID:oie35lhonohb95bn2l1vo3dit4@google.com
CREATED:20150901T140019Z
DESCRIPTION:2016-04-15 The FDA has accepted the NDA for filing and the PDUF
 A date is April 15\, 2016. The PDUFA date is the target date for the FDA to
  complete its review of the NDA. There also can be no assurance that the FD
 A will complete its review by the PDUFA target date. http://www.sec.gov/Arc
 hives/edgar/data/1339469/000119312515308218/d39538dex991.htm
LAST-MODIFIED:20150901T140020Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:CHMA CHIASMA INC PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20151005
DTSTAMP:20171003T193836Z
UID:sedmfk9ld5gir2ts84ov9imbhk@google.com
CREATED:20150827T140018Z
DESCRIPTION:2015-10-05 FDA has granted a standard review and set a target r
 eview date under the Prescription Drug User Fee Act (PDUFA) of October 5\, 
 2015. http://www.businesswire.com/news/home/20150826006141/en/Results-AMBIT
 ION-Study-First-Line-Treatment-Letairis-Tadalafil
LAST-MODIFIED:20150827T140018Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:GILD GILEAD SCIENCES\, INC. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160410
DTSTAMP:20171003T193836Z
UID:h5k5iclv7fcisnt5koc1ehaff8@google.com
CREATED:20150818T140007Z
DESCRIPTION:2016-04-10 PDUFA decision expected April 10\, 2016\, 10 months 
 following NDA submission http://www.businesswire.com/news/home/201508170062
 05/en/InSite-Vision-Announces-FDA-Acceptance-NDA-Filing
LAST-MODIFIED:20150818T140007Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:INSV INSITE VISION INCORPORATED PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160319
DTSTAMP:20171003T193836Z
UID:adareq32c1gcq4kclinfmcidio@google.com
CREATED:20150812T140007Z
DESCRIPTION:2016-03-19 The FDA action date for this NDA under PDUFA is Marc
 h 19\, 2016\; http://www.businesswire.com/news/home/20150811005349/en/Eagle
 -Pharmaceuticals-Reports-Quarter-2015-Results
LAST-MODIFIED:20150812T140008Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:EGRX EAGLE PHARMACEUTICALS\, INC. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20150526
DTSTAMP:20171003T193836Z
UID:6fadjjlcg6mubqag8r07k6u2l4@google.com
CREATED:20150807T140018Z
DESCRIPTION:2015-05-26 We submitted our New Drug Application\, or NDA\, in 
 the United States on May 26\, 2015 and we have been informed by the FDA tha
 t our Prescription Drug User Fee Act (PDUFA) goal date is May 26\, 2016. ht
 tp://www.sec.gov/Archives/edgar/data/1459266/000119312515281000/R7.htm
LAST-MODIFIED:20150807T140019Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ZSPH ZS Pharma Inc PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20150814
DTSTAMP:20171003T193836Z
UID:hterlt5mn151r4gh5sck3c0sr8@google.com
CREATED:20150807T140009Z
DESCRIPTION:2015-08-14 The Prescription Drug User Fee Act (PDUFA) date for 
 the FDA s decision on the potential label expansion for PROCYSBI to include
  nephropathic cystinosis patients aged 2-6 years is August 14\, 2015. http:
 //www.sec.gov/Archives/edgar/data/1070698/000114036115030179/ex99_1.htm
LAST-MODIFIED:20150807T140009Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:RPTP Raptor Pharmaceutical Corp PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160329
DTSTAMP:20171003T193836Z
UID:ti432jv9psss3di5eemmhkfugs@google.com
CREATED:20150806T140012Z
DESCRIPTION:2016-03-29 RayaldeeTM New Drug Application (NDA) Submission Acc
 epted by FDA\; Expected PDUFA date of March 29\, 2016 http://www.businesswi
 re.com/news/home/20150805006592/en/OPKO-Announces-Quarter-Operating-Financi
 al-Results
LAST-MODIFIED:20150806T140012Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:OPK OPKO HEALTH\, INC. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160526
DTSTAMP:20171003T193836Z
UID:jqog8cm256mlk9bkd2iirad1po@google.com
CREATED:20150730T140009Z
DESCRIPTION:2016-05-26 We have been informed that the Prescription Drug Use
 r Fee Act (PDUFA) goal date for a decision by the FDA is May 26\, 2016. Hyp
 erkalemia is a serious condition with few treatment options and ZS-9 could 
 be the first selective agent approved for the treatment of this condition. 
 http://www.sec.gov/Archives/edgar/data/1459266/000119312515268241/d66049dex
 991.htm
LAST-MODIFIED:20150730T140009Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ZSPH ZS Pharma Inc PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20160128
DTSTAMP:20171003T193836Z
UID:q9sg5qs5oni9a7vljks5ebobb8@google.com
CREATED:20150729T140020Z
DESCRIPTION:2016-01-28 KENILWORTH\, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK)
 \, known as MSD outside the United States and Canada\, today announced that
  the U.S. Food and Drug Administration (FDA) has accepted for review the Ne
 w Drug Application for grazoprevir/elbasvir (100mg/50mg)\, an investigation
 al\, once-daily\, single-tablet combination therapy for the treatment of ad
 ult patients infected with chronic hepatitis C virus (HCV) genotypes (GT) 1
 \, 4 or 6.1 The FDA granted Priority Review for grazoprevir/elbasvir (100mg
 /50mg)\, with a Prescription Drug User Fee Act (PDUFA) action date of Janua
 ry 28\, 2016. http://www.businesswire.com/news/home/20150728005827/en/Merck
 -Announces-Second-Quarter-2015-Financial-Results
LAST-MODIFIED:20150729T140021Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:MRK MERCK PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20151219
DTSTAMP:20171003T193836Z
UID:gq93bktio235nb1stpcmmkqivc@google.com
CREATED:20150729T140011Z
DESCRIPTION:2015-12-19 The FDA has accepted the resubmission of the NDA for
  sugammadex injection\, an investigational medicine for the reversal of neu
 romuscular blockade induced by rocuronium or vecuronium\, with a PDUFA acti
 on date of Dec. 19\, 2015. http://www.businesswire.com/news/home/2015072800
 5827/en/Merck-Announces-Second-Quarter-2015-Financial-Results
LAST-MODIFIED:20150729T140011Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:MRK MERCK PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20150905
DTSTAMP:20171003T193836Z
UID:08d6os0vqgiknppg07fd328nls@google.com
CREATED:20150119T202329Z
DESCRIPTION:2015-09-05 Oral rolapitant\, an NK-1 receptor antagonist for th
 e prevention of chemotherapy-induced nausea and vomiting (CINV)\, is the su
 bject of a New Drug Application (NDA) that is currently under review by the
  U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee 
 Action (PDUFA) goal date of September 5\, 2015. http://www.globenewswire.co
 m/news-release/2015/01/12/696800/10115192/en/CORRECTING-and-REPLACING-TESAR
 O-Announces-Expansion-of-Niraparib-Clinical-Program-and-Outlines-Late-Stage
 -Program-Milestones-for-2015.html
LAST-MODIFIED:20150707T031853Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:TSRO TESARO\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20151023
DTSTAMP:20171003T193836Z
UID:7a149eb02fvna9lbtdtccffsk0@google.com
CREATED:20150310T140008Z
DESCRIPTION:2015-10-23 PDUFA decision expected October 23\, 2015\, 10 month
 s from NDA filing. http://www.businesswire.com/news/home/20150309005287/en/
 Spectrum-Pharmaceuticals-Announces-FDAs-Acceptance-NDA-Filing
LAST-MODIFIED:20150707T031853Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SPPI SPECTRUM PHARMACEUTICALS PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20150724
DTSTAMP:20171003T193836Z
UID:njad1vpr7bjtvgli5p7c5h4ia8@google.com
CREATED:20150127T150026Z
DESCRIPTION:2015-07-24 Under the Prescription Drug User Fee Act (PDUFA)\, t
 he goal for a priority review is six months\, for a target action date of J
 uly 24\, 2015. http://www.sec.gov/Archives/edgar/data/1121404/0001104659150
 04359/a15-3112_1ex99d8.htm
LAST-MODIFIED:20150707T031853Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SNY Sanofi PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20150818
DTSTAMP:20171003T193836Z
UID:g6ai2lb3dspvffv42ndvqt0hp8@google.com
CREATED:20150421T140011Z
DESCRIPTION:2015-08-18 -PDUFA Action Date August 18\, 2015- http://www.busi
 nesswire.com/news/home/20150420005165/en/FDA-Accepts-Supplemental-BLA-Grant
 s-Priority-Review
LAST-MODIFIED:20150707T031853Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SGEN SEATTLE GENETICS\, INC. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20151130
DTSTAMP:20171003T193836Z
UID:urh18lq1hlkiao20l02hogdphc@google.com
CREATED:20150416T140018Z
DESCRIPTION:2015-11-30 EXHIBIT 99.1 Repros Announces November 30\, 2015 PDU
 FA Goal Date for New Drug Application THE WOODLANDS\, Texas\, April 15\, 20
 15 (GLOBE NEWSWIRE) - Repros Therapeutics Inc. (Nasdaq:RPRX) today announce
 d that the U.S. Food and Drug Administration (FDA) assigned a Prescription 
 Drug User Fee Act (PDUFA) http://www.sec.gov/Archives/edgar/data/897075/000
 117184315001976/newsrelease.htm
LAST-MODIFIED:20150707T031853Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:RPRX REPROS THERAPEUTICS INC PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20151021
DTSTAMP:20171003T193836Z
UID:7h5fmbf3sd9k8g2lgc5fj1o88g@google.com
CREATED:20150119T202316Z
DESCRIPTION:2015-10-21 REDWOOD CITY\, Calif.\, Jan. 5\, 2015 (GLOBE NEWSWIR
 E) -- Relypsa\, Inc. (Nasdaq:RLYP)\, today announced that the U.S. Food and
  Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (P
 DUFA) action date of October 21\, 2015 for completion of the review of the 
 New Drug Application (NDA) for the investigational agent Patiromer for Oral
  Suspension (Patiromer FOS) for the treatment of hyperkalemia\, a serious c
 ondition defined as abnormally elevated levels of potassium in the blood. h
 ttp://www.globenewswire.com/news-release/2015/01/05/694921/10113653/en/Rely
 psa-Announces-Assignment-of-October-21-2015-PDUFA-Date-for-New-Drug-Applica
 tion-for-Patiromer-for-Oral-Suspension.html
LAST-MODIFIED:20150707T031853Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:RLYP Relypsa\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20150724
DTSTAMP:20171003T193836Z
UID:n39oulcnhvfm7rks8cvvacb0vs@google.com
CREATED:20150127T150015Z
DESCRIPTION:2015-07-24 Under the Prescription Drug User Fee Act (PDUFA)\, t
 he goal for a priority review is six months\, for a target action date of J
 uly 24\, 2015. http://www.prnewswire.com/news-releases/regeneron-and-sanofi
 -announce-praluent-alirocumab-biologics-license-application-has-been-accept
 ed-for-priority-review-by-us-fda-300025157.html
LAST-MODIFIED:20150707T031853Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:REGN Regeneron Pharmaceuticals\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20151225
DTSTAMP:20171003T193836Z
UID:j30570vbblgv8qmij3uc09vln4@google.com
CREATED:20150513T140019Z
DESCRIPTION:2015-12-25 The FDA has assigned a Prescription Drug User Fee Ac
 t (PDUFA) action date of December 25\, 2015. http://www.sec.gov/Archives/ed
 gar/data/1493566/000119312515183916/d923774dex991.htm
LAST-MODIFIED:20150707T031853Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:OTIC Otonomy Inc PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20150905
DTSTAMP:20171003T193836Z
UID:glulr3qij9bem5ft08isq54sb8@google.com
CREATED:20150302T150023Z
DESCRIPTION:2015-09-05 Rolapitant™ NDA Submitted by OPKO Licensee\, TESARO\
 ; Accepted for Review by FDA with a PDUFA date of September 5\, 2015\; OPKO
  Received $5 Million of $121 Million Total Potential Up Front and Milestone
  Payments http://www.businesswire.com/news/home/20150227006127/en/OPKO-Anno
 unces-Fourth-Quarter-Operating-Financial-Results
LAST-MODIFIED:20150707T031853Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:OPK OPKO HEALTH\, INC. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20151002
DTSTAMP:20171003T193836Z
UID:6t49135butr9sq64j2cl6of538@google.com
CREATED:20150602T140018Z
DESCRIPTION:2015-10-02 The FDA granted Priority Review with a PDUFA\, or ta
 rget action\, date of October 2\, 2015\; the sBLA will be reviewed under th
 e FDA’s Accelerated Approval program. http://www.businesswire.com/news/home
 /20150601006690/en/FDA-Accepts-Supplemental-Biologics-License-Application-s
 BLA
LAST-MODIFIED:20150707T031853Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:MRK MERCK PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20151024
DTSTAMP:20171003T193836Z
UID:s4ha2pvhusdmim0v0ga3mhttsg@google.com
CREATED:20150626T135954Z
DESCRIPTION:2015-10-24 The FDA has set a goal of October 24\, 2015 to take 
 action under the Prescription Drug User Fee Act (PDUFA). http://www.prnewsw
 ire.com/news-releases/us-fda-grants-priority-review-for-mm-398-new-drug-app
 lication-300104674.html
LAST-MODIFIED:20150707T031853Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:MACK Merrimack Pharmaceuticals\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20151023
DTSTAMP:20171003T193836Z
UID:if3aqk3abbbuq62tvpdfh8crmc@google.com
CREATED:20150512T140036Z
DESCRIPTION:2015-10-23 Spectrum Pharmaceuticals announced that its NDA for 
 Captisol-Enabled Melphalan was accepted by the FDA and assigned a PDUFA dat
 e of October 23\, 2015. http://www.businesswire.com/news/home/2015051100526
 1/en/Ligand-Reports-Quarter-2015-Financial-Results
LAST-MODIFIED:20150707T031853Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:LGND LIGAND PHARMACEUTICALS INCORPORATED PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20150726
DTSTAMP:20171003T193836Z
UID:0lfv9g2pl3qtogdemvtihnv6dc@google.com
CREATED:20150512T140020Z
DESCRIPTION:2015-07-26 The FDA granted Kyprolis priority review with a PDUF
 A date of July 26\, 2015. Additional Pipeline and Partner Developments Spec
 trum Pharmaceuticals announced that its NDA for Captisol-Enabled Melphalan 
 was accepted by the FDA and assigned a PDUFA date of October 23\, 2015. htt
 p://www.sec.gov/Archives/edgar/data/886163/000088616315000060/q12015earning
 srelease.htm
LAST-MODIFIED:20150707T031853Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:LGND LIGAND PHARMACEUTICALS INC PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20151104
DTSTAMP:20171003T193836Z
UID:39t8bh9arn1vhtro5fosmars0k@google.com
CREATED:20150612T140006Z
DESCRIPTION:2015-11-04 The Prescription Drug User Fee Act (PDUFA) goal date
  for mepolizumab is 4 November 2015. http://www.sec.gov/Archives/edgar/data
 /1131399/000119163815000804/gsk201506116k2.htm
LAST-MODIFIED:20150707T031853Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:GSK GLAXOSMITHKLINE PLC PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20151105
DTSTAMP:20171003T193836Z
UID:ic25g5lg5203d1okm1j9rvfee4@google.com
CREATED:20150702T140010Z
DESCRIPTION:2015-11-05 Under the PDUFA\, the FDA has set a target action da
 te of November 5\, 2015\, for E/C/F/TAF and April 7\, 2016\, for F/TAF. htt
 p://www.businesswire.com/news/home/20150701006447/en/Gilead-Submits-Drug-Ap
 plication-U.S.-Food-Drug
LAST-MODIFIED:20150707T031853Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:GILD GILEAD SCIENCES\, INC. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20151213
DTSTAMP:20171003T193836Z
UID:3b1erbpt47u8gnf3blit81vg8k@google.com
CREATED:20150513T140009Z
DESCRIPTION:2015-12-13 Our New Drug Application (“NDA”) for the rapid infus
 ion bendamustine product for the treatment of patients with CLL and patient
 s with indolent B-cell NHL that has progressed during or within six months 
 of treatment with rituximab or a rituximab-containing regime was accepted f
 or filing by the FDA with a December 13\, 2015 PDUFA date\; http://www.busi
 nesswire.com/news/home/20150512005169/en/Eagle-Pharmaceuticals-Reports-Quar
 ter-2015-Results
LAST-MODIFIED:20150707T031853Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:EGRX EAGLE PHARMACEUTICALS\, INC. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20151012
DTSTAMP:20171003T193836Z
UID:qt8nar4u7q0dmeaeuksm8qh9cc@google.com
CREATED:20150602T140008Z
DESCRIPTION:2015-10-12 The FDA set a Prescription Drug User Fee Act\, or PD
 UFA\, goal date of October 12\, 2015 for completion of its review of the Xt
 ampza NDA. http://www.globenewswire.com/news-release/2015/06/01/740815/1013
 6683/en/Collegium-Expands-Commercial-Organization-With-Key-Appointments.htm
 l
LAST-MODIFIED:20150707T031853Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:COLL Collegium Pharmaceutical PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20151227
DTSTAMP:20171003T193836Z
UID:cverjok9a7it8i6mv4kcdoa8k4@google.com
CREATED:20150630T140011Z
DESCRIPTION:2015-12-27 FDA PDUFA Date is December 27\, 2015 http://www.glob
 enewswire.com/news-release/2015/06/29/748147/10140004/en/BioMarin-Announces
 -FDA-Accepts-Drisapersen-NDA-for-Treatment-of-Duchenne-Muscular-Dystrophy-A
 menable-to-Exon-51-Skipping.html
LAST-MODIFIED:20150707T031853Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:BMRN BioMarin Pharmaceutical Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20151023
DTSTAMP:20171003T193836Z
UID:og0rdsvhhm5hib48caufg6lt24@google.com
CREATED:20150512T140010Z
DESCRIPTION:2015-10-23 BELBUCA™ (buprenorphine HCl) buccal film for treatme
 nt of chronic pain PDUFA date of October 23\, 2015 associated with $50 mill
 ion milestone if approved http://www.prnewswire.com/news-releases/biodelive
 ry-sciences-provides-corporate-update-and-reports-first-quarter-2015-financ
 ial-results-300080700.html
LAST-MODIFIED:20150707T031853Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:BDSI BioDelivery Sciences International\, PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20150827
DTSTAMP:20171003T193836Z
UID:sdcni3f0d5p667qokql8juoo78@google.com
CREATED:20150119T202258Z
DESCRIPTION:2015-08-27 The FDA has set a Prescription Drug User Fee Act (PD
 UFA) target action date of Aug. 27\, 2015\, for the evolocumab application.
  http://www.prnewswire.com/news-releases/fda-accepts-amgens-biologics-licen
 se-application-for-ldl-cholesterol-lowering-medication-evolocumab-282132321
 .html
LAST-MODIFIED:20150707T031853Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AMGN Amgen PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20150726
DTSTAMP:20171003T193836Z
UID:rgptjo1qcdcqecrghvgitetn9c@google.com
CREATED:20150331T140013Z
DESCRIPTION:2015-07-26 As part of the acceptance\, the FDA granted Kyprolis
  priority review with a Prescription Drug User Fee Act (PDUFA) target actio
 n date of July 26\, 2015. http://www.prnewswire.com/news-releases/fda-grant
 s-amgen-priority-review-for-kyprolis-carfilzomib-supplemental-new-drug-appl
 ication-for-the-treatment-of-relapsed-multiple-myeloma-300057440.html
LAST-MODIFIED:20150707T031853Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AMGN Amgen PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20150728
DTSTAMP:20171003T193836Z
UID:5mmac1lpjhhrd2di4kvrqc9lng@google.com
CREATED:20150120T061514Z
DESCRIPTION:2015-07-28 FDA has set a review goal date under the Prescriptio
 n Drug User Fee Act (PDUFA) of July 28\, 2015. http://www.prnewswire.com/ne
 ws-releases/new-trial-initiated-evaluating-amgens-talimogene-laherparepvec-
 in-combination-with-mercks-anti-pd-1-therapy-keytruda-pembrolizumab-for-adv
 anced-melanoma-300006422.html
LAST-MODIFIED:20150707T031853Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AMGN Amgen PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20151027
DTSTAMP:20171003T193836Z
UID:2a43iptu23snm84db6lf28nejk@google.com
CREATED:20150213T150004Z
DESCRIPTION:2015-10-27 The Prescription Drug User Fee Act (PDUFA) action da
 te for completion of FDA review of the talimogene laherparepvec BLA is Oct.
  27\, 2015. http://www.prnewswire.com/news-releases/amgen-announces-fda-adv
 isory-committees-to-review-talimogene-laherparepvec-for-the-treatment-of-pa
 tients-with-metastatic-melanoma-300034805.html
LAST-MODIFIED:20150707T031853Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AMGN Amgen PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20150822
DTSTAMP:20171003T193836Z
UID:8bfqq7aaukh6u1f94ila49q8sk@google.com
CREATED:20150119T202251Z
DESCRIPTION:2015-08-22 A New Drug Application (NDA) for aripiprazole laurox
 il one-month is currently under review with the U.S. Food and Drug Administ
 ration (FDA) and has been assigned a Prescription Drug User Fee Act (PDUFA)
  date of Aug. 22\, 2015. http://www.businesswire.com/news/home/201412150051
 00/en/Alkermes-Announces-Initiation-Clinical-Study-Extended-Durations
LAST-MODIFIED:20150707T031853Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ALKS ALKERMES PLC PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20150705
DTSTAMP:20171003T193836Z
UID:i33oaif8ou3jtnn2okodvd86f8@google.com
CREATED:20150113T150001Z
DESCRIPTION:2015-07-05 The FDA granted Vertex s request for Priority Review
 \, with a target review (PDUFA) date of July 5\, 2015 for the FDA's approva
 l decision. http://www.sec.gov/Archives/edgar/data/875320/00008753201500000
 2/jpmpressrelease.htm
LAST-MODIFIED:20150702T094532Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:VRTX VERTEX PHARMACEUTICALS INC MA PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20150623
DTSTAMP:20171003T193836Z
UID:9lg5pg4t9nvkneosj6i762o3d4@google.com
CREATED:20150506T140013Z
DESCRIPTION:2015-06-23 The PDUFA date is June 23\, 2015. http://www.busines
 swire.com/news/home/20150505005666/en/Medicines-Company-Reports-Quarter-201
 5-Financial-Results
LAST-MODIFIED:20150506T140014Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:MDCO THE MEDICINES COMPANY PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20150528
DTSTAMP:20171003T193836Z
UID:7t92e98eg5bap5ekn2pbbmkbko@google.com
CREATED:20150430T140015Z
DESCRIPTION:2015-05-28 Valeant currently in labeling discussions with the F
 DA regarding IBS-D indication for Xifaxan\, ahead of the May 28\, 2015 PDUF
 A date http://www.prnewswire.com/news-releases/valeant-pharmaceuticals-repo
 rts-first-quarter-2015-financial-results-300074030.html
LAST-MODIFIED:20150430T140015Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:VRX Valeant Pharmaceuticals Internation PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20150622
DTSTAMP:20171003T193836Z
UID:qjo5kmodqicdhi5bs2emahuulg@google.com
CREATED:20150302T150013Z
DESCRIPTION:2015-06-22 The Prescription Drug User Fee Act (PDUFA) goal date
  for a decision is June 22\, 2015. http://www.businesswire.com/news/home/20
 150227005922/en/U.S.-Food-Drug-Administration-Accepts-Biologics-Licensing
LAST-MODIFIED:20150302T150013Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:BMY BRISTOL-MYERS SQUIBB COMPANY PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20150430
DTSTAMP:20171003T193836Z
UID:md476jvash6nvf1g6c405opg7g@google.com
CREATED:20150209T150007Z
DESCRIPTION:2015-04-30 The Prescription Drug User Fee Act (PDUFA) goal date
  is April 30\, 2015. http://www.marketwired.com/press-release/theravance-an
 nounces-fda-advisory-committee-review-breor-elliptar-ff-vi-asthma-nasdaq-th
 rx-1989486.htm
LAST-MODIFIED:20150209T150008Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:THRX Theravance\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20150430
DTSTAMP:20171003T193836Z
UID:tp2r458q8j7t4d7oqopet4f4f4@google.com
CREATED:20150128T150010Z
DESCRIPTION:2015-04-30 The FDA has set a Prescription Drug User Fee Act (PD
 UFA) target date for conclusion of its review of 30 April 2015. http://www.
 marketwired.com/press-release/vernalis-plc-announces-fda-accepts-tuzistra-x
 r-nda-for-full-review-lse-ver-1946925.htm
LAST-MODIFIED:20150128T150011Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:VNLPY Vernalis PLC PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20150222
DTSTAMP:20171003T193836Z
UID:daarldgffrtn3a8c5p3lpuqkng@google.com
CREATED:20141024T050302Z
DESCRIPTION:20141023 The U.S. Food and Drug Administration (FDA) has assign
 ed a Prescription Drug User Fee Act (PDUFA) goal date of February 22\, 2015
 .
LAST-MODIFIED:20150127T075522Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:CELG CELGENE CORP DE PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20150201
DTSTAMP:20171003T193836Z
UID:u79rajsq5qgah8m7q8bn0sgeso@google.com
CREATED:20150120T061517Z
DESCRIPTION:2015-02-01 The PDUFA date is February 1\, 2015. http://www.prne
 wswire.com/news-releases/shire-rd-day-profiles-innovative-pipeline-expected
 -to-contribute-3-billion-in-product-sales-by-2020-285335181.html
LAST-MODIFIED:20150120T061517Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SHPG Shire plc PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20150417
DTSTAMP:20171003T193836Z
UID:gcmuno7dhqoqag7rrib03ab448@google.com
CREATED:20150120T061515Z
DESCRIPTION:2015-04-17 SUNNYVALE\, Calif.\, Dec. 22\, 2014 /PRNewswire/ -- 
 Pharmacyclics\, Inc. (NASDAQ: PCYC) announced today that the U.S Food and D
 rug Administration (FDA) has provided a Prescription Drug User Fee Act (PDU
 FA) target date of April 17\, 2015 by which time the FDA is planning to fin
 alize its review of a supplemental New Drug Application (sNDA) for IMBRUVIC
 A (ibrutinib) as a treatment for patients with Waldenstrom's macroglobuline
 mia (WM). http://www.prnewswire.com/news-releases/pharmacyclics-announces-u
 pdate-on-imbruvica-ibrutinib-waldenstroms-macroglobulinemia-wm-submission-3
 00012925.html
LAST-MODIFIED:20150120T061516Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:PCYC Pharmacyclics\, Inc. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20150305
DTSTAMP:20171003T193836Z
UID:jfvekda346624fue03k5denvno@google.com
CREATED:20150120T061515Z
DESCRIPTION:2015-03-05 Pacira has submitted a supplemental New Drug Applica
 tion (sNDA) to the U.S. Food and Drug Administration (FDA) for a nerve bloc
 k indication for EXPAREL\, with a target Prescription Drug User Fee Act (PD
 UFA) date of March 5\, 2015. http://www.businesswire.com/news/home/20141212
 005065/en/Pacira-Pharmaceuticals-Announces-EXPAREL%C2%AE-Label
LAST-MODIFIED:20150120T061515Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:PCRX PACIRA PHARMACEUTICALS\, INC. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20150519
DTSTAMP:20171003T193836Z
UID:1fnqmcs35jame4me5hodqegdc4@google.com
CREATED:20150120T061514Z
DESCRIPTION:2015-05-19 The BLA is for the treatment of adults with Philadel
 phia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leu
 kemia (ALL)\, a rapidly progressing cancer of the blood and bone marrow.1 A
 s part of the acceptance\, the FDA granted blinatumomab priority review wit
 h a Prescription Drug User Fee Act (PDUFA) action date of May 19\, 2015. ht
 tp://www.prnewswire.com/news-releases/amgens-bite-immunotherapy-blinatumoma
 b-receives-fda-priority-review-designation-in-acute-lymphoblastic-leukemia-
 278704401.html
LAST-MODIFIED:20150120T061514Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AMGN Amgen PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20150317
DTSTAMP:20171003T193836Z
UID:4lk0rr29tt3935qpiq2uq3l4as@google.com
CREATED:20150119T202333Z
DESCRIPTION:2015-03-17 Vertex today announced that its New Drug Application
  (NDA) for the use of ivacaftor in children ages 2 to 5 who have the G551D 
 or one of the eight additional gating mutations was accepted for filing by 
 the Food and Drug Administration (FDA)\, and a target review date of March 
 17\, 2015 was set under the Prescription Drug User Fee Act (PDUFA) for the 
 FDA's approval decision. http://www.businesswire.com/news/home/201501110050
 88/en/Vertex-Outlines-2015-Business-Priorities-Support-Development
LAST-MODIFIED:20150119T202334Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:VRTX VERTEX PHARMACEUTICALS INCORPORATED PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20150124
DTSTAMP:20171003T193836Z
UID:d7s9vscntf250qcrgpa3frfcfc@google.com
CREATED:20150119T202320Z
DESCRIPTION:2015-01-24 NATPARA/NATPAR\, NPS Pharma's parathyroid hormone (r
 hPTH [1-84]) for the treatment of hypoparathyroidism (HPT)\, a rare endocri
 ne disorder characterized by insufficient levels of parathyroid hormone (PT
 H)\, is currently under review in the U.S. with an FDA Prescription Drug Us
 er Fee Act (PDUFA) action date for the Biologics License Application (BLA) 
 on January 24\, 2015. http://www.prnewswire.com/news-releases/plshire-to-ac
 quire-nps-pharma-as-further-step-in-building-a-leading-biotech-288188461.ht
 ml
LAST-MODIFIED:20150119T202320Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SHPG Shire plc and NPS PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20150413
DTSTAMP:20171003T193836Z
UID:5th5gdihdjn6ol4309iii7d1oc@google.com
CREATED:20150119T202312Z
DESCRIPTION:2015-04-13 The Prescription Drug User Fee Act (PDUFA) goal date
  for a decision by the FDA is April 13\, 2015. http://www.businesswire.com/
 news/home/20150108005536/en/Pfizer-Update-IBRANCE%C2%AE-palbociclib
LAST-MODIFIED:20150119T202313Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:PFE PFIZER INC. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20141020
DTSTAMP:20171003T193836Z
UID:eb01tbqoihp36t6t9rrtrfumfk@google.com
CREATED:20150119T202303Z
DESCRIPTION:2014-10-20 The PDUFA date by which the FDA is expected to take 
 action on the sBLA is October 20\, 2014. http://www.prnewswire.com/news-rel
 eases/biospecifics-technologies-corp-announces-new-multicord-and-retreatmen
 t-data-for-xiaflex-for-dupuytrens-contracture-presented-at-american-society
 -for-surgery-of-the-hand-annual-meeting-275649051.html
LAST-MODIFIED:20150119T202303Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:BSTC BioSpecifics Technologies Corp. PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20150430
DTSTAMP:20171003T193836Z
UID:dbnj67715jure5kom633cb27qo@google.com
CREATED:20150110T203046Z
DESCRIPTION:2015-04-30 The FDA action date\, known as the PDUFA date\, whic
 h is the date by which the FDA is expected to make a decision on the sNDA\,
  is April 30\, 2015. http://www.sec.gov/Archives/edgar/data/1113481/0001104
 65915000742/a14-26266_28k.htm
LAST-MODIFIED:20150110T203046Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:MDCO MEDICINES CO DE PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20150124
DTSTAMP:20171003T193836Z
UID:606jc53gj2da0tkc7j73q0slps@google.com
CREATED:20141226T025503Z
DESCRIPTION:2014-11-17 Rockwell s lead investigational drug Triferic is cur
 rently under NDA review by the FDA for the treatment of iron replacement an
 d hemoglobin maintenance in dialysis patients\, with a PDUFA date of Januar
 y 24\, 2015.\nhttp://www.sec.gov/Archives/edgar/data/1041024/00011046591408
 1384/a14-24600_2ex99d1.htm
LAST-MODIFIED:20141226T025503Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:RMTI ROCKWELL MEDICAL INC PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20150130
DTSTAMP:20171003T193836Z
UID:38iohpvhmn13g9bf1f8ljfj2bk@google.com
CREATED:20141107T060041Z
DESCRIPTION:20141106 The The FDA assigned a Prescription Drug User Free Act
 \, or PDUFA\, target action date on the sNDA of January 30\, 2015\, and\, i
 f approved\, we anticipate a transition from the currently marketed product
  to this new capsule formulation of Zohydro ER in the second quarter of 201
 5.
LAST-MODIFIED:20141107T060042Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ZGNX ZOGENIX INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20141105
DTSTAMP:20171003T193836Z
UID:9mtlk396d523ekgbg7feh66i1g@google.com
CREATED:20141105T060034Z
DESCRIPTION:20141104 The results from the FDA's review are expected imminen
 tly\, as the NDA has a Prescription Drug User Fee Act ("PDUFA") date of Nov
 ember 5\, 2014\, which is the goal date for the FDA to complete its review 
 of the NDA.
LAST-MODIFIED:20141105T060034Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AEZS Aeterna Zentaris Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20150109
DTSTAMP:20171003T193836Z
UID:ohrinndcsv1fb947de4r12os3o@google.com
CREATED:20141102T050037Z
DESCRIPTION:20141031 A New Drug Application is pending at the FDA with a Pr
 escription Drug User Fee Act (PDUFA) review date of January 9\, 2015.
LAST-MODIFIED:20141102T050038Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:IPXL IMPAX LABORATORIES INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20141221
DTEND;VALUE=DATE:20141222
DTSTAMP:20171003T193836Z
UID:dami29uur9ld0vvo1vq4nruk7g@google.com
ATTENDEE;CUTYPE=INDIVIDUAL;ROLE=REQ-PARTICIPANT;PARTSTAT=ACCEPTED;CN=PDUFA;
 X-NUM-GUESTS=0:mailto:5dso8589486irtj53sdkr4h6ek@group.calendar.google.com
CREATED:20141031T074450Z
DESCRIPTION:http://ir.enanta.com/phoenix.zhtml?c=147990&p=irol-newsArticle&
 ID=1939816
LAST-MODIFIED:20141031T074505Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ABBV PDUFA
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20141221
DTEND;VALUE=DATE:20141222
DTSTAMP:20171003T193836Z
UID:8m55h26asuer521jqcc05p9c80@google.com
CREATED:20141031T074320Z
DESCRIPTION:http://ir.enanta.com/phoenix.zhtml?c=147990&p=irol-newsArticle&
 ID=1939816
LAST-MODIFIED:20141031T074320Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ENTA PDUFA
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20150104
DTEND;VALUE=DATE:20150105
DTSTAMP:20171003T193836Z
UID:ouofpqhmja203b3pgs6t65k3pg@google.com
ATTENDEE;CUTYPE=INDIVIDUAL;ROLE=REQ-PARTICIPANT;PARTSTAT=ACCEPTED;CN=PDUFA;
 X-NUM-GUESTS=0:mailto:5dso8589486irtj53sdkr4h6ek@group.calendar.google.com
CREATED:20141031T073719Z
DESCRIPTION:http://investor.frx.com/press-release/product-news/forest-labor
 atories-and-adamas-pharmaceuticals-announce-forests-submissio
LAST-MODIFIED:20141031T073728Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:FRX PDUFA
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20150104
DTEND;VALUE=DATE:20150105
DTSTAMP:20171003T193836Z
UID:hcdp4lks2969f57qqftne0eoqk@google.com
CREATED:20141031T073705Z
DESCRIPTION:http://investor.frx.com/press-release/product-news/forest-labor
 atories-and-adamas-pharmaceuticals-announce-forests-submissio
LAST-MODIFIED:20141031T073710Z
LOCATION:
SEQUENCE:1
STATUS:CONFIRMED
SUMMARY:ADMS PDUFA
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20141230
DTEND;VALUE=DATE:20141231
DTSTAMP:20171003T193836Z
UID:2qqm5nb8aujr23euukhqildcf4@google.com
CREATED:20141031T072802Z
DESCRIPTION:https://finance.yahoo.com/news/pozn-solid-second-quarter-financ
 ial-191500644.html
LAST-MODIFIED:20141031T072802Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:POZN PDUFA
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20150228
DTEND;VALUE=DATE:20150301
DTSTAMP:20171003T193836Z
UID:ts7pd026mg3bugm3c124np36nk@google.com
CREATED:20141031T071135Z
DESCRIPTION:http://news.salix.com/press-release/salix-announces-fda-user-fe
 e-goal-date-february-28-2015-xifaxan-550mg-snda-treatment
LAST-MODIFIED:20141031T071135Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SLXP Salix Pharmaceuticals PDUFA
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20110714
DTSTAMP:20171003T193836Z
UID:96isaf4odfvgoee4aeqnuadb7g@google.com
CREATED:20110220T080804Z
DESCRIPTION:20110131 Exhibit 99.1 Transcept Pharmaceuticals Announces Inter
 mezzo PDUFA Action Date of July 14\, 2011 Point Richmond\, Calif.\, January
  31\, 2011 Transcept Pharmaceuticals\, Inc. (Nasdaq: TSPT) today announced 
 that the U.S. Food and Drug Administration (FDA) has classified the recent 
 Intermezzo New
LAST-MODIFIED:20140923T121516Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:TSPT Transcept Pharmaceuticals Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20130512
DTSTAMP:20171003T193836Z
UID:slddleofhq547cdudqiovesv2k@google.com
CREATED:20121026T053443Z
DESCRIPTION:20120926 The Prescription Drug User Fee Act (PDUFA) goal date h
 as also been confirmed as May 12\, 2013.
LAST-MODIFIED:20140923T121516Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:THRX THERAVANCE INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20110825
DTEND;VALUE=DATE:20110826
DTSTAMP:20171003T193836Z
UID:e1brj8npr09v4e38rha0acrm5k@google.com
CREATED:20110406T175739Z
DESCRIPTION:20110321 Exhibit 99.1 Press Release www.shire.com FDA Assigns P
 DUFA Date for Shire s FIRAZYR (icatibant) for the Treatment of Acute Attack
 s of Hereditary Angioedema Dublin\, Ireland and Lexington\, Massachusetts\,
  US March 21\, 2011 Shire plc (LSE: SHP\, NASDAQ: SHPGY)\, the global speci
 alty
LAST-MODIFIED:20140923T121516Z
LOCATION:
SEQUENCE:2
STATUS:CONFIRMED
SUMMARY:SHPGY Shire plc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20110623
DTSTAMP:20171003T193836Z
UID:qsmpk7avcccc3cvff4pg7laa4c@google.com
CREATED:20110220T080752Z
DESCRIPTION:20110203 The FDA has set a Prescription Drug User Fee Act (PDUF
 A) goal date of June 23\, 2011.
LAST-MODIFIED:20140923T121516Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:PTIE PAIN THERAPEUTICS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20110829
DTSTAMP:20171003T193836Z
UID:1tm3upn6ar4bf3vngnvjds8b3k@google.com
CREATED:20110406T175740Z
DESCRIPTION:20110318 The Prescription Drug User Fee Act date\, or PDUFA dat
 e\, for our NDA is August 29\, 2011. The PDUFA date is the target date for 
 the FDA to complete its review of the NDA.
LAST-MODIFIED:20140923T121516Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:PATH NUPATHE INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20110530
DTSTAMP:20171003T193836Z
UID:4cabg1o0adrauhonh7s22osb10@google.com
CREATED:20110406T175743Z
DESCRIPTION:20110310 The FDA granted the Company s request for six-month Pr
 iority Review of fidaxomicin\, and has assigned a Prescription Drug User Fe
 e Act (PDUFA) goal date of May 30\, 2011.
LAST-MODIFIED:20140923T121516Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:OPTR OPTIMER PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20130531
DTSTAMP:20171003T193836Z
UID:hb45la9eodfbn82n4grbls2llg@google.com
CREATED:20121026T053440Z
DESCRIPTION:20121019 Flamel has received a Prescription Drug User Fee Act (
 PDUFA) date\, the target date for the FDA to complete its review of the NDA
 \, of May 31\, 2013.
LAST-MODIFIED:20140923T121516Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:FLML FLAMEL TECHNOLOGIES SA PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20110615
DTSTAMP:20171003T193836Z
UID:cv4alk5l2t8tatcfb9h59qtlv0@google.com
CREATED:20110220T080804Z
DESCRIPTION:20110127 A new PDUFA date of June 15\, 2011\, was set. In Janua
 ry\, the Company and its partner\, sanofi-aventis\, voluntarily withdrew ce
 rtain lots of AVALIDE from the U.S.\, Puerto Rican\, Canadian\, Mexican and
  Argentinean markets.
LAST-MODIFIED:20140923T121516Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:BRISTOL MYERS SQUIBB CO PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20110901
DTEND;VALUE=DATE:20110902
DTSTAMP:20171003T193836Z
UID:llldefm3mr4c131atth4tffl84@google.com
CREATED:20110125T183432Z
DESCRIPTION:20110119 ADVENTRX PHARMACEUTICALS RECEIVES PDUFA DATE FOR EXELB
 INE NDA SAN DIEGO January 19\, 2011 ADVENTRX Pharmaceuticals\, Inc. (NYSE A
 mex: ANX) announced today that the U.S. Food and Drug Administration (FDA) 
 has established a Prescription Drug User Fee Act (PDUFA) date of September 
 1\, 2011 for
LAST-MODIFIED:20140923T121516Z
LOCATION:
SEQUENCE:2
STATUS:CONFIRMED
SUMMARY:ANX ADVENTRX PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20110617
DTSTAMP:20171003T193836Z
UID:5hm4tu9rh0mutcde0t83gb91qg@google.com
CREATED:20110406T173736Z
DESCRIPTION:20110301 The priority review classification establishes a non-b
 inding date of June 17\, 2011 for the FDA to complete its review of the Acu
 rox Tablets NDA under the Prescription Drug User Fee Act (PDUFA).
LAST-MODIFIED:20140923T121516Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ACUR ACURA PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20141020
DTSTAMP:20171003T193836Z
UID:7fb5npvvjbo3nj7is057pfjles@google.com
CREATED:20140920T155702Z
DESCRIPTION:20140912 The Prescription Drug User Fee Act (PDUFA) date for co
 mpletion of the FDA review of the Saxenda NDA is 20 October 2014.
LAST-MODIFIED:20140920T155702Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:NVO NOVO NORDISK A S PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20141024
DTSTAMP:20171003T193836Z
UID:ql5d2ca2bju6vsusrfb32rojrg@google.com
CREATED:20140920T155701Z
DESCRIPTION:20140912 The Committee s recommendation will be considered by t
 he FDA in its review of the company s Biologics License Application (BLA) f
 or Natpara\, which has a Prescription Drug User Fee Act (PDUFA) date of Oct
 ober 24\, 2014. We are very pleased with the Committee s vote.
LAST-MODIFIED:20140920T155701Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:NPSP NPS PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20141020
DTSTAMP:20171003T193836Z
UID:mkvtpnkjibrtuifs2nu7v2m2rg@google.com
CREATED:20140920T155701Z
DESCRIPTION:20140918 The PDUFA date for the sBLA is October 20\, 2014.
LAST-MODIFIED:20140920T155701Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AUXL AUXILIUM PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20141223
DTSTAMP:20171003T193836Z
UID:4fhc9s87hiumo66n9k0cul1g48@google.com
CREATED:20140920T155556Z
DESCRIPTION:20140805 Earlier this year\, the i.v. peramivir New Drug Applic
 ation (NDA) was accepted by the FDA\, which also set a PDUFA date of Decemb
 er 23\, 2014.
LAST-MODIFIED:20140920T155556Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:BCRX BIOCRYST PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140607
DTSTAMP:20171003T193836Z
UID:3rje11urlue6nrnbiguhb30ck8@google.com
CREATED:20140920T155553Z
DESCRIPTION:20140807 Our New Drug Application\, or NDA\, is currently under
  review by the FDA and was originally assigned a Prescription Drug User Fee
  Act\, or PDUFA\, goal date of June 7\, 2014. On May 21\, 2014\, we receive
 d notice from the FDA that the PDUFA goal date was extended to September 7\
 , 2014.
LAST-MODIFIED:20140920T155553Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:KERX KERYX BIOPHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140918
DTSTAMP:20171003T193836Z
UID:7lbq75b460hl5eqbbggn79089g@google.com
CREATED:20140920T155552Z
DESCRIPTION:20140807 The Prescription Drug User Fee Act (PDUFA) date for th
 e completion of the FDA s review of the sNDA is September 18\, 2014.
LAST-MODIFIED:20140920T155552Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:MDVN MEDIVATION INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20131220
DTSTAMP:20171003T193836Z
UID:v4aq1aonp6jr0ilqm4ol2bnuf0@google.com
CREATED:20140920T155550Z
DESCRIPTION:20140807 The FDA did not take action on the ANCHOR sNDA by the 
 Prescription Drug User Fee Act\, or PDUFA\, goal date for completion of FDA
  s review\, December 20\, 2013. No new PDUFA goal date for the ANCHOR sNDA 
 was established.
LAST-MODIFIED:20140920T155550Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AMRN AMARIN CORP PLC UK PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140911
DTSTAMP:20171003T193836Z
UID:95l1nhqshkhedlq4qd3i4v6cik@google.com
CREATED:20140920T155550Z
DESCRIPTION:20140807 The new Prescription Drug User Fee Act (PDUFA) action 
 date has been set for September 11\, 2014.
LAST-MODIFIED:20140920T155550Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:OREX Orexigen Therapeutics Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20141126
DTSTAMP:20171003T193836Z
UID:9hjnced468fqunn87t1fi49e6c@google.com
CREATED:20140920T155549Z
DESCRIPTION:20140807 In March 2014\, the FDA accepted the Company s New Dru
 g Application ( NDA ) and the Prescription Drug User Fee Act (PDUFA) date i
 s scheduled for November 26\, 2014.
LAST-MODIFIED:20140920T155549Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AVNR AVANIR PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20150513
DTSTAMP:20171003T193836Z
UID:kdg7c5a704n1gfrjc0610lm1ho@google.com
CREATED:20140920T155547Z
DESCRIPTION:20140807 The NDA will be subject to a standard review and will 
 have a Prescription Drug User Fee Act (PDUFA) action date of May 13\, 2015.
  The PDUFA date is the goal date for the FDA to complete its review of the 
 NDA.
LAST-MODIFIED:20140920T155548Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:KYTH KYTHERA BIOPHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140926
DTSTAMP:20171003T193836Z
UID:oahuuj6umo24com6ebn28kvvkc@google.com
CREATED:20140920T155547Z
DESCRIPTION:20140811 In April 2014\, the Company was notified by the FDA th
 at the resubmission of its NDA for ILUVIEN had been acknowledged as receive
 d by the FDA as a complete class 2 response to the third CRL\, and that a P
 rescription Drug User Fee Act (PDUFA) goal date of September 26\, 2014 had 
 been established.
LAST-MODIFIED:20140920T155547Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ALIM ALIMERA SCIENCES INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140920
DTSTAMP:20171003T193836Z
UID:gbrh413jd9hrsk49bs3m1i8vk8@google.com
CREATED:20140920T155546Z
DESCRIPTION:20140812 The PDUFA date for this application is September 20\, 
 2014.
LAST-MODIFIED:20140920T155546Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:VVUS VIVUS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20141123
DTSTAMP:20171003T193836Z
UID:oqr3ktf0g49ulj8tvk0et6uta4@google.com
CREATED:20140920T155545Z
DESCRIPTION:20140825 This medicine has already been approved in Canada and 
 the EU. In the U.S.\, pirfenidone was granted breakthrough designation in J
 uly 2014 and the PDUFA date is November 23\, 2014.
LAST-MODIFIED:20140920T155545Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ITMN INTERMUNE INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140926
DTSTAMP:20171003T193836Z
UID:ifuatuc29l0soucgrqqln3deuc@google.com
CREATED:20140920T155543Z
DESCRIPTION:20140909 The New Drug Application (NDA) was refiled earlier thi
 s year\, with a resulting Prescription Drug User Fee Act (PDUFA) goal date 
 of September 26\, 2014.
LAST-MODIFIED:20140920T155543Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:PSDV pSivida Corp PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20141119
DTSTAMP:20171003T193836Z
UID:c0dcnc3j54au3ol4b5c6082010@google.com
CREATED:20140820T045957Z
DESCRIPTION:20140819 Page 1 PDL BioPharma\, Inc. Q2 2014 August 19\, 2014 O
 n July 21\, 2014\, Genentech announced that its application for approval fo
 r the treatment of recurrent platinum-resistant ovarian cancer in US had be
 en granted priority review with a PDUFA date of November 19\, 2014.
LAST-MODIFIED:20140820T072555Z
LOCATION:
SEQUENCE:2
STATUS:CONFIRMED
SUMMARY:PDL BIOPHARMA INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20141003
DTSTAMP:20171003T193836Z
UID:ki5ptfphrolhk932a9388bo0ic@google.com
CREATED:20140802T045959Z
DESCRIPTION:20140731 The FDA granted priority review status for the NDA in 
 April and set a Prescription Drug User Fee Act (PDUFA) action date of 3 Oct
 ober 2014.
LAST-MODIFIED:20140802T045959Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ASTRAZENECA PLC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140916
DTSTAMP:20171003T193836Z
UID:4sr5rll5bhlvqce3l3lg04mcr8@google.com
CREATED:20140801T045956Z
DESCRIPTION:20140731 The scheduled Prescription Drug User Fee Act (PDUFA) d
 ate for MOVANTIK TM is September 16\, 2014. The FDA endeavors to complete i
 ts review of NDAs by the PDUFA date but does not always do so.
LAST-MODIFIED:20140801T045956Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:NEKTAR THERAPEUTICS PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20141221
DTSTAMP:20171003T193836Z
UID:cre4aj3dekduvkbb0qnd91m80o@google.com
CREATED:20140724T050000Z
DESCRIPTION:20140722 The FDA has assigned a Prescription Drug User Fee Act 
 (PDUFA) action date of December 21\, 2014.
LAST-MODIFIED:20140724T050000Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:CUBIST PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20141003
DTSTAMP:20171003T193836Z
UID:iogupjpn8fl834hf80ht5ckras@google.com
CREATED:20140724T045959Z
DESCRIPTION:20140723 FDA set target review dates under the Prescription Dru
 g User Fee Act (PDUFA) of October 3\, 2014 for cobicistat and October 4\, 2
 014 for elvitegravir. The FDA set a target action date under PDUFA of Octob
 e
LAST-MODIFIED:20140724T045959Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:GILEAD SCIENCES INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140627
DTEND;VALUE=DATE:20140628
DTSTAMP:20171003T193836Z
UID:d1mq2g2rhm9fum4ifjrs40rj6s@google.com
CREATED:20140408T050008Z
DESCRIPTION:20140407 On April 7\, 2014\, we announced that the U.S. Food an
 d Drug Administration (FDA) has extended the Prescription Drug User Fee Act
  (PDUFA) date for AFREZZA by three months to July 15\, 2014 in order to pro
 vide time for a full review of information submitted by us in response to t
 he FDA's requests.
LAST-MODIFIED:20140702T055001Z
LOCATION:
SEQUENCE:4
STATUS:CONFIRMED
SUMMARY:MNKD MANNKIND CORP PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140916
DTSTAMP:20171003T193836Z
UID:lo8tcd23h2elq58kum89avkk3g@google.com
CREATED:20140630T140655Z
DESCRIPTION:20140613 The Prescription Drug User Fee Act (PDUFA) date set by
  the FDA for MOVANTIK is 16 September 2014.
LAST-MODIFIED:20140630T140656Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ASTRAZENECA PLC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20141016
DTSTAMP:20171003T193836Z
UID:3448gecvj0ec0ppd59091anjbk@google.com
CREATED:20140630T140655Z
DESCRIPTION:20140616 This second sNDA focuses on more flexible and extended
  utilization practices\, and has been assigned a PDUFA date set for October
  16\, 2014.
LAST-MODIFIED:20140630T140655Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:NAVIDEA BIOPHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140907
DTSTAMP:20171003T193836Z
UID:dirk9r6p8r1bjok31lu628dhhk@google.com
CREATED:20140524T050006Z
DESCRIPTION:20140522 The new PDUFA goal date is September 7\, 2014.
LAST-MODIFIED:20140524T050006Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:KERYX BIOPHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140722
DTSTAMP:20171003T193836Z
UID:erp7e414463kko5rruge43o0cc@google.com
CREATED:20140516T045958Z
DESCRIPTION:20140514 The U.S. Food and Drug Administration ( FDA ) granted 
 priority review to our New Drug Application ( NDA ) for Ryanodex \, our enh
 anced formulation of dantrolene sodium for injectable suspension ( dantrole
 ne ) for use in malignant hypothermia ( MH )\; the PDUFA date is July 22\, 
 2014.
LAST-MODIFIED:20140516T045958Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:EAGLE PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140729
DTSTAMP:20171003T193836Z
UID:faoa0mdbmr0vbuuk4ji45607ao@google.com
CREATED:20140514T050001Z
DESCRIPTION:20140512 The Company submitted a New Drug Application (NDA) for
  Kerydin in July 2013\, which was accepted for review by the United States 
 Food and Drug Administration (FDA) in September 2013 with a Prescription Dr
 ug User Fee Act (PDUFA) V goal date of July 29\, 2014.
LAST-MODIFIED:20140514T050001Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:Anacor Pharmaceuticals Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20141003
DTSTAMP:20171003T193836Z
UID:9mc1j7v3otcmckf5k86sd05u8c@google.com
CREATED:20140507T050005Z
DESCRIPTION:20140506 AstraZeneca recently announced that it has received pr
 iority review status from the FDA for olaparib with a PDUFA date of October
  3\, 2014 setting up a potential FDA approval for olaparib in late calendar
  year 2014.
LAST-MODIFIED:20140507T050005Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:MYRIAD GENETICS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20141010
DTSTAMP:20171003T193836Z
UID:3c7i443qtcbu3hvli7kbhn5u84@google.com
CREATED:20140423T050004Z
DESCRIPTION:20140422 The FDA has set a target review date under the Prescri
 ption Drug User Fee Act (PDUFA) of October 10\, 2014.
LAST-MODIFIED:20140423T050005Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:GILEAD SCIENCES INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140607
DTSTAMP:20171003T193836Z
UID:u6cjmbvjktc7hu3p9hmjh5sak0@google.com
CREATED:20140328T050008Z
DESCRIPTION:20140327 BUNAVAIL is currently under review at the U.S. Food an
 d Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) d
 ate of June 7\, 2014.
LAST-MODIFIED:20140328T050009Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:BDSI BIODELIVERY SCIENCES INTERNATIONAL INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140415
DTSTAMP:20171003T193836Z
UID:fotpenui66oa5f9ue5hm2imqjs@google.com
CREATED:20140327T050007Z
DESCRIPTION:20140326 Albiglutide is currently undergoing review by other au
 thorities\, including the US Food and Drug Administration (FDA) and the US 
 Prescription Drug User Fee Act (PDUFA) target date is 15 April 2014.
LAST-MODIFIED:20140327T050008Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:GSK GLAXOSMITHKLINE PLC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140727
DTSTAMP:20171003T193836Z
UID:iufihtp91crgjtmdp9m1uc1a4g@google.com
CREATED:20140307T060004Z
DESCRIPTION:20140305 The acceptance indicates the FDA has determined that t
 he application is sufficiently complete to permit a substantive review and 
 the FDA has subsequently confirmed a PDUFA action date of July 27\, 2014.
LAST-MODIFIED:20140307T060004Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ACRX ACELRX PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140405
DTSTAMP:20171003T193836Z
UID:gn2ojf6lvvdt6n7fcd147ntcg4@google.com
CREATED:20140226T071734Z
DESCRIPTION:20140225 The FDA established a 4-month PDUFA goal\, April 5\, 2
 014\, for approval of the manufacturing PAS.
LAST-MODIFIED:20140226T071735Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:PCRX Pacira Pharmaceuticals Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140616
DTSTAMP:20171003T193836Z
UID:opcvlfvmssmnj4a45qm43837vs@google.com
CREATED:20140220T060006Z
DESCRIPTION:20140219 Under the Prescription Drug User Fee Act (PDUFA)\, the
  FDA has set a target review date for the Lymphoseek sNDA of June 16\, 2014
 .
LAST-MODIFIED:20140220T060007Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:NAVB NAVIDEA BIOPHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140809
DTSTAMP:20171003T193836Z
UID:iqdscra46thu48c4ifv9dt9i04@google.com
CREATED:20140207T060000Z
DESCRIPTION:20140206 The FDA has assigned a Prescription Drug User Fee Act 
 (PDUFA) action date of August 9\, 2014.
LAST-MODIFIED:20140207T060000Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SPPI SPECTRUM PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140915
DTSTAMP:20171003T193836Z
UID:ln5ldbgqevkp6du15f0mtr22bo@google.com
CREATED:20140204T060001Z
DESCRIPTION:20140203 The FDA has issued an action date of September 15\, 20
 14 under the Prescription Drug User Fee Act (PDUFA).
LAST-MODIFIED:20140204T060002Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SLXP SALIX PHARMACEUTICALS LTD PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140825
DTSTAMP:20171003T193836Z
UID:gqsc45tg8v83b238ul7ts4i6b8@google.com
CREATED:20140125T060008Z
DESCRIPTION:20140124 The Prescription Drug User Fee Act (PDUFA) goal date f
 or a decision by the FDA is August 25\, 2014. The PDUFA goal date for metre
 leptin is February 24\, 2014.
LAST-MODIFIED:20140125T060008Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:BRISTOL MYERS SQUIBB CO PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140620
DTSTAMP:20171003T193836Z
UID:sld49inb1hnt5o9hr6rie2lf70@google.com
CREATED:20140124T060005Z
DESCRIPTION:20140123 The FDA has assigned a Prescription Drug User Fee Act 
 (PDUFA) action date of June 20\, 2014.
LAST-MODIFIED:20140124T060006Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:CBSTZ CUBIST PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140203
DTSTAMP:20171003T193836Z
UID:cv8i1frscslsek65vh9m09nbgs@google.com
CREATED:20140118T053707Z
DESCRIPTION:20131118 The FDA is currently conducting a substantive review o
 f the NDA and has assigned a Prescription Drug User Fee Act (PDUFA) goal da
 te of February 3\, 2014.
LAST-MODIFIED:20140118T053707Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:RDHL RedHill Biopharma Ltd PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140327
DTSTAMP:20171003T193836Z
UID:qv2nk0pcv5inpe46r7l248meog@google.com
CREATED:20140118T053655Z
DESCRIPTION:20140113 A target review date of March 27\, 2014 was set under 
 the Prescription Drug User Fee Act (PDUFA) for the FDA's approval decision.
LAST-MODIFIED:20140118T053655Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:VRTX VERTEX PHARMACEUTICALS INC MA PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140425
DTSTAMP:20171003T193836Z
UID:cvs739k8osd63nvldfmilcs9i0@google.com
CREATED:20140112T160038Z
DESCRIPTION:20131223 FDA has informed the Company that the Company s user f
 ee date (the PDUFA Date ) is now April 25\, 2014.
LAST-MODIFIED:20140112T160038Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:POZN POZEN INC NC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140109
DTSTAMP:20171003T193836Z
UID:dlapk273i860ojm8gl6h68qg14@google.com
CREATED:20140112T160037Z
DESCRIPTION:20140109 The PDUFA date for the update to the Tafinlar label is
  9 January 2014.
LAST-MODIFIED:20140112T160038Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:GSK GLAXOSMITHKLINE PLC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140224
DTSTAMP:20171003T193836Z
UID:vm2naif6di0hv5j1ths1f9oan4@google.com
CREATED:20131226T193605Z
DESCRIPTION:20131212 The Prescription Drug User Fee Act (PDUFA) goal date f
 or metreleptin is 24 February 2014.
LAST-MODIFIED:20131226T193606Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AZN ASTRAZENECA PLC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140111
DTSTAMP:20171003T193836Z
UID:61qi8ucnouco2m82mqnvo00nlk@google.com
CREATED:20131226T193605Z
DESCRIPTION:20131213 The Prescription Drug User Fee Act (PDUFA) goal date f
 or dapagliflozin is 11 January 2014.
LAST-MODIFIED:20131226T193605Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AZN ASTRAZENECA PLC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140601
DTEND;VALUE=DATE:20140602
DTSTAMP:20171003T193836Z
UID:e0rvvr7tip5n56420bcdb2ddds@google.com
CREATED:20131204T060705Z
DESCRIPTION:http://www.prnewswire.com/news-releases/omeros-submits-new-drug
 -application-to-us-fda-for-oms302-217901241.html
LAST-MODIFIED:20131204T060705Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:OMER OMEROS PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140526
DTEND;VALUE=DATE:20140527
DTSTAMP:20171003T193836Z
UID:2dcf9b51p0e3vc48c12ufsou1o@google.com
CREATED:20131204T060059Z
DESCRIPTION:http://ir.duratatherapeutics.com/press-releases/detail/644
LAST-MODIFIED:20131204T060101Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:DRTX DURATA THERAPEUTICS PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20131113
DTEND;VALUE=DATE:20131114
DTSTAMP:20171003T193836Z
UID:cgfki26os9ct2f4fmarnbbh9p8@google.com
CREATED:20131117T022837Z
DESCRIPTION:20131112 The FDA accepted final review completion date\, otherw
 ise known as PDUFA date to February 28\, 2014.
LAST-MODIFIED:20131117T024434Z
LOCATION:
SEQUENCE:2
STATUS:CONFIRMED
SUMMARY:PCYC PHARMACYCLICS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140628
DTEND;VALUE=DATE:20140629
DTSTAMP:20171003T193836Z
UID:m1e6miqndpjgqqu3u2n9uarqm0
CREATED:20131117T024123Z
DESCRIPTION:http://www.npsp.com/investors-pr?trxml_v=nrd&trxml_nr_id=187581
 4
LAST-MODIFIED:20131117T024123Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:NPSP NPS Pharmaceuticals PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20131206
DTSTAMP:20171003T193836Z
UID:c06rte2t4g1al325g3aoo47ib4@google.com
CREATED:20131117T022838Z
DESCRIPTION:20131112 That PDUFA date is now December 6\, 2013.
LAST-MODIFIED:20131117T022838Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:BSTC BIOSPECIFICS TECHNOLOGIES CORP PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140131
DTSTAMP:20171003T193836Z
UID:vk59sjh9ifsl2daspf71ol9nkc@google.com
CREATED:20131117T022834Z
DESCRIPTION:20131115 Vanda s tasimelton NDA is currently under Priority Rev
 iew by the FDA for the treatment of Non-24 in the totally blind\, with an a
 ction target date under the Prescription Drug User Fee Act (PDUFA-V) of Jan
 uary 31\, 2014.
LAST-MODIFIED:20131117T022835Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:VNDA Vanda Pharmaceuticals Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20131017
DTSTAMP:20171003T193836Z
UID:ge0ipc71lr7dkip9sa3df0r9ps@google.com
CREATED:20131019T180649Z
DESCRIPTION:20130925 In the U.S.\, the FDA is reviewing the New Drug Applic
 ation for ILUVIEN for DME resubmitted earlier this year and has set a Presc
 ription Drug User Fee Act (PDUFA) target date of October 17\, 2013.
LAST-MODIFIED:20131019T180650Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:PSDV pSivida Corp PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140214
DTSTAMP:20171003T193836Z
UID:ke5etbg1745548m3bb2b2cps9o@google.com
CREATED:20131019T180641Z
DESCRIPTION:20131010 The FDA recently assigned to NORTHERA a Prescription D
 rug User Fee Act (PDUFA) goal date of February 14\, 2014.
LAST-MODIFIED:20131019T180642Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:CHTP Chelsea Therapeutics International Ltd PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140121
DTSTAMP:20171003T193836Z
UID:nikdubicu6tkoneltic90cjl9s@google.com
CREATED:20131019T180639Z
DESCRIPTION:20131017 The new prescription drug user fee act (PDUFA) action 
 date has been set for January 21\, 2014. Over the past few weeks\, we have 
 had a productive dialogue with the FDA and have provided them with addition
 al information related to the review of the sNDA for Feraheme.
LAST-MODIFIED:20131019T180640Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AMAG AMAG PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20131218
DTSTAMP:20171003T193836Z
UID:6igo6nc8ngbpfsrrm55nqdfd2g@google.com
CREATED:20130922T074040Z
DESCRIPTION:20130910 The Prescription Drug User Fee Act (PDUFA) goal date f
 or UMEC/VI is 18 December 2013.
LAST-MODIFIED:20130922T074040Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:THRX THERAVANCE INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140108
DTSTAMP:20171003T193836Z
UID:9cbc08tcg8tktdhckkqsgo5ecs@google.com
CREATED:20130922T074038Z
DESCRIPTION:20130916 The FDA has assigned a Prescription Drug User Fee Act 
 (PDUFA) target date of 8 January 2014 for the Mekinist (trametinib) supplem
 ent and 9 January 2014 for the Tafinlar (dabrafenib) supplement.
LAST-MODIFIED:20130922T074039Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:GSK GLAXOSMITHKLINE PLC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20131206
DTSTAMP:20171003T193836Z
UID:29hasat6k7fk9qd0jmeoqu7to0@google.com
CREATED:20130920T050501Z
DESCRIPTION:20130828 The FDA determined that this submission qualified as a
  major amendment filed during the final three months of the review and exte
 nded the PDUFA goal date to December 6\, 2013.
LAST-MODIFIED:20130920T050501Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AUXL AUXILIUM PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20131218
DTSTAMP:20171003T193836Z
UID:hknu0koasasu28eff1udklnamg@google.com
CREATED:20130920T050500Z
DESCRIPTION:20130911 The Prescription Drug User Fee Act (PDUFA) goal date f
 or UMEC/VI is 18 December 2013.
LAST-MODIFIED:20130920T050500Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:GSK GLAXOSMITHKLINE PLC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140228
DTSTAMP:20171003T193836Z
UID:5aedoehmgd8f1i4q3adf1egkr4@google.com
CREATED:20130818T174626Z
DESCRIPTION:20130725 The FDA granted Vimizim priority review designation an
 d assigned a PDUFA date of February 28\, 2014.
LAST-MODIFIED:20130818T174626Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:BMRN BIOMARIN PHARMACEUTICAL INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20130913
DTSTAMP:20171003T193836Z
UID:7v9jacq0uk7i12c9o85i26mets@google.com
CREATED:20130818T174617Z
DESCRIPTION:20130807 The Prescription Drug User Fee Act (PDUFA) goal date f
 or completion of the FDA s evaluation and decision regarding approval of th
 e Melblez Kit NDA is September 13\, 2013.
LAST-MODIFIED:20130818T174618Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:DCTH DELCATH SYSTEMS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20131014
DTSTAMP:20171003T193836Z
UID:mnlnficd7lgude7tfdu1p4l12o@google.com
CREATED:20130818T174615Z
DESCRIPTION:20130807 The Prescription Drug User Fee Act ( PDUFA ) goal date
  for FDA approval is October 14\, 2013.
LAST-MODIFIED:20130818T174616Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ATRS ANTARES PHARMA INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20130701
DTSTAMP:20171003T193836Z
UID:b8dt8u91ttn21ja37nfv6labc4@google.com
CREATED:20130818T174613Z
DESCRIPTION:20130808 On July 1\, 2013\, Genentech/Roche announced that it h
 ad been granted priority review by FDA for use in neo-adjuvant setting for 
 HER2
LAST-MODIFIED:20130818T174614Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:PDLI PDL BIOPHARMA INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140203
DTEND;VALUE=DATE:20140204
DTSTAMP:20171003T193836Z
UID:8f30a12a-ef06-4bf4-b205-932cff2c0d02
CREATED:20130623T163346Z
DESCRIPTION:Partnered with RedHill\n\nhttp://www.marketwatch.com/story/inte
 lgenx-announces-fda-acceptance-of-new-drug-application-for-anti-migraine-ve
 rsafilmtm-oral-film-product-2013-06-18
LAST-MODIFIED:20130623T163350Z
LOCATION:
SEQUENCE:1
STATUS:CONFIRMED
SUMMARY:IGXT IntelGenx PDUFA
TRANSP:TRANSPARENT
X-LIC-ERROR;X-LIC-ERRORTYPE=VALUE-PARSE-ERROR:No value for LOCATION propert
 y. Removing entire property:
X-MOZ-GENERATION:1
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20130914
DTEND;VALUE=DATE:20130915
DTSTAMP:20171003T193836Z
UID:bb483bca-4fbe-4337-953b-9d974e957854
CREATED:20130622T160842Z
DESCRIPTION:http://investor.seagen.com/phoenix.zhtml?c=124860&p=irol-newsAr
 ticle&ID=1819231&highlight=
LAST-MODIFIED:20130622T160842Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SGEN Seattle Genetics PDUFA
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140416
DTSTAMP:20171003T193836Z
UID:rresbnrgfi81v9j56uafsj08oc@google.com
CREATED:20130622T160315Z
DESCRIPTION:20130618 Pursuant to the Prescription Drug User Fee Act (PDUFA)
  guidelines\, Santarus and Pharming expect the FDA will complete its review
  or otherwise respond to the RUCONEST BLA by April 16\, 2014.
LAST-MODIFIED:20130622T160316Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SNTS SANTARUS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20140212
DTSTAMP:20171003T193836Z
UID:kug3o6obsvnmv6ufnm3po9kk9o@google.com
CREATED:20130622T160311Z
DESCRIPTION:20130620 The Prescription Drug User Fee Act (PDUFA) goal date (
 the date the FDA expects to complete its review of the NDA) has been confir
 med as February 12\, 2014. We re extremely pleased that this NDA submission
  has been accepted for review and that our PDUFA date is now less than eigh
 t months away.
LAST-MODIFIED:20130622T160312Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:DRRX DURECT CORP PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20130605
DTSTAMP:20171003T193836Z
UID:s0m6fdg8dlodcfvcdddlcduje0@google.com
CREATED:20130519T075017Z
DESCRIPTION:20130425 The Agency assigned a priority review to the applicati
 on with a Prescription Drug User Fee Act (PDUFA) goal date of June 5\, 2013
 .
LAST-MODIFIED:20130519T075017Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:CELGZ CELGENE CORP DE PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20121106
DTSTAMP:20171003T193836Z
UID:e9a4sgofjjk7nnab815julu5dk@google.com
CREATED:20130519T075015Z
DESCRIPTION:20130429 The sBLA for XIAFLEX for the treatment of Peyronie s d
 isease was submitted to the FDA on November 6\, 2012 and has been accepted 
 for standard review with a PDUFA date of September 6\, 2013.
LAST-MODIFIED:20130519T075016Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AUXL AUXILIUM PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20131017
DTSTAMP:20171003T193836Z
UID:q8o4a2jv3j4fp3nd1q8kvkvfq8@google.com
CREATED:20130519T075015Z
DESCRIPTION:20130501 Exhibit 99.1 FOR IMMEDIATE RELEASE ALIMERA SCIENCES AN
 NOUNCES NEW PDUFA DATE FOR ILUVIEN PDUFA goal date set for October 17\, 201
 3 ATLANTA\, May 1\, 2013 Alimera Sciences\, Inc. (NASDAQ: ALIM) (Alimera)\,
  a biopharmaceutical company that specializes in the research\, development
  and
LAST-MODIFIED:20130519T075015Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ALIM ALIMERA SCIENCES INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20130531
DTSTAMP:20171003T193836Z
UID:0q8c2g4jsn8vqcesmbof64fn34@google.com
CREATED:20130519T075006Z
DESCRIPTION:20130509 The Prescription Drug User Fee Act (PDUFA) date for SE
 FELSA is May 31\, 2013\, which is the goal date for the FDA to complete its
  review of the NDA.
LAST-MODIFIED:20130519T075007Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:DEPO DEPOMED INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20130423
DTEND;VALUE=DATE:20130424
DTSTAMP:20171003T193836Z
UID:4e3d5c8b-cbc5-46b6-a2d9-d0a5bf478812
CREATED:20130423T164930Z
DESCRIPTION:
LAST-MODIFIED:20130423T164930Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SCMP Sucampo PDUFA
TRANSP:OPAQUE
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20130301
DTSTAMP:20171003T193836Z
UID:ncggf4su79krhj5r2lt9uj9gpk@google.com
CREATED:20130421T202000Z
DESCRIPTION:20130327 In February 2013\, the FDA informed us that we were un
 likely to receive an action letter for our NDA for Zohydro ER by the PDUFA 
 target action date of March 1\, 2013.
LAST-MODIFIED:20130421T202001Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ZGNX ZOGENIX INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20130325
DTEND;VALUE=DATE:20130326
DTSTAMP:20171003T193836Z
UID:22215be7-0772-41ec-936a-26633b75b75a
CREATED:20130216T172836Z
DESCRIPTION:http://www.biocentury.com/DailyNews/company/2013-02-14/fda-acce
 pts-oral-treprostinil-resubmission
LAST-MODIFIED:20130328T003009Z
LOCATION:
SEQUENCE:1
STATUS:CONFIRMED
SUMMARY:UTHR United Therapeutics PDUFA
TRANSP:TRANSPARENT
X-LIC-ERROR;X-LIC-ERRORTYPE=VALUE-PARSE-ERROR:No value for LOCATION propert
 y. Removing entire property:
X-MOZ-GENERATION:1
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20130327
DTEND;VALUE=DATE:20130328
DTSTAMP:20171003T193836Z
UID:7bc02012-5fa1-45fc-b935-dbca9138b0cd
CREATED:20130216T174629Z
DESCRIPTION:3 month delay from original date for BG-12\n\nDelay: http://www
 .biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1747042\n\nOrigina
 l Submission 2/28/12: http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?
 ID=5981&ReqId=1666509
LAST-MODIFIED:20130328T003001Z
LOCATION:
SEQUENCE:1
STATUS:CONFIRMED
SUMMARY:BIIB Biogen Idec PDUFA
TRANSP:TRANSPARENT
X-LIC-ERROR;X-LIC-ERRORTYPE=VALUE-PARSE-ERROR:No value for LOCATION propert
 y. Removing entire property:
X-MOZ-GENERATION:3
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20130728
DTSTAMP:20171003T193836Z
UID:ia0lefd992id50i7jfrgf7qp5c@google.com
CREATED:20130318T212035Z
DESCRIPTION:20130311 According to the timelines established by the Prescrip
 tion Drug User Fee Act\, or PDUFA\, the review of the NDA is expected to be
  complete by July 28\, 2013.
LAST-MODIFIED:20130318T212035Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AVEO AVEO PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20121015
DTSTAMP:20171003T193836Z
UID:8fp4n1oh78f8amscbb42b2phus@google.com
CREATED:20130318T212031Z
DESCRIPTION:20130313 Our NDA was accepted for filing by the FDA on October 
 15\, 2012 and has been designated for standard review with a Prescription D
 rug User Fee Act (PDUFA) goal date of June 15\, 2013.
LAST-MODIFIED:20130318T212032Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:DCTH DELCATH SYSTEMS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20130313
DTEND;VALUE=DATE:20130314
DTSTAMP:20171003T193836Z
UID:3ushgt6qtnkg6fqo36m0ip1bq4@google.com
CREATED:20121223T002029Z
DESCRIPTION:20121219 The U.S. Food and Drug Administration (FDA) has assign
 ed the Lymphoseek New Drug Application (NDA) a Prescription Drug User Fee A
 ct (PDUFA) goal date of April 30\, 2013.
LAST-MODIFIED:20130315T191326Z
LOCATION:
SEQUENCE:2
STATUS:CONFIRMED
SUMMARY:NAVB NAVIDEA BIOPHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
X-LIC-ERROR;X-LIC-ERRORTYPE=VALUE-PARSE-ERROR:No value for LOCATION propert
 y. Removing entire property:
X-MOZ-GENERATION:2
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20130228
DTEND;VALUE=DATE:20130301
DTSTAMP:20171003T193836Z
UID:fe9d1d99-8ac3-4fd2-9ac4-321b1384df3f
CREATED:20130216T175237Z
DESCRIPTION:6 month priority review following 8/30/12 NDA submission\n\nhtt
 p://www.onyx.com/view.cfm/631/bayer-submits-new-drug-application-for-regora
 fenib-for-the-treatment-of-gastrointestinal-stromal-tumors-gist\n\npriority
  review: http://www.onyx.com/view.cfm/639/bayers-stivarga-regorafenib-table
 ts-new-drug-application-granted-priority-review-by-us-fda-for-the-treatment
 -of-patients-with-gastrointestinal-stromal-tumors
LAST-MODIFIED:20130216T180056Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:(estimated) ONXX Onyx PDUFA
TRANSP:TRANSPARENT
X-LIC-ERROR;X-LIC-ERRORTYPE=VALUE-PARSE-ERROR:No value for LOCATION propert
 y. Removing entire property:
X-MOZ-GENERATION:1
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20130210
DTEND;VALUE=DATE:20130211
DTSTAMP:20171003T193836Z
UID:qp9o594iiov1gnp4caqflok0n0@google.com
CREATED:20130216T171539Z
DESCRIPTION:20130124 In the U.S.\, an action by the FDA is expected by the 
 February 10\, 2013 Prescription Drug User Fee Act (PDUFA) date.
LAST-MODIFIED:20130216T175258Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:CELG CELGENE CORP DE PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
X-MOZ-GENERATION:1
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20130526
DTEND;VALUE=DATE:20130527
DTSTAMP:20171003T193836Z
UID:9e211d63-9cee-46db-8cec-9dcd8870a0b9
CREATED:20130216T174024Z
DESCRIPTION:Efinaconazole\nhttp://ir.valeant.com/files/3Q12%20PresentationF
 inal2.pdf\n
LAST-MODIFIED:20130216T174024Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:VRX Valeant PDUFA
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20130415
DTSTAMP:20171003T193836Z
UID:52cvk6blr93etskaa9ta2d7rl4@google.com
CREATED:20130216T171540Z
DESCRIPTION:20130124 In October 2012\, MAP resubmitted a file to the FDA\, 
 and we re hopeful that LEVADEX will be approved by the FDA by its PDUFA act
 ion date of April 15\, 2013. David\, can you just talk about the timing of 
 the deal being pre the PDUFA not post?
LAST-MODIFIED:20130216T171540Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:MAPP MAP Pharmaceuticals Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20130226
DTSTAMP:20171003T193836Z
UID:brn9pr3n354h2ro5a6o060che0@google.com
CREATED:20130216T171538Z
DESCRIPTION:20130125 Roche has noted that the US submission has been grante
 d priority review status by the FDA with a PDUFA goal date of February 26\,
  2013.
LAST-MODIFIED:20130216T171538Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:IMGN IMMUNOGEN INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20131003
DTSTAMP:20171003T193836Z
UID:sdbltuk58d3uvp5bru9lsh73bo@google.com
CREATED:20130216T171531Z
DESCRIPTION:20130213 The FDA Prescription Drug User Fee Act (PDUFA) date is
  October 3\, 2013. Ligand presented preclinical data on LG-7501 at the 63 r
 d Annual Meeting of the American Association for the Study of Liver Disease
 s.
LAST-MODIFIED:20130216T171531Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:LGND LIGAND PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20130201
DTEND;VALUE=DATE:20130202
DTSTAMP:20171003T193836Z
UID:dguou08cv1r53938olm5f7gbtg@google.com
CREATED:20130121T202326Z
DESCRIPTION:http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm33
 7639.htm\n\n20130116 Exhibit 99.1 Hyperion Notified that FDA Will Not Meet 
 the PDUFA Action Date for Ravicti South San Francisco\, CA January 16\, 201
 3 Hyperion Therapeutics\, Inc. (Nasdaq GM:HPTX) said that the U.S. Food and
  Drug Administration (FDA) has advised the Company not to expect a final ac
 tion by the
LAST-MODIFIED:20130201T172559Z
LOCATION:
SEQUENCE:2
STATUS:CONFIRMED
SUMMARY:HPTX HYPERION THERAPEUTICS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
X-LIC-ERROR;X-LIC-ERRORTYPE=VALUE-PARSE-ERROR:No value for LOCATION propert
 y. Removing entire property:
X-MOZ-GENERATION:6
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20130430
DTEND;VALUE=DATE:20130501
DTSTAMP:20171003T193836Z
UID:dhjm56967ors2v1piph5ju4fs8@google.com
CREATED:20130121T202341Z
DESCRIPTION:http://ir.raptorpharma.com/releasedetail.cfm?ReleaseID=728535\n
 \nPDUFA delayed 3 months\n\n20121226 The New Drug Application and Marketing
  Authorization Application for RP103 for the potential treatment of nephrop
 athic cystinosis have been submitted to the FDA and the European Medicines 
 Agency\, respectively\, and the NDA has been assigned a PDUFA date of Janua
 ry 30\, 2013.
LAST-MODIFIED:20130121T203302Z
LOCATION:
SEQUENCE:1
STATUS:CONFIRMED
SUMMARY:RPTP Raptor Pharmaceutical Corp PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
X-MOZ-GENERATION:1
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20121212
DTSTAMP:20171003T193836Z
UID:7rasmg0nt13g808apodil867vo@google.com
CREATED:20130121T202343Z
DESCRIPTION:20121220 In connection with the extension of the PDUFA date\, t
 he FDA also notified Santarus that the FDA planned to communicate proposed 
 labeling to Santarus by December 12\, 2012.
LAST-MODIFIED:20130121T202343Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SNTS SANTARUS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20130202
DTSTAMP:20171003T193836Z
UID:vm85ho4qc9nksg5qkq0spvruf8@google.com
CREATED:20130121T202341Z
DESCRIPTION:20121221 The Prescription Drug User Fee Act ( PDUFA ) review go
 al for the FDA to complete its review of the NDA is February 2\, 2013.
LAST-MODIFIED:20130121T202342Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:HEB HEMISPHERX BIOPHARMA INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20130430
DTSTAMP:20171003T193836Z
UID:pomeeuq5t550918p70srhdvs70@google.com
CREATED:20130121T202331Z
DESCRIPTION:20130107 Probuphine NDA has been granted a Priority Review desi
 gnation with the PDUFA date of April 30\, 2013.
LAST-MODIFIED:20130121T202332Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:TITAN PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120531
DTSTAMP:20171003T193836Z
UID:oh5ssfdkrsu69fifl6gg0u1jnc@google.com
CREATED:20121223T002034Z
DESCRIPTION:20121204 Highlights from the quarter and subsequent period incl
 ude: Flamel s New Drug Application (NDA) was accepted by the FDA in October
  2012 with Prescription Drug User Fee Act (PDUFA) target action date of May
  31\, 2012.
LAST-MODIFIED:20121223T002034Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:FLML FLAMEL TECHNOLOGIES SA PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20121221
DTSTAMP:20171003T193836Z
UID:puomm1870hladt1jp1m5nbknbo@google.com
CREATED:20121223T002030Z
DESCRIPTION:20121214 Page 1 of 3 ADASUVE is not authorized for marketing in
  the US. Alexza has submitted a New Drug Application (NDA) to the U.S. Food
  and Drug Administration\, which is currently under review with a Prescript
 ion Drug User Fee Act (PDUFA) goal date of December 21\, 2012.
LAST-MODIFIED:20121223T002031Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ALXA Alexza Pharmaceuticals Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20121221
DTEND;VALUE=DATE:20121222
DTSTAMP:20171003T193836Z
UID:7loqk6usp6jud19t65tddkahds@google.com
CREATED:20121128T050849Z
DESCRIPTION:20121109 The Prescription Drug User Fee Act (PDUFA) action date
  for the Gattex NDA is December 30\, 2012.
LAST-MODIFIED:20121221T171353Z
LOCATION:
SEQUENCE:1
STATUS:CONFIRMED
SUMMARY:NPSP NPS PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
X-MOZ-GENERATION:1
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20121214
DTEND;VALUE=DATE:20121215
DTSTAMP:20171003T193836Z
UID:qpg3nj0sg8b826j6e30s9kb4p8@google.com
CREATED:20121128T050851Z
DESCRIPTION:20121107 The FDA granted ARIAD s request for Priority Review of
  ponatinib and established an action date of March 27\, 2013 under the Pres
 cription Drug User Fee Act (PDUFA).
LAST-MODIFIED:20121214T170818Z
LOCATION:
SEQUENCE:1
STATUS:CONFIRMED
SUMMARY:ARIA ARIAD PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
X-MOZ-GENERATION:1
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120329
DTSTAMP:20171003T193836Z
UID:shc0jqe710pps0ao0ru780t280@google.com
CREATED:20121128T050902Z
DESCRIPTION:20121025 Genzyme submitted the NDA on March 29\, 2012\, and the
  FDA has set a target action date under the Prescription Drug User Fee Act 
 (PDUFA) of January 29\, 2013.
LAST-MODIFIED:20121128T050902Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SNY Sanofi PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120301
DTSTAMP:20171003T193836Z
UID:4iteg564sruvpghklm2tvo7aik@google.com
CREATED:20121128T050859Z
DESCRIPTION:20121102 In addition\, the Agreement provides for certain reten
 tion incentive payments and other consideration that will vest and be payab
 le to Dr. Martin if he remains as an employee through the later of March 1\
 , 2012 or the actual PDUFA action date for HEPLISAV (the "Acceleration Date
 ").
LAST-MODIFIED:20121128T050900Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:DVAX DYNAVAX TECHNOLOGIES CORP PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20130224
DTSTAMP:20171003T193836Z
UID:47eee99dlj4coqc8dp8oj4crf0@google.com
CREATED:20121128T050842Z
DESCRIPTION:20121115 The scheduled Prescription Drug User Fee Act (PDUFA) d
 ate for HEPLISAV is February 24\, 2013. The PDUFA date for completion of th
 e FDA review of the HEPLISAV Biologic License Application (BLA) is February
  24\, 2013.
LAST-MODIFIED:20121128T050844Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:DVAX DYNAVAX TECHNOLOGIES CORP PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120204
DTSTAMP:20171003T193836Z
UID:qmg7gp84ddkp23ub6cnah038dc@google.com
CREATED:20121128T050841Z
DESCRIPTION:20121119 In January 2012\, Alexza received notice of a 90-day e
 xtension of the PDUFA goal date\, from February 4\, 2012 to May 4\, Page 1 
 of 2 2012. The resubmitted ADASUVE NDA has a PDUFA goal date of December 21
 \, 2012.
LAST-MODIFIED:20121128T050841Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ALXA Alexza Pharmaceuticals Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20130327
DTEND;VALUE=DATE:20130328
DTSTAMP:20171003T193836Z
UID:30bqo0f3re8q97m4ffa8v317ik@google.com
CREATED:20121026T053439Z
DESCRIPTION:20121019 A.P. Pharma resubmitted its New Drug Application (NDA)
  for APF530 to the U.S. Food and Drug Administration in September 2012 and 
 has been assigned a Prescription Drug User Fee Act (PDUFA) action date of M
 arch 27\, 2013.
LAST-MODIFIED:20121026T062321Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:APPA AP PHARMA INC DE PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
X-MOZ-GENERATION:1
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20121023
DTEND;VALUE=DATE:20121024
DTSTAMP:20171003T193836Z
UID:b6a51dad-97ec-48f4-9249-707a87cd716c
CREATED:20120317T164529Z
DESCRIPTION:United Therapeutics Corporation (NASDAQ: UTHR) announced today 
 that the U.S. Food and Drug Administration has accepted for review the new 
 drug application (NDA) for treprostinil diethanolamine sustained release ta
 blets (oral treprostinil) for the treatment of pulmonary arterial hypertens
 ion.  The NDA will be subjected to a standard 10-month review period\, with
  a targeted user fee deadline of October 27\, 2012.
LAST-MODIFIED:20121026T061828Z
LOCATION:
SEQUENCE:1
STATUS:CONFIRMED
SUMMARY:UTHR United Therapeutics PDUFA
TRANSP:TRANSPARENT
X-LIC-ERROR;X-LIC-ERRORTYPE=VALUE-PARSE-ERROR:No value for LOCATION propert
 y. Removing entire property:
X-MOZ-GENERATION:1
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20130121
DTEND;VALUE=DATE:20130122
DTSTAMP:20171003T193836Z
UID:grfklg1jo4di1grvkcokvi0bvo@google.com
CREATED:20120317T162410Z
DESCRIPTION:20120228 The Prescription Drug User Fee Date ( PDUFA ) for a de
 cision by the FDA is October 21\, 2012.
LAST-MODIFIED:20121022T223653Z
LOCATION:
SEQUENCE:1
STATUS:CONFIRMED
SUMMARY:IPXL IMPAX LABORATORIES INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
X-MOZ-GENERATION:1
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120513
DTSTAMP:20171003T193836Z
UID:f22gr92005kjdvf5aqmijnqnrk@google.com
CREATED:20120922T194931Z
DESCRIPTION:20120907 As disclosed above\, the FDA had previously accepted t
 he Company s NDA for Marqibo in September 2011\, setting a PDUFA date of Ma
 y 13\, 2012\, which date was subsequently extended to August 12\, 2012.
LAST-MODIFIED:20120922T194932Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:Talon Therapeutics Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120321
DTSTAMP:20171003T193836Z
UID:jim8ti4silqvuf8rl4mfno49ok@google.com
CREATED:20120922T194931Z
DESCRIPTION:20120907 After a hearing in front of a panel of the FDA s Oncol
 ogic Drugs Advisory Committee\, or ODAC\, on March 21\, 2012\, which result
 ed in a positive vote (7 to 4 with 2 abstentions) for Marqibo\, the FDA ext
 ended the PDUFA date for 3 months to August 12\, 2012.
LAST-MODIFIED:20120922T194931Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:Talon Therapeutics Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20110405
DTEND;VALUE=DATE:20110406
DTSTAMP:20171003T193836Z
ORGANIZER;CN=Adcom:mailto:evgohovm2m3tuvqakdf4hfeq84@group.calendar.google.
 com
UID:ek1vjmiv8gspvdqno39dcdvbdg@google.com
ATTENDEE;CUTYPE=INDIVIDUAL;ROLE=REQ-PARTICIPANT;PARTSTAT=ACCEPTED;CN=PDUFA;
 X-NUM-GUESTS=0:mailto:5dso8589486irtj53sdkr4h6ek@group.calendar.google.com
CREATED:20120910T204850Z
DESCRIPTION:
LAST-MODIFIED:20120910T204904Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:OPTR FDA Panel
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120830
DTEND;VALUE=DATE:20120831
DTSTAMP:20171003T193836Z
UID:aebbcd96-008e-45f0-a3ab-452fb555dacf
CREATED:20120317T165039Z
DESCRIPTION:CAMBRIDGE\, Mass. and NEW YORK\, April 23\, 2012 (BUSINESS WIRE
 ) — Ironwood Pharmaceuticals\, Inc. (NASDAQ: IRWD) and Forest Laboratories\
 , Inc. (NYSE: FRX) today announced that the U.S. Food and Drug Administrati
 on (FDA) notified the companies that it will require a three‐month extensio
 n to complete its review of the data supporting the New Drug Application (N
 DA) for linaclotide for the treatment of irritable bowel syndrome with cons
 tipation (IBS‐C) and chronic constipation (CC).\n\nAn additional analysis o
 f existing data was recently requested by the FDA to further characterize t
 he relative effect of the two doses of linaclotide that were studied in the
  Phase 3 CC clinical trials. Since this analysis was submitted to the FDA w
 ithin three months of the user fee goal date\, the date has been extended b
 y three months\, in accordance with applicable regulation. No new data have
  been requested by the agency to complete the review. FDA action is now exp
 ected by September 2012. Ironwood and Forest continue to plan for a 2012 la
 unch.
LAST-MODIFIED:20120831T200714Z
LOCATION:
SEQUENCE:4
STATUS:CONFIRMED
SUMMARY:IRWD Ironwood Pharmaceuticals PDUFA
TRANSP:TRANSPARENT
X-LIC-ERROR;X-LIC-ERRORTYPE=VALUE-PARSE-ERROR:No value for LOCATION propert
 y. Removing entire property:
X-MOZ-GENERATION:3
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120831
DTEND;VALUE=DATE:20120901
DTSTAMP:20171003T193836Z
UID:pgo4i11e6itqr87ei0te0fl31k@google.com
CREATED:20120819T220800Z
DESCRIPTION:20120809 The Prescription Drug User Fee Act (PDUFA) date for th
 e completion of the FDA s review of the NDA is November 22\, 2012.
LAST-MODIFIED:20120831T200644Z
LOCATION:
SEQUENCE:1
STATUS:CONFIRMED
SUMMARY:MDVN MEDIVATION INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
X-MOZ-GENERATION:1
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120504
DTEND;VALUE=DATE:20120505
DTSTAMP:20171003T193836Z
UID:6ufhtdkgue7ieeghs2cps54hgo@google.com
CREATED:20120730T000222Z
DESCRIPTION:20120706 In January 2012\, Alexza received notice of a 90-day e
 xtension of the PDUFA goal date\, from February 4\, 2012 to May 4\, 2012. T
 he resubmitted ADASUVE NDA has a PDUFA goal date of December 21\, 2012.
LAST-MODIFIED:20120826T062202Z
LOCATION:
SEQUENCE:1
STATUS:CONFIRMED
SUMMARY:ALXA Alexza Pharmaceuticals Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
X-MOZ-GENERATION:1
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20130116
DTEND;VALUE=DATE:20130117
DTSTAMP:20171003T193836Z
UID:fde2395a-57ac-40aa-83e4-f1dc713538c5
CREATED:20120317T164439Z
DESCRIPTION:\n\nSantarus\, Inc. (NASDAQ: SNTS) today announced that the U.S
 . Food and Drug Administration (FDA) has extended the Prescription Drug Use
 r Fee Act (PDUFA) target action date for the review of the New Drug Applica
 tion (NDA) for UCERIS™ (budesonide) tablets 9 mg for the induction of remis
 sion of mild to moderate active ulcerative colitis from October 16\, 2012 t
 o January 16\, 2013. The three-month extension is a standard extension peri
 od.\n\nOn August 3\, 2012\, following the FDA's request\, Santarus submitte
 d additional information for the Office of Scientific Investigations\, whic
 h is the division of the FDA responsible for ensuring compliance with Good 
 Clinical Practices (GCP)\, in connection with U.S. and ex-U.S. pre-approval
  inspections. On August 10\, 2012\, the company received a communication fr
 om the FDA that the submission has been classified as a major amendment to 
 the NDA. Since the submission was received within three months of the targe
 t action date\, the FDA is extending the PDUFA date by three months to prov
 ide time for a full review of the submitted information.\n
LAST-MODIFIED:20120819T222938Z
LOCATION:
SEQUENCE:3
STATUS:CONFIRMED
SUMMARY:SNTS Santarus PDUFA
TRANSP:TRANSPARENT
X-LIC-ERROR;X-LIC-ERRORTYPE=VALUE-PARSE-ERROR:No value for LOCATION propert
 y. Removing entire property:
X-MOZ-GENERATION:2
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20121129
DTSTAMP:20171003T193836Z
UID:rta05igtakvrdiniqv7dgsb7tc@google.com
CREATED:20120819T220800Z
DESCRIPTION:20120809 The Prescription Drug User Fee Act (PDUFA) action date
  is November 29\, 2012.
LAST-MODIFIED:20120819T220800Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:EXEL EXELIXIS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20130117
DTSTAMP:20171003T193836Z
UID:80bc4i42g9k5vr9m6fgre6lqb0@google.com
CREATED:20120819T220759Z
DESCRIPTION:20120814 Exhibit 99.1 NuPathe Announces Second Quarter 2012 Fin
 ancial Results and Operational Highlights Migraine Patch NDA Resubmission A
 ccepted for Filing by FDA PDUFA Date of January 17\, 2013 CONSHOHOCKEN\, PA
  August 14\, 2012 NuPathe Inc. (NASDAQ: PATH)\, a specialty pharmaceutical
LAST-MODIFIED:20120819T220759Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:PATH NUPATHE INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120809
DTEND;VALUE=DATE:20120810
DTSTAMP:20171003T193836Z
UID:4jt7k6mdvuipvcr4bstpf9opc8@google.com
CREATED:20120519T160730Z
DESCRIPTION:20120515 Extension of PDUFA Date On May 3\, 2012\, the FDA info
 rmed the Company of an extended PDUFA date for its review of the Marqibo ND
 A from May 13\, 2012 to August 12\, 2012.
LAST-MODIFIED:20120809T184150Z
LOCATION:
SEQUENCE:3
STATUS:CONFIRMED
SUMMARY:Talon Therapeutics Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
X-LIC-ERROR;X-LIC-ERRORTYPE=VALUE-PARSE-ERROR:No value for LOCATION propert
 y. Removing entire property:
X-MOZ-GENERATION:2
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120810
DTSTAMP:20171003T193836Z
UID:t84h0g2af18j6t1o0pl88sn4l4@google.com
CREATED:20120804T014326Z
DESCRIPTION:20120802 PDUFA date for this application for approval is August
  10\, 2012.
LAST-MODIFIED:20120804T014327Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:PDLI PDL BIOPHARMA INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20121215
DTEND;VALUE=DATE:20121216
DTSTAMP:20171003T193836Z
UID:5a8075ad-6a34-4e82-bcab-e9bef10afbca
CREATED:20120730T001935Z
DESCRIPTION:http://phx.corporate-ir.net/phoenix.zhtml?c=83257&p=irol-newsAr
 ticle&ID=1713040&highlight=
LAST-MODIFIED:20120730T001935Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:HGSI PDUFA
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20121130
DTEND;VALUE=DATE:20121201
DTSTAMP:20171003T193836Z
UID:856f435a-a920-491f-ae93-ced436778952
CREATED:20120730T001828Z
DESCRIPTION:Partner with GSK on promacta\nhttp://investor.ligand.com/Invest
 ors/News-and-Events/Press-Releases/Press-Release-Details/2012/Ligand-Partne
 r-GlaxoSmithKline-Announces-Priority-Review-for-Supplemental-New-Drug-Appli
 cation-for-Promacta-for-the-Treatment/default.aspx?print=1
LAST-MODIFIED:20120730T001848Z
LOCATION:
SEQUENCE:1
STATUS:CONFIRMED
SUMMARY:LGND PDUFA
TRANSP:TRANSPARENT
X-LIC-ERROR;X-LIC-ERRORTYPE=VALUE-PARSE-ERROR:No value for LOCATION propert
 y. Removing entire property:
X-MOZ-GENERATION:2
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20121012
DTEND;VALUE=DATE:20121013
DTSTAMP:20171003T193836Z
UID:0a61155e-ac63-493e-8993-e47a663e4334
CREATED:20120507T052913Z
DESCRIPTION:http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-newsArticle
 &ID=1701834&highlight=
LAST-MODIFIED:20120730T001432Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:CELG PDUFA
TRANSP:TRANSPARENT
X-LIC-ERROR;X-LIC-ERRORTYPE=VALUE-PARSE-ERROR:No value for LOCATION propert
 y. Removing entire property:
X-MOZ-GENERATION:2
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20130129
DTEND;VALUE=DATE:20130130
DTSTAMP:20171003T193836Z
UID:98077501-22f3-4a02-9260-98e4cf261406
CREATED:20120507T052037Z
DESCRIPTION:Kynamro\n\nhttp://www.businesswire.com/portal/site/home/email/a
 lert/?ndmViewId=news_view&newsLang=en&newsId=20120329005973
LAST-MODIFIED:20120730T001035Z
LOCATION:
SEQUENCE:3
STATUS:CONFIRMED
SUMMARY:ISIS PDUFA
TRANSP:TRANSPARENT
X-LIC-ERROR;X-LIC-ERRORTYPE=VALUE-PARSE-ERROR:No value for LOCATION propert
 y. Removing entire property:
X-MOZ-GENERATION:2
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120720
DTEND;VALUE=DATE:20120721
DTSTAMP:20171003T193836Z
UID:8024bfc3-7cb0-45bf-a947-9fc5da48a74a
CREATED:20120317T164105Z
DESCRIPTION:Partner with ONXX
LAST-MODIFIED:20120730T000516Z
LOCATION:
SEQUENCE:1
STATUS:CONFIRMED
SUMMARY:LGND Ligand Pharmaceuticals PDUFA
TRANSP:TRANSPARENT
X-LIC-ERROR;X-LIC-ERRORTYPE=VALUE-PARSE-ERROR:No value for LOCATION propert
 y. Removing entire property:
X-MOZ-GENERATION:1
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120720
DTEND;VALUE=DATE:20120721
DTSTAMP:20171003T193836Z
UID:a4987113-13dd-4b18-b298-9cad78d83f61
CREATED:20120317T163814Z
DESCRIPTION:Onyx Pharmaceuticals\, Inc. (Nasdaq: ONXX) announced today that
  the U.S. Food and Drug Administration (FDA) has granted Standard Review de
 signation to the New Drug Application (NDA) for carfilzomib for the potenti
 al treatment of patients with relapsed and refractory multiple myeloma. The
  Prescription Drug User Fee Act (PDUFA) date for completion of review by th
 e FDA of the NDA is July 27\, 2012.
LAST-MODIFIED:20120730T000512Z
LOCATION:
SEQUENCE:1
STATUS:CONFIRMED
SUMMARY:ONXX Onyx Pharmaceuticals PDUFA
TRANSP:TRANSPARENT
X-LIC-ERROR;X-LIC-ERRORTYPE=VALUE-PARSE-ERROR:No value for LOCATION propert
 y. Removing entire property:
X-MOZ-GENERATION:1
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120522
DTSTAMP:20171003T193836Z
UID:spvtonm571n50dritfegbdec70@google.com
CREATED:20120730T000227Z
DESCRIPTION:20120522 EXHIBIT 99.1 Repros Updates Special Protocol Assessmen
 t Documentation for Pivotal Studies for Androxal(R) Update Re-Starts 45 Day
  PDUFA Response Clock for FDA Comments THE WOODLANDS\, Texas \, May 22\, 20
 12 (GLOBE NEWSWIRE) - Repros Therapeutics Inc. (Nasdaq:RPRX)today announced
  it has modified the
LAST-MODIFIED:20120730T000227Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:RPRXZ REPROS THERAPEUTICS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120424
DTSTAMP:20171003T193836Z
UID:nam81cpqrsh1himl6e2stsa86o@google.com
CREATED:20120730T000226Z
DESCRIPTION:20120531 The FDA was unable to accommodate the Company s reques
 t to reschedule\, and given the April 24\, 2012 Prescription Drug User Fee 
 Act (PDUFA) date for Pixuvri\, the only way to have Pixuvri possibly consid
 ered at a later ODAC meeting was to withdraw and later resubmit the NDA.
LAST-MODIFIED:20120730T000226Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:CTIC CELL THERAPEUTICS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20121019
DTSTAMP:20171003T193836Z
UID:ldqs8s4p30anfjl9956rckl9to@google.com
CREATED:20120730T000222Z
DESCRIPTION:20120713 The NDA for SPN-804 is currently under review by the F
 DA with a PDUFA date of October 19\, 2012. We are fortunate to have develop
 ed a deep and diverse pipeline in CNS including two NDAs in the same therap
 eutic area.
LAST-MODIFIED:20120730T000222Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SUPN SUPERNUS PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120923
DTSTAMP:20171003T193836Z
UID:5f7v3i7qu3pp8r4fnpop53nfj4@google.com
CREATED:20120730T000218Z
DESCRIPTION:20120725 Enrollment in the U.S. Phase 3 study was completed in 
 the fourth quarter of 2011. 1 Regeneron s application to market EYLEA for C
 RVO in the United States has a PDUFA date of September 23\, 2012.
LAST-MODIFIED:20120730T000218Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:REGN REGENERON PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120804
DTEND;VALUE=DATE:20120805
DTSTAMP:20171003T193836Z
UID:9e52218f-c4d9-436b-8c1b-949f832d5fdc
CREATED:20120507T052826Z
DESCRIPTION:Zaltrap for colon cancer
LAST-MODIFIED:20120519T174637Z
LOCATION:
SEQUENCE:2
STATUS:CONFIRMED
SUMMARY:REGN PDUFA
TRANSP:TRANSPARENT
X-LIC-ERROR;X-LIC-ERRORTYPE=VALUE-PARSE-ERROR:No value for LOCATION propert
 y. Removing entire property:
X-MOZ-GENERATION:2
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120827
DTEND;VALUE=DATE:20120828
DTSTAMP:20171003T193836Z
UID:758681a7-31a5-453e-be96-3805d0cc42f0
CREATED:20120317T164201Z
DESCRIPTION:http://www.gilead.com/pr_1324679432\n\nFOSTER CITY\, Calif.\, D
 ec 23\, 2011 (BUSINESS WIRE) --Gilead Sciences\, Inc. (Nasdaq: GILD) announ
 ced today that the U.S. Food and Drug Administration (FDA) has accepted for
  review the New Drug Application (NDA) for the Quad\, a complete single-tab
 let HIV regimen containing elvitegravir\, cobicistat\, emtricitabine and te
 nofovir disoproxil fumarate.\n\nGilead submitted the Quad NDA on October 27
 \, 2011. The FDA has set a target review date for the Quad under the Prescr
 iption Drug User Fee Act (PDUFA) of August 27\, 2012.\n\nAdcom was May 11
LAST-MODIFIED:20120519T174503Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:GILD Gilead PDUFA
TRANSP:TRANSPARENT
X-LIC-ERROR;X-LIC-ERRORTYPE=VALUE-PARSE-ERROR:No value for LOCATION propert
 y. Removing entire property:
X-MOZ-GENERATION:2
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120627
DTEND;VALUE=DATE:20120628
DTSTAMP:20171003T193836Z
UID:2nrsnpu1s3is4bvd6chkl1hnvg@google.com
CREATED:20120519T160731Z
DESCRIPTION:20120515 The PDUFA target date for lorcaserin is June 27\, 2012
 . There is no assurance that we will receive approval for lorcaserin on the
  PDUFA target date or ever. The FDA may decide not to approve lorcaserin\, 
 may issue another CRL\, may extend the PDUFA target date or may take variou
 s other actions.\n\nAdcom was May 10
LAST-MODIFIED:20120519T174434Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ARNA ARENA PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
X-MOZ-GENERATION:1
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120730
DTEND;VALUE=DATE:20120731
DTSTAMP:20171003T193836Z
UID:7d32a7c4-8570-413d-9e54-a0520808e1b0
CREATED:20120507T050801Z
DESCRIPTION:Arcalyst\n\nAdcom was May 8
LAST-MODIFIED:20120519T174403Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:REGN Regeneron PDUFA
TRANSP:TRANSPARENT
X-LIC-ERROR;X-LIC-ERRORTYPE=VALUE-PARSE-ERROR:No value for LOCATION propert
 y. Removing entire property:
X-MOZ-GENERATION:1
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20130105
DTEND;VALUE=DATE:20130106
DTSTAMP:20171003T193836Z
UID:61381991-b64f-4c19-84ba-26889c5f5f94
CREATED:20120519T174245Z
DESCRIPTION:http://ir.aegerion.com/releasedetail.cfm?ReleaseID=668490
LAST-MODIFIED:20120519T174251Z
LOCATION:
SEQUENCE:2
STATUS:CONFIRMED
SUMMARY:AEGR PDUFA
TRANSP:TRANSPARENT
X-LIC-ERROR;X-LIC-ERRORTYPE=VALUE-PARSE-ERROR:No value for LOCATION propert
 y. Removing entire property:
X-MOZ-GENERATION:1
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120628
DTSTAMP:20171003T193836Z
UID:am8losfee70ilidkfp16jis6d0@google.com
CREATED:20120519T160748Z
DESCRIPTION:20120426 The new Prescription Drug User Fee Act (PDUFA) date th
 e date by which action from the FDA is expected is June 28\, 2012.
LAST-MODIFIED:20120519T160748Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:BRISTOL MYERS SQUIBB CO PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120621
DTSTAMP:20171003T193836Z
UID:ue3qrgt0u9b9rs7njratrlhh3c@google.com
CREATED:20120519T160745Z
DESCRIPTION:20120426 Under the Prescription Drug User Fee Act (PDUFA)\, the
  FDA s goal for completing review of the NDA is June 21\, 2012.
LAST-MODIFIED:20120519T160746Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:RGEN REPLIGEN CORP PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120726
DTSTAMP:20171003T193836Z
UID:24k62uaullhughfc9em5uufjd8@google.com
CREATED:20120519T160744Z
DESCRIPTION:20120502 As a result\, we have a Prescription Drug User Fee Act
 \, or PDUFA\, goal date for RAYOS of July 26\, 2012.
LAST-MODIFIED:20120519T160744Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:HZNP HORIZON PHARMA INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120717
DTSTAMP:20171003T193836Z
UID:idphm8596scckaivs240s31toc@google.com
CREATED:20120519T160741Z
DESCRIPTION:20120507 As the submission of the comprehensive REMS was within
  three months of the PDUFA target date it was considered a major amendment 
 to the Qnexa NDA\, and in order to provide time for a full review of the su
 bmission\, the FDA extended the PDUFA target date by three months\, to July
  17\, 2012.
LAST-MODIFIED:20120519T160741Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:VVUS VIVUS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120727
DTSTAMP:20171003T193836Z
UID:k4rou4ec2rjh9fdf9cveju4i08@google.com
CREATED:20120519T160739Z
DESCRIPTION:20120508 In addition to the FDA-approved indication for advance
 d illness patients\, the U.S. Prescription Drug User Fee Act (PDUFA) action
  date for Salix's pending supplemental New Drug Application (sNDA) for subc
 utaneous Relistor in non-cancer pain patients is now July 27\, 2012.
LAST-MODIFIED:20120519T160739Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:PGNX PROGENICS PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120727
DTEND;VALUE=DATE:20120728
DTSTAMP:20171003T193836Z
UID:7069a813-5b7a-4bd7-b4b0-c1f34f662e99
CREATED:20120122T005136Z
DESCRIPTION:Relistor
LAST-MODIFIED:20120507T054203Z
LOCATION:
SEQUENCE:2
STATUS:CONFIRMED
SUMMARY:SLXP SALIX PHARMACEUTICALS LTD PDUFA
TRANSP:TRANSPARENT
X-LIC-ERROR;X-LIC-ERRORTYPE=VALUE-PARSE-ERROR:No value for LOCATION propert
 y. Removing entire property:
X-MOZ-GENERATION:2
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120605
DTEND;VALUE=DATE:20120606
DTSTAMP:20171003T193836Z
UID:ab533b4a-7d56-4b44-8dee-76bd24d4af3b
CREATED:20120317T164856Z
DESCRIPTION:WHITEHOUSE STATION\, N.J. & CAMBRIDGE\, Mass.\, Oct 05\, 2011 (
 BUSINESS WIRE) --\n\nMerck (NYSE:MRK)\, known outside the United States and
  Canada as MSD\, and ARIAD Pharmaceuticals\, Inc.\, (NASDAQ:ARIA)\, today a
 nnounced that the U.S. Food and Drug Administration (FDA) has accepted for 
 filing and review the New Drug Application (NDA) for ridaforolimus\, an inv
 estigational oral mTOR inhibitor under development for the treatment of met
 astatic soft-tissue or bone sarcomas in patients who had a favorable respon
 se to chemotherapy. The FDA assigned a Standard review classification to th
 is application.
LAST-MODIFIED:20120425T183238Z
LOCATION:
SEQUENCE:4
STATUS:CONFIRMED
SUMMARY:ARIA Ariad PDUFA
TRANSP:TRANSPARENT
X-LIC-ERROR;X-LIC-ERRORTYPE=VALUE-PARSE-ERROR:No value for LOCATION propert
 y. Removing entire property:
X-MOZ-GENERATION:2
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120501
DTSTAMP:20171003T193836Z
UID:v0pno65j5g2f1bdoibua5vrrpk@google.com
CREATED:20120425T151932Z
DESCRIPTION:20120319 The U.S. Food and Drug Administration granted Protalix
  a Prescription Drug User Fee Act (PDUFA) target action date of May 1\, 201
 2 for taliglucerase alfa.
LAST-MODIFIED:20120425T151932Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:PLX Protalix BioTherapeutics Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120404
DTEND;VALUE=DATE:20120405
DTSTAMP:20171003T193836Z
UID:32f229cb-3635-451e-9b8b-67225ff89ed0
CREATED:20120317T172924Z
DESCRIPTION:On April 4\, 2012\, the committee will discuss the data provide
 d to support the safety and efficacy of levofloxacin for the treatment of p
 neumonic plague in humans. Johnson and Johnson Pharmaceutical Research and 
 Development\, LLC (on behalf of Janssen Pharmaceuticals\, Inc.) has submitt
 ed efficacy supplements for Levaquin (levofloxacin) tablets\, injection\, a
 nd oral solution (NDA 20-634\, NDA 20-635\, and NDA 21-721\, respectively) 
 for treatment of pneumonic plague. Efficacy data for levofloxacin is based 
 on treatment in an animal model of plague. Safety and other supportive info
 rmation is derived from clinical studies and post-marketing experience in h
 umans.
LAST-MODIFIED:20120317T172924Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:JNJ Adcom
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20121029
DTEND;VALUE=DATE:20121030
DTSTAMP:20171003T193836Z
UID:45f076d5-d2e9-4a1f-b6be-9c4917097aea
CREATED:20120317T164608Z
DESCRIPTION:Cornerstone Therapeutics Inc. (NASDAQ: CRTX)\, a specialty phar
 maceutical company focused on acquiring\, developing and commercializing pr
 oprietary products for the hospital\, niche respiratory and related special
 ty markets\, announced today that the U.S. Food and Drug Administration (FD
 A) accepted a New Drug Application (NDA) for CRTX 080\, Cornerstone's produ
 ct candidate for the treatment of hyponatremia. The FDA has assigned a Pres
 cription Drug User Fee Act (PDUFA) goal date of October 29\, 2012. 
LAST-MODIFIED:20120317T164608Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:CRTX Cornerstone Therapeutics PDUFA
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120327
DTSTAMP:20171003T193836Z
UID:nmqtmuiq0ia2s6js74iksquifk@google.com
CREATED:20120317T162414Z
DESCRIPTION:20120227 In the United States\, the scheduled Prescription Drug
  User Fee Act (PDUFA) date for peginesatide is March 27\, 2012.
LAST-MODIFIED:20120317T162414Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AFFY AFFYMAX INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120726
DTSTAMP:20171003T193836Z
UID:g23n3lkuu63u7ldi2qlljvvo2k@google.com
CREATED:20120317T162406Z
DESCRIPTION:20120229 In November 2011\, Amarin announced that the NDA for A
 MR101 was accepted for filing by the FDA\, and that the FDA assigned a PDUF
 A date of July 26\, 2012. The PDUFA date is the goal date for the FDA to co
 mplete its review of the NDA.
LAST-MODIFIED:20120317T162406Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AMRN AMARIN CORP PLC UK PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120328
DTSTAMP:20171003T193836Z
UID:3fs9s801ohbp28ndvoa3us7s70@google.com
CREATED:20120317T162403Z
DESCRIPTION:20120307 In addition\, the FDA granted our request for a priori
 ty review of the NDA and\, under the Prescription Drug User Fee Act VI\, or
  PDUFA\, the FDA s goal is to review and act on the NDA by March 28\, 2012.
LAST-MODIFIED:20120317T162404Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:CHTP Chelsea Therapeutics International Ltd PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120123
DTSTAMP:20171003T193836Z
UID:g92ee1rh8cq34u75303s9ovv4c@google.com
CREATED:20120220T200621Z
DESCRIPTION:20120123 Exhibit Number Description 99.1 Press Release titled A
 lexza Announces Extension of the ADASUVE PDUFA Goal Date by Three Months\, 
 dated January 23\, 2012.
LAST-MODIFIED:20120220T200621Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ALXA Alexza Pharmaceuticals Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120307
DTSTAMP:20171003T193836Z
UID:dj3kjvfc44d0m02ismmcnl9cu8@google.com
CREATED:20120220T200619Z
DESCRIPTION:20120209 A decision from the Agency is expected by March 7\, 20
 12\, under the Prescription Drug User Fee Act (PDUFA).
LAST-MODIFIED:20120220T200619Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:NGSX NeurogesX Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20111227
DTSTAMP:20171003T193836Z
UID:kfv4ctkil59abn4dh833ai1c8k@google.com
CREATED:20120121T190400Z
DESCRIPTION:20120103 The FDA received our submission on December 27\, 2011\
 , and we expect that later this month the FDA will confirm its acceptance o
 f the response and assign a new Prescription Drug User Fee Act\, or PDUFA\,
  date.
LAST-MODIFIED:20120121T190400Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ARNA ARENA PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120306
DTEND;VALUE=DATE:20120307
DTSTAMP:20171003T193836Z
UID:3a0728f7-ece9-479a-a3fc-75550c71c347
CREATED:20111218T150337Z
DESCRIPTION:sNDA Dacogen AML
LAST-MODIFIED:20111218T151118Z
LOCATION:
SEQUENCE:4
STATUS:CONFIRMED
SUMMARY:ASTX Astex Pharmaceuticals PDUFA
TRANSP:TRANSPARENT
X-LIC-ERROR;X-LIC-ERRORTYPE=VALUE-PARSE-ERROR:No value for LOCATION propert
 y. Removing entire property:
X-MOZ-GENERATION:2
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120104
DTEND;VALUE=DATE:20120105
DTSTAMP:20171003T193837Z
UID:ok7cdqh1p0u0dkos6auat6elfo@google.com
CREATED:20110917T162200Z
DESCRIPTION:20110829 Subsys is under review for marketing approval by the U
 .S. Food and Drug Administration\, or FDA\, and the FDA has assigned a Pres
 cription Drug User Fee Act\, or PDUFA\, goal date of January 4\, 2012 for i
 ts review of our application.
LAST-MODIFIED:20111218T145506Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:NEOL.PK Insys Therapeutics Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
X-LIC-ERROR;X-LIC-ERRORTYPE=VALUE-PARSE-ERROR:No value for LOCATION propert
 y. Removing entire property:
X-MOZ-GENERATION:2
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120217
DTSTAMP:20171003T193837Z
UID:ovussf27d1e4tfqtqkd4e35iks@google.com
CREATED:20111218T143553Z
DESCRIPTION:20111215 The FDA's decision with respect to REMS does not alter
  the Prescription Drug User Fee Act (PDUFA) date for completion of FDA revi
 ew of the NDA\, which remains February 17\, 2012.
LAST-MODIFIED:20111218T143554Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:CORT CORCEPT THERAPEUTICS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120429
DTEND;VALUE=DATE:20120430
DTSTAMP:20171003T193837Z
UID:603b0053-9093-4ddd-b50a-c8c0de924cb9
CREATED:20110820T185918Z
DESCRIPTION:Avanafil
LAST-MODIFIED:20111119T194659Z
LOCATION:
SEQUENCE:1
STATUS:CONFIRMED
SUMMARY:VVUS Vivus PDUFA
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120609
DTSTAMP:20171003T193837Z
UID:8taj7mifsh90a83sj77gqhmtvc@google.com
CREATED:20111119T190915Z
DESCRIPTION:20111102 The U.S. Food and Drug Administration (FDA) has accept
 ed the sNDA and provided an effective Prescription Drug User Fee Act (PDUFA
 ) date to complete its review of June 9\, 2012.
LAST-MODIFIED:20111119T190915Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:XNPT XENOPORT INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20111112
DTSTAMP:20171003T193837Z
UID:n25buu663o99ch70pjc8ect3kg@google.com
CREATED:20111119T190912Z
DESCRIPTION:20111107 The Prescription Drug User Fee Act (PDUFA) date for IL
 UVIEN for DME is November 12\, 2011.
LAST-MODIFIED:20111119T190912Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:PSDV pSivida Corp PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120128
DTSTAMP:20171003T193837Z
UID:2rr0lcd9hjraseoak2hgl49ahs@google.com
CREATED:20111119T190907Z
DESCRIPTION:20111108 BYDUREON received marketing authorization in the Europ
 ean Union in June 2011 and is currently under review in the U.S.\, with a P
 rescription Drug User Fee Action (PDUFA) date of January 28\, 2012.
LAST-MODIFIED:20111119T190907Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AMLN AMYLIN PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20111208
DTSTAMP:20171003T193837Z
UID:e4ir6godneo2fijn1cup7c6kus@google.com
CREATED:20111119T190906Z
DESCRIPTION:20111108 The FDA has assigned a Prescription Drug User Fee Act 
 ( PDUFA ) date of December 8\, 2011.
LAST-MODIFIED:20111119T190906Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AIS ANTARES PHARMA INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120226
DTSTAMP:20171003T193837Z
UID:kpvu4n4a0fe821lrkl9gg3v9ms@google.com
CREATED:20111119T190903Z
DESCRIPTION:20111110 The FDA's goal is to review and act on the NDA by Febr
 uary 26\, 2012 under the Prescription Drug User Fee Act IV (PDUFA).
LAST-MODIFIED:20111119T190903Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:CBRX COLUMBIA LABORATORIES INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120425
DTSTAMP:20171003T193837Z
UID:m41702in7v8brt1elu41l4oi94@google.com
CREATED:20111119T190857Z
DESCRIPTION:20111118 The new Prescription Drug User Fee Act (PDUFA) action 
 date has been set for April 25\, 2012.
LAST-MODIFIED:20111119T190857Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:FURX Furiex Pharmaceuticals Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120214
DTEND;VALUE=DATE:20120215
DTSTAMP:20171003T193837Z
UID:4s9qon3sl6ose4cqd1qrac50d0@google.com
CREATED:20110627T005728Z
DESCRIPTION:20110510 The FDA has assigned a PDUFA date of November 14\, 201
 1. The PDUFA date is the target date for the FDA to complete its review of 
 the NDA.
LAST-MODIFIED:20111023T011040Z
LOCATION:
SEQUENCE:1
STATUS:CONFIRMED
SUMMARY:BPAX BIOSANTE PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20111127
DTSTAMP:20171003T193837Z
UID:binkop7hipkg8gnfuv4ge73khk@google.com
CREATED:20111023T002009Z
DESCRIPTION:20111005 The FDA has assigned a Prescription Drug User Fee Act 
 (PDUFA) action date of November 27\, 2011 for the completion of the NDA rev
 iew.
LAST-MODIFIED:20111023T002009Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:TSPT Transcept Pharmaceuticals Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120306
DTSTAMP:20171003T193837Z
UID:d6c4urub387aactc61v3dn03r4@google.com
CREATED:20111023T002009Z
DESCRIPTION:20110928 The FDA classified the review of the Complete Response
  as a Class 2 review and established March 6\, 2012 as the target action da
 te under the Prescription Drug User Fee Act (PDUFA) to complete its review 
 and potentially grant marketing approval for SURFAXIN.
LAST-MODIFIED:20111023T002009Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:DSCO DISCOVERY LABORATORIES INC DE PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20111028
DTSTAMP:20171003T193837Z
UID:pph800tsu8joubqq09v7hb02ug@google.com
CREATED:20110917T162158Z
DESCRIPTION:20110906 The FDA has assigned a Prescription Drug User Fee Act 
 (PDUFA) goal date of October 28\, 2011 for the review of the EXPAREL NDA.
LAST-MODIFIED:20110917T162158Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:PCRX Pacira Pharmaceuticals Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20111007
DTEND;VALUE=DATE:20111008
DTSTAMP:20171003T193837Z
UID:7021c1b8-fad6-4da8-b442-161d5e99c8f5
CREATED:20110820T185734Z
DESCRIPTION:Soliris® (eculizumab) as a treatment for patients with atypical
  Hemolytic Uremic Syndrome (aHUS). 
LAST-MODIFIED:20110820T185734Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ALXN Alexion PDUFA
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120128
DTEND;VALUE=DATE:20120129
DTSTAMP:20171003T193837Z
UID:bbed27be-82ae-45cd-afd8-9bc6719a22e6
CREATED:20110820T185045Z
DESCRIPTION:Bydureon
LAST-MODIFIED:20110820T185045Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ALKS Alkermes PDUFA
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20111120
DTEND;VALUE=DATE:20111121
DTSTAMP:20171003T193837Z
UID:a4821720-ebe1-4c03-bc1c-a552a5e43904
CREATED:20110820T184531Z
DESCRIPTION:
LAST-MODIFIED:20110820T184531Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SPPI SPECTRUM PHARMACEUTICALS PDUFA
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20111213
DTEND;VALUE=DATE:20111214
DTSTAMP:20171003T193837Z
UID:e5p2e05nc9rffbpmjqvnl9o7gc@google.com
ATTENDEE;CUTYPE=INDIVIDUAL;ROLE=REQ-PARTICIPANT;PARTSTAT=ACCEPTED;CN=PDUFA;
 X-NUM-GUESTS=0:mailto:5dso8589486irtj53sdkr4h6ek@group.calendar.google.com
CREATED:20110820T173356Z
DESCRIPTION:
LAST-MODIFIED:20110820T173403Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ENDP ENDO PHARMACEUTICALS PDUFA
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20111118
DTEND;VALUE=DATE:20111119
DTSTAMP:20171003T193837Z
UID:9t4dsqd8h6mn2mvemspffo8g10@google.com
CREATED:20110522T033455Z
DESCRIPTION:
LAST-MODIFIED:20110820T173003Z
LOCATION:
SEQUENCE:2
STATUS:CONFIRMED
SUMMARY:REGN Regeneron PDUFA
TRANSP:TRANSPARENT
X-LIC-ERROR;X-LIC-ERRORTYPE=VALUE-PARSE-ERROR:No value for LOCATION propert
 y. Removing entire property:
X-MOZ-GENERATION:1
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20111203
DTSTAMP:20171003T193837Z
UID:eui0ni5d0840abgel2t61fagss@google.com
CREATED:20110820T170042Z
DESCRIPTION:20110803 The FDA also assigned a Prescription Drug User Fee Act
  (PDUFA) date of December 3\, 2011 for its review of the NDA.
LAST-MODIFIED:20110820T170042Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:INCY INCYTE CORP PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20120326
DTSTAMP:20171003T193837Z
UID:7ae7q4751dvfff3mmcln3raek0@google.com
CREATED:20110820T170041Z
DESCRIPTION:20110804 Announced that the New Drug Application (NDA) for LEVA
 DEX for the potential acute treatment of migraine in adults was submitted t
 o and accepted for filing by the U.S. Food and Drug Administration (FDA)\, 
 with a goal date of March 26\, 2012 under the Prescription Drug User Fee Ac
 t (PDUFA).
LAST-MODIFIED:20110820T170041Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:MAPP MAP Pharmaceuticals Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20111112
DTSTAMP:20171003T193837Z
UID:pfnm5e37ra2vtij7r7c7ba93u4@google.com
CREATED:20110820T170038Z
DESCRIPTION:20110804 The FDA classified Alimera s response as a Class 2 res
 ubmission\, resulting in a six month review period and a Prescription Drug 
 User Fee Act or PDUFA date of November 12\, 2011.
LAST-MODIFIED:20110820T170038Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ALIM ALIMERA SCIENCES INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20110810
DTEND;VALUE=DATE:20110811
DTSTAMP:20171003T193837Z
UID:tf9vm43biqsd8cbf9pr2hs8aqg@google.com
CREATED:20110522T035846Z
DESCRIPTION:In February\, Gilead announced that it had refiled its New Drug
  Application (NDA) with the U.S. Food and Drug Administration (FDA) for the
  single-tablet regimen of Truvada and Tibotec’s investigational non-nucleos
 ide reverse transcriptase inhibitor TMC278 (rilpivirine hydrochloride) for 
 HIV-1 infection in adults. Gilead previously submitted an NDA for the singl
 e-tablet regimen of Truvada/TMC278 in 2010. Gilead announced in January tha
 t it had received a “refuse to file” notification from the FDA requesting a
 dditional information on the analytical methodology and qualification data 
 used to establish acceptable levels of recently identified degradants relat
 ed to emtricitabine\; this information was included in the refiling. Gilead
  was notified on April 6\, 2011\, that the FDA has accepted the filing\, gr
 anting it a “Priority Review” and assigning a Prescription Drug User Fee Ac
 t (PDUFA) date of August 10\, 2011. 
LAST-MODIFIED:20110810T154823Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:GILD Gilead PDUFA
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20110622
DTSTAMP:20171003T193837Z
UID:p42mjuk6b1ninrviltsi0hd1ck@google.com
CREATED:20110627T005733Z
DESCRIPTION:20110407 Six-month data are currently being reviewed by the FDA
  with a PDUFA goal of June 22\, 2011. The Complete Response was accepted by
  the FDA on January 11\, 2011\, with a PDUFA date of June 22\, 2011.
LAST-MODIFIED:20110627T005733Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:Fibrocell Science Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20110623
DTSTAMP:20171003T193837Z
UID:41q0hdj2u9s8rrart7m2d39r8k@google.com
CREATED:20110627T005731Z
DESCRIPTION:20110505 The U.S. Food and Drug Administration (FDA) has set a 
 June 23\, 2011 PDUFA goal date for the REMOXY New Drug Application (NDA) wh
 ich was resubmitted in December 2010 by King Pharmaceuticals (King) followi
 ng a Complete Response Letter received by Pain Therapeutics in December 200
 8.
LAST-MODIFIED:20110627T005731Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:DRRX DURECT CORP PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20110830
DTSTAMP:20171003T193837Z
UID:0god5nfqh9g51a4he9v1t2o6n4@google.com
CREATED:20110627T005730Z
DESCRIPTION:20110505 The FDA has granted priority review to Biologics Licen
 se Applications for its lead product candidate\, brentuximab vedotin\, for 
 the treatment of relapsed or refractory Hodgkin lymphoma and systemic anapl
 astic large cell lymphoma\, with a PDUFA date of August 30\, 2011.
LAST-MODIFIED:20110627T005730Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SGEN SEATTLE GENETICS INC WA PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20111113
DTEND;VALUE=DATE:20111114
DTSTAMP:20171003T193837Z
UID:kk0al73ts7gaakv7vjc2359f1s@google.com
CREATED:20110619T212649Z
DESCRIPTION:
LAST-MODIFIED:20110619T212649Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:IGXT IntelGenx
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20110615
DTEND;VALUE=DATE:20110616
DTSTAMP:20171003T193837Z
UID:e69qrlqpsi7lhumvdj5qa34cn8@google.com
CREATED:20110522T040230Z
DESCRIPTION:ezogabine
LAST-MODIFIED:20110601T050056Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:VRX Valeant PDUFA
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20111028
DTEND;VALUE=DATE:20111029
DTSTAMP:20171003T193837Z
UID:3tocp5gju7niokgp6rtc5v4790@google.com
CREATED:20110522T033157Z
DESCRIPTION:20110428 The Prescription Drug User Fee Act (PDUFA) date the da
 te by which action from the FDA is expected is October 28\, 2011.
LAST-MODIFIED:20110601T050056Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:BRISTOL MYERS SQUIBB CO PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20110617
DTEND;VALUE=DATE:20110618
DTSTAMP:20171003T193837Z
UID:9tj2o468cp2h14l5h17mg9fitc@google.com
ATTENDEE;CUTYPE=INDIVIDUAL;ROLE=REQ-PARTICIPANT;PARTSTAT=ACCEPTED;CN=PDUFA;
 X-NUM-GUESTS=0:mailto:5dso8589486irtj53sdkr4h6ek@group.calendar.google.com
CREATED:20110406T181325Z
DESCRIPTION:
LAST-MODIFIED:20110505T050749Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:CELG PDUFA
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20110429
DTSTAMP:20171003T193837Z
UID:ovikdjdhu3dj293d2v7kecs0rs@google.com
CREATED:20110406T175744Z
DESCRIPTION:20110310 Approximately 7 million warrants expired unexercised i
 n 2010. 2011/2012 Corporate Events and Potential Valuation Catalysts FUSILE
 V FDA PDUFA Action date in metastatic colorectal cancer by April 29\, 2011.
LAST-MODIFIED:20110505T050749Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SPPI SPECTRUM PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20101231
DTSTAMP:20171003T193837Z
UID:7cul2vralim49qnenrj4ftq0ms@google.com
CREATED:20110406T175742Z
DESCRIPTION:20110316 Transcept reported cash\, cash equivalents and marketa
 ble securities of $68.0 million at December 31\, 2010\, and currently proje
 cts its monthly cash use to range between $1.6 million and $2.1 million dur
 ing the period January 1\, 2011 to July 14\, 2011\, the PDUFA action date f
 or Intermezzo
LAST-MODIFIED:20110406T175742Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:TSPT Transcept Pharmaceuticals Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20110310
DTSTAMP:20171003T193837Z
UID:8j3bl4fvaee5hfbamv74agk0a8@google.com
CREATED:20110406T173736Z
DESCRIPTION:20110224 In December 2010\, the FDA extended the Prescription D
 rug User Fee Act (PDUFA) target date for the priority review of BENLYSTA to
  March 10\, 2011.
LAST-MODIFIED:20110406T173736Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:HGSI HUMAN GENOME SCIENCES INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20110523
DTSTAMP:20171003T193837Z
UID:avaauh2mn8r4jmcugbor1jjbcg@google.com
CREATED:20110220T080751Z
DESCRIPTION:20110203 A target review date of May 23\, 2011 was set under th
 e Prescription Drug User Fee Act (PDUFA) for the FDA s approval decision.
LAST-MODIFIED:20110304T053834Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:VRTX VERTEX PHARMACEUTICALS INC MA PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20110225
DTSTAMP:20171003T193837Z
UID:5u92q78ff7r4aafdf1u432ls9s@google.com
CREATED:20110220T080749Z
DESCRIPTION:20110218 The Company received a Prescription Drug User Fee Act 
 (PDUFA) date of February 25\, 2011 from the U.S. Food and Drug Administrati
 on for the taliglucerase alfa NDA.
LAST-MODIFIED:20110304T053834Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:PLX Protalix BioTherapeutics Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20110406
DTSTAMP:20171003T193837Z
UID:ia49i3ms04l5bb9giptt9tfc1s@google.com
CREATED:20110220T080750Z
DESCRIPTION:20110216 The FDA has designated the new drug application (NDA) 
 resubmission as a Class 2 response and set a new Prescription Drug User Fee
  Act (PDUFA) date of April 6\, 2011.
LAST-MODIFIED:20110304T053833Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:XNPT XENOPORT INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20110512
DTEND;VALUE=DATE:20110513
DTSTAMP:20171003T193837Z
UID:2mv2ub8pv20a18ccnfsc1hu2a0@google.com
ATTENDEE;CUTYPE=INDIVIDUAL;ROLE=REQ-PARTICIPANT;PARTSTAT=ACCEPTED;CN=PDUFA;
 X-NUM-GUESTS=0:mailto:5dso8589486irtj53sdkr4h6ek@group.calendar.google.com
CREATED:20110220T081739Z
DESCRIPTION:http://www.businesswire.com/news/home/20110131005622/en/BioMime
 tic-Therapeutics-Announces-Date-FDA-Advisory-Panel
LAST-MODIFIED:20110304T053833Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:BMTI FDA Panel
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20090225
DTSTAMP:20171003T193837Z
UID:jb3j2952udk55k34s28ijb72p0@google.com
CREATED:20110220T080803Z
DESCRIPTION:20110202 Under the Prescription Drug User Fee Act ( PDUFA )\, t
 he original deadline for the FDA s decision on the Ampligen NDA was Februar
 y 25\, 2009.
LAST-MODIFIED:20110220T080803Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:HEB HEMISPHERX BIOPHARMA INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20110307
DTSTAMP:20171003T193837Z
UID:4tfluqi32fpg0qmtd5bk7gsldg@google.com
CREATED:20110125T183507Z
DESCRIPTION:20110107 The Prescription Drug User Fee Act (PDUFA) goal date f
 or the Agency s Priority Review of the application is March 7\, 2011.
LAST-MODIFIED:20110209T015359Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SLXP SALIX PHARMACEUTICALS LTD PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20110413
DTSTAMP:20171003T193837Z
UID:mu1981ehuol493eeiu5t51aavk@google.com
CREATED:20110125T183448Z
DESCRIPTION:20110114 In order to provide for additional time to review the 
 information that was solicited by the FDA and provided by Hologic\, the FDA
  has extended the PDUFA date to April 13\, 2011.
LAST-MODIFIED:20110209T015358Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:KV KV PHARMACEUTICAL CO DE PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20110130
DTSTAMP:20171003T193837Z
UID:r2vg5su8co25mnnqrmmud51tcs@google.com
CREATED:20110125T183440Z
DESCRIPTION:20110118 DM-1796 Regulatory Status\; Orphan Drug Designation Th
 e DM-1796 NDA is under review by the FDA with a PDUFA date of January 30\, 
 2011.
LAST-MODIFIED:20110209T015357Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:DEPO DEPOMED INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20100521
DTSTAMP:20171003T193837Z
UID:e2b1tj9g1p8scttlpnhnhsnras@google.com
CREATED:20110125T183518Z
DESCRIPTION:20110105 A New Drug Application for vilazodone was accepted for
  review by the U.S. Food and Drug Administration (FDA) on May 21\, 2010\, w
 ith January 22\, 2011 currently assigned for decision-making by the FDA und
 er the Prescription Drug User Fee Act or PDUFA.
LAST-MODIFIED:20110125T183518Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:CLDA CLINICAL DATA INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20101230
DTEND;VALUE=DATE:20101231
DTSTAMP:20171003T193837Z
UID:smd91gltf500c7ul6onqc4al48@google.com
CREATED:20101017T192613Z
DESCRIPTION:The FDA has informed Endo Pharmaceuticals that the response is 
 considered to be complete and has issued a PDUFA date of Dec. 30\, 2010.
LAST-MODIFIED:20110116T020153Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ENDP Endo Pharmaceuticals PDUFA
TRANSP:TRANSPARENT
X-MOZ-LASTACK:20101230T184255Z
X-MOZ-GENERATION:1
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20100830
DTSTAMP:20171003T193837Z
UID:rber8998s8sg2nuigglkro85po@google.com
CREATED:20101219T211955Z
DESCRIPTION:20101201 The PDUFA date for VIOKASE was August 30\, 2010. The F
 DA subsequently informed us that it postponed the PDUFA date for the VIOKAS
 E NDA to November 30\, 2010.
LAST-MODIFIED:20101219T211955Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:Axcan Intermediate Holdings Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20110122
DTSTAMP:20171003T193837Z
UID:dj4i74kl6h7u5rpokg023tlo7g@google.com
CREATED:20101121T184727Z
DESCRIPTION:20101109 The Company confirmed that its commercial preparations
  for the launch of vilazodone\, if approved for the treatment of depression
 \, are accelerating as the decision date assigned under the Prescription Dr
 ug User Fee Act (PDUFA) of January 22\, 2011 rapidly approaches.
LAST-MODIFIED:20101209T062401Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:CLDA CLINICAL DATA INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20101207
DTSTAMP:20171003T193837Z
UID:eua010dlieheru86jm11c6du9s@google.com
CREATED:20101121T184735Z
DESCRIPTION:20100809 Based on this classification\, the FDA has issued an a
 ction date of December 7\, 2010 under the Prescription Drug User Fee Act (P
 DUFA). We are pleased with the FDA s acceptance of the sNDA for XIFAXAN550 
 and their decision to grant Priority Review for our application\, said Bill
  Forbes\, Pharm.
LAST-MODIFIED:20101209T062401Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SLXP SALIX PHARMACEUTICALS LTD PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20101229
DTSTAMP:20171003T193837Z
UID:pg68vufnfj1u6g6559sorcio24@google.com
CREATED:20101121T184738Z
DESCRIPTION:20100802 In July 2010\, the FDA accepted MannKind s reply to th
 e Complete Response letter and set a PDUFA action date of December 29\, 201
 0.
LAST-MODIFIED:20101209T062401Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:MNKD MANNKIND CORP PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20101209
DTSTAMP:20171003T193837Z
UID:996n4b8vup6h9ji0ahag2nt2no@google.com
CREATED:20101121T184729Z
DESCRIPTION:20101027 The FDA has assigned belimumab a PDUFA target date of 
 December 9\, 2010\, and an FDA Advisory Committee meeting to consider the b
 elimumab Biologics License Application (BLA) is scheduled to take place on 
 November 16\, 2010.
LAST-MODIFIED:20101209T062401Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:HGSI HUMAN GENOME SCIENCES INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20101207
DTSTAMP:20171003T193837Z
UID:gci9s3mbdqmlh8ifumlhsvjroo@google.com
CREATED:20101121T184728Z
DESCRIPTION:20101103 The U.S. Food and Drug Administration (FDA) has schedu
 led the Endocrinologic and Metabolic Drugs Advisory Committee meeting on De
 cember 7\, 2010 and the Prescription Drug User Fee Act (PDUFA) action date 
 has been set for January 31\, 2011.
LAST-MODIFIED:20101209T062400Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:OREX Orexigen Therapeutics Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20100914
DTSTAMP:20171003T193837Z
UID:31khfnhubp2b36n5pt0mtbgpp8@google.com
CREATED:20101121T184737Z
DESCRIPTION:20100805 The FDA requested that this data package be submitted 
 to the FDA at least 30 days prior to the Prescription Drug User Fee Act (PD
 UFA) action date of September 14\, 2010.
LAST-MODIFIED:20101121T184737Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SVNT SAVIENT PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20101022
DTSTAMP:20171003T193837Z
UID:4u39sbklf9fo5e3q3j1cdoi1l0@google.com
CREATED:20101121T184731Z
DESCRIPTION:20101020 The agency issued a complete response letter to the co
 mpanies in March 2010 and in May 2010 classified the companies first comple
 te response as a Class 2 resubmission with a PDUFA action date of October 2
 2\, 2010.
LAST-MODIFIED:20101121T184731Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ALKS ALKERMES INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20101028
DTSTAMP:20171003T193837Z
UID:0327rgntg7ars2vnu6lh4oa2uk@google.com
CREATED:20101121T184546Z
DESCRIPTION:20100802 We intend to work closely with the FDA leading up to o
 ur October 28\, 2010 PDUFA date to address the labeling and safety question
 s raised during the proceedings.
LAST-MODIFIED:20101121T184546Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:VVUS VIVUS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20101012
DTSTAMP:20171003T193837Z
UID:9kg244l01dfh6lsi8a49dm9kbc@google.com
CREATED:20101121T184540Z
DESCRIPTION:20100917 The current Prescription Drug User Fee Act (PDUFA) dat
 e for VIVITROL is October 12\, 2010\; the PDUFA date is the target date for
  the FDA to complete its review of the VIVITROL sNDA.
LAST-MODIFIED:20101121T184540Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ALKS ALKERMES INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20101022
DTSTAMP:20171003T193837Z
UID:n5cltmn39bjua2iqc6pi2rjta4@google.com
CREATED:20101121T184538Z
DESCRIPTION:20101021 The agency issued a complete response letter to the co
 mpanies in March 2010 and in May 2010 classified the companies first comple
 te response as a Class 2 resubmission with a PDUFA action date of October 2
 2\, 2010.
LAST-MODIFIED:20101121T184538Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AMLN AMYLIN PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20100504
DTSTAMP:20171003T193837Z
UID:imbf58tbuu67fcg1623eu88npg@google.com
CREATED:20101118T033950Z
DESCRIPTION:20100429 Our New Drug Application (NDA) for pirfenidone was gra
 nted Priority Review status on January 4\, with a PDUFA action date of May 
 4\, 2010.
LAST-MODIFIED:20101118T033950Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ITMN INTERMUNE INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20101011
DTSTAMP:20171003T193837Z
UID:2om0k83b5hrfhe8ik24u94magc@google.com
CREATED:20101118T033945Z
DESCRIPTION:20100526 Alexza has completed and announced positive results fr
 om both of its AZ-004 Phase 3 clinical trials\, submitted a New Drug Applic
 ation submission in December 2009\, and has a Prescription Drug User Fee Ac
 t (PDUFA) goal date of October 11\, 2010.
LAST-MODIFIED:20101118T033945Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ALXA Alexza Pharmaceuticals Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20100911
DTSTAMP:20171003T193837Z
UID:1ube6k68ppvo70pa9tmjrfl4l8@google.com
CREATED:20101118T033940Z
DESCRIPTION:20100728 With the current PDUFA date set for September 11\, 201
 0\, we are working with the FDA to finalize labeling\, REMS and other post-
 approval commitments in support of an approval for the IS indication\, adde
 d Mr. Bailey.
LAST-MODIFIED:20101118T033940Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:QCOR QUESTCOR PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20101022
DTSTAMP:20171003T193837Z
UID:kkv12ef2vl98um1ojdo1frsdis@google.com
CREATED:20101118T033931Z
DESCRIPTION:20100916 The FDA has assigned a PDUFA date\, the target date fo
 r the agency to complete its review of the lorcaserin New Drug Application 
 (NDA)\, of October 22\, 2010.
LAST-MODIFIED:20101118T033931Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ARNA ARENA PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20101024
DTSTAMP:20171003T193837Z
UID:evvdpgakf580so3crj5f3n192c@google.com
CREATED:20101107T173240Z
DESCRIPTION:20100716 The new PDUFA date is October 24\, 2010.
LAST-MODIFIED:20101111T055911Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:WCRX Warner Chilcott plc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20101016
DTSTAMP:20171003T193837Z
UID:qf477niihpine4r866fni0ei20@google.com
CREATED:20101107T173247Z
DESCRIPTION:20100430 The FDA has granted XiDay a standard review time of te
 n months\, assigning ISTA a Prescription Drug User Fee Act\, or PDUFA\, act
 ion date of October 16\, 2010.
LAST-MODIFIED:20101111T055911Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ISTA ISTA PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20100507
DTSTAMP:20171003T193837Z
UID:anb6v7krtlt5glond7mj9170hc@google.com
CREATED:20101107T173248Z
DESCRIPTION:20100419 Oral arguments are scheduled for May 7\, 2010. - 2 - T
 he company confirmed that the Prescription Drug User Fee Act (PDUFA) date f
 or Cymbalta in chronic pain passed without action by the U.S. Food and Drug
  Administration (FDA).
LAST-MODIFIED:20101107T173248Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:LLY LILLY ELI CO PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20101104
DTEND;VALUE=DATE:20101105
DTSTAMP:20171003T193837Z
UID:57BF7DEF-EC2B-456D-9027-4A5BAAC7C5D7
CREATED:20101017T191245Z
DESCRIPTION:On May 14\, 2010\, the Company announced that the FDA had class
 ified the OFIRMEV NDA resubmission as a complete Class 2 response and assig
 ned a Prescription Drug User Fee Act (“PDUFA”) action date of November 4\, 
 2010. 
LAST-MODIFIED:20101020T034814Z
LOCATION:
SEQUENCE:4
STATUS:CONFIRMED
SUMMARY:CADX Cadence Pharmaceuticals PDUFA
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20110131
DTEND;VALUE=DATE:20110201
DTSTAMP:20171003T193837Z
UID:823D86E4-B8F0-4C4D-AEDE-9DAA3EE534D6
CREATED:20101017T191451Z
DESCRIPTION:Contrave NDA filing was accepted by FDA and assigned a Prescrip
 tion Drug User Fee Act (PDUFA) action date of January 31\, 2011. 
LAST-MODIFIED:20101020T034813Z
LOCATION:
SEQUENCE:4
STATUS:CONFIRMED
SUMMARY:OREX Orexigen PDUFA
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20101116
DTEND;VALUE=DATE:20101117
DTSTAMP:20171003T193837Z
UID:032DC78B-46B7-4270-847B-7217DA06F6C0
CREATED:20100917T151059Z
DESCRIPTION:The committee will discuss biologic license application (BLA) 1
 25370\, belimumab\, proposed trade name BENLYSTA\, sponsored by Human Genom
 e Sciences\, for the proposed indication of reducing disease activity in ad
 ult patients with active\, autoantibody-positive systemic lupus erythematos
 us (SLE).
LAST-MODIFIED:20101020T034813Z
LOCATION:
SEQUENCE:4
STATUS:CONFIRMED
SUMMARY:HGSI Human Genome Sciences FDA Panel
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20101030
DTEND;VALUE=DATE:20101031
DTSTAMP:20171003T193837Z
UID:562603E2-AEFB-41D3-BB89-CF5A12EC3220
CREATED:20101017T191039Z
DESCRIPTION:We are very pleased that the FDA has accepted our Complete Resp
 onse submission and assigned a PDUFA date of October 30\, 2010\,” said Keit
 h Katkin\, Avanir’s President and CEO. “An FDA decision on the PBA applicat
 ion is fast approaching and we continue to make excellent progress on marke
 t development activities to support the planned launch of AVP-923 in the fi
 rst calendar quarter of 2011. With the additional capital from our recent f
 inancing\, we have been able to fill key leadership positions in our commer
 cial organization and increase efforts in PBA disease awareness to set the 
 stage for what we hope will be a successful launch of AVP-923. We hope to p
 rovide an important therapy to an underserved patient population that curre
 ntly has no approved treatment options.
LAST-MODIFIED:20101020T034813Z
LOCATION:
SEQUENCE:5
STATUS:CONFIRMED
SUMMARY:AVNR Avanir PDUFA
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20101216
DTEND;VALUE=DATE:20101217
DTSTAMP:20171003T193837Z
UID:41320294-CB98-40FA-83F9-A7BDCA581D30
CREATED:20101014T060535Z
DESCRIPTION:AstraZeneca today announced that the US Food and Drug Administr
 ation (FDA) has extended the time to complete its review of the New Drug Ap
 plication (NDA) for ticagrelor (BRILINTA).\n\nAccordingly\, the FDA extende
 d the Prescription Drug User Fee Act (PDUFA) date from 16 September 2010 to
  16 December 2010. AstraZeneca will continue to work closely with the FDA t
 o support the review of the ticagrelor NDA.\n\nTicagrelor is currently unde
 r regulatory review in nine additional territories around the world\, inclu
 ding the European Union\, Canada\, and Brazil.\n\n
LAST-MODIFIED:20101020T034812Z
LOCATION:
SEQUENCE:5
STATUS:CONFIRMED
SUMMARY:AZN Astrazeneca PDUFA
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20101011
DTEND;VALUE=DATE:20101012
DTSTAMP:20171003T193837Z
UID:hhvl0d82ftncv83is19m75gid8@google.com
CREATED:20100912T033903Z
DESCRIPTION:20100303 The NDA for JZP-6 was filed by the FDA in February 201
 0 and the target date for the FDA to complete its review under the Prescrip
 tion Drug User Fee Act (PDUFA) is October 11\, 2010.
LAST-MODIFIED:20101020T034811Z
LOCATION:
SEQUENCE:3
STATUS:CONFIRMED
SUMMARY:JAZZ JAZZ PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20100916
DTEND;VALUE=DATE:20100917
DTSTAMP:20171003T193837Z
UID:B73BF26C-F811-4D7C-9A36-EBC396AFAE35
URL:http://www.ft.com/cms/s/2/e86c0d58-b775-11df-8ef6-00144feabdc0\,dwp_uui
 d=e8477cc4-c820-11db-b0dc-000b5df10621.html
CREATED:20100913T013334Z
DESCRIPTION:The committee will discuss the available safety and efficacy da
 ta for supplemental new drug application (sNDA) 21-897/015\, VIVITROL (nalt
 rexone for extended-release injectable suspension)\, sponsored by Alkermes\
 , Inc.\, for the treatment of opioid dependence.
LAST-MODIFIED:20101003T040822Z
LOCATION:
SEQUENCE:8
STATUS:CONFIRMED
SUMMARY:ALKS Alkermes Pharma Vivitrol FDA Panel
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20101118
DTEND;VALUE=DATE:20101119
DTSTAMP:20171003T193837Z
UID:3778FD9D-0BEF-47FA-8C53-824F5A0C1E85
CREATED:20100912T040624Z
DESCRIPTION:Agenda: On November 18\, 2010\, the committee will discuss\, ma
 ke recommendations\, and vote on information related to the premarket appro
 val application for MelaFind\, sponsored by MELA Sciences. MelaFind is a co
 mputer-controlled multi-spectral dermoscope that uses light\, wavelengths f
 rom 430 nanometers (nm) (blue) through 950 nm (near infrared)\, to image th
 e skin through a thin layer of liquid (alcohol or oil)\, making lesion stru
 ctures under the skin surface visible to the observer. A complementary meta
 l oxide semiconductor digital camera inside the probe captures the images a
 nd then differentiates them among pigmented skin lesions for melanoma risk 
 using predefined software statistical pattern recognition algorithms.
LAST-MODIFIED:20100912T040735Z
LOCATION:
SEQUENCE:4
STATUS:CONFIRMED
SUMMARY:MELA Mela Sciences FDA Panel
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20100916
DTEND;VALUE=DATE:20100917
DTSTAMP:20171003T193837Z
UID:BB2CCD00-4E40-4FA3-82AA-0F71669BB8BD
CREATED:20100912T035427Z
DESCRIPTION:On September 16\, 2010\, the committee will discuss the safety 
 and efficacy of new drug application (NDA) 22–529\, with the proposed trade
  name LORQESS (lorcaserin hydrochloride) Tablets\, sponsored by Arena Pharm
 aceuticals\, Inc.\, as an adjunct to diet and exercise for weight managemen
 t in patients with a body mass index (BMI) of equal to or greater than 30 k
 ilograms (kg) per square meter\, or a BMI equal to or greater than 27 kg pe
 r square meter if accompanied by weight-related co-morbidities (which inclu
 de\, for example: high blood pressure\, heart disease\, or diabetes). The B
 MI is a measure of body weight (mass) based on a person’s weight and height
 \, and is a widely-used tool for doctors in assessing optimum weights for a
  patient.
LAST-MODIFIED:20100912T040534Z
LOCATION:
SEQUENCE:4
STATUS:CONFIRMED
SUMMARY:ARNA Arena Pharmaceuticals Lorcaserin FDA Panel
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20100924
DTEND;VALUE=DATE:20100925
DTSTAMP:20171003T193837Z
UID:089ADE30-3262-42C8-B92C-279380E78FC1
CREATED:20100912T035844Z
DESCRIPTION:Agenda: On September 24\, 2010\, the committee will discuss\, m
 ake\nrecommendations\, and vote on a premarket approval application for the
 \nSelenia C Digital Breast Tomosynthesis System\, sponsored by Hologic\, In
 c. The\nSelenia C Digital Breast Tomosynthesis System is intended for use i
 n the same\nclinical applications as traditional mammographic systems.
LAST-MODIFIED:20100912T035913Z
LOCATION:
SEQUENCE:4
STATUS:CONFIRMED
SUMMARY:HOLX Hologic Inc FDA Panel
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20061006
DTSTAMP:20171003T193837Z
UID:52vuuss6opfiigjulcc775gnuo@google.com
CREATED:20100912T034426Z
DESCRIPTION:20060912 It is currently under review with the U.S. Food and Dr
 ug Administration for the treatment of ADHD in pediatric populations (ages 
 6 - 12)\, with an October 6\, 2006 PDUFA date.
LAST-MODIFIED:20100912T034426Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:NEW RIVER PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20061029
DTSTAMP:20171003T193837Z
UID:nedt5ci3cd0h05iijk1fpofhmo@google.com
CREATED:20100912T034425Z
DESCRIPTION:20061006 The NDA has a target action date for a marketing appro
 val decision by October 29\, 2006 under the Prescription Drug User Fee Act 
 (PDUFA).
LAST-MODIFIED:20100912T034426Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:GENTA INC DE PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20061209
DTSTAMP:20171003T193837Z
UID:quhbf0t4rbvq9vssbss3d0emo0@google.com
CREATED:20100912T034424Z
DESCRIPTION:20061026 Millennium was recently granted priority review by the
  U.S. Food and Drug Administration for its supplementary new drug applicati
 on (sNDA) covering VELCADE for relapsed mantle cell lymphoma (MCL)\, with a
  PDUFA date of December 9\, 2006.
LAST-MODIFIED:20100912T034424Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:MILLENNIUM PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20070531
DTSTAMP:20171003T193837Z
UID:5ijo76shhvai1t3mb9t0j8o8e8@google.com
CREATED:20100912T034424Z
DESCRIPTION:20061027 Under PDUFA guidelines\, the PDUFA date for our NDA is
  May 31\, 2007\, which is the date by which we expect to receive an action 
 letter from the FDA on this filing.
LAST-MODIFIED:20100912T034424Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:CRITICAL THERAPEUTICS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20070521
DTSTAMP:20171003T193837Z
UID:iu5u3ej9rjmc7jifffbploroqs@google.com
CREATED:20100912T034423Z
DESCRIPTION:20061027 The Prescription Drug User Fee Act (PDUFA) date is May
  21\, 2007 for this application. The PDUFA date for this application is Jun
 e 24\, 2007. The PDUFA date for the application is January 21\, 2007.
LAST-MODIFIED:20100912T034423Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SHPGY Shire plc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20070503
DTSTAMP:20171003T193837Z
UID:9i5jgf15a6t67vbvv267eio3kc@google.com
CREATED:20100912T034422Z
DESCRIPTION:20061108 The FDA established a PDUFA date of May 3\, 2007 for t
 he expected completion of its review of the NDA.
LAST-MODIFIED:20100912T034422Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:Valera Pharmaceuticals Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20070503
DTSTAMP:20171003T193837Z
UID:82iu28k8cgbjcpj3u24oab68vc@google.com
CREATED:20100912T034421Z
DESCRIPTION:20061212 The Company has filed a New Drug Application (NDA) for
  SUPPRELIN-LA and under the Prescription Drug User Fee Act (PDUFA)\, the FD
 A is expected to complete its review and act upon this NDA submission by Ma
 y 3\, 2007.
LAST-MODIFIED:20100912T034421Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:INDEVUS PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20070813
DTSTAMP:20171003T193837Z
UID:rtsbcppaghf9ipmmc0alqpogdk@google.com
CREATED:20100912T034420Z
DESCRIPTION:20061215 The FDA Prescription Drug User Fee Act (PDUFA) target 
 action date for SANCTURA XR is August 13\, 2007.
LAST-MODIFIED:20100912T034420Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:INDEVUS PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20061102
DTSTAMP:20171003T193837Z
UID:d5ftdcrgang35kmvu21q4323ko@google.com
CREATED:20100912T034418Z
DESCRIPTION:20061215 If the FDA agrees that the submission\, taken together
  with the Company s November 2\, 2006 submission\, represents a complete re
 sponse\, the FDA will establish a new Prescription Drug User Fee Act (PDUFA
 ) action date.
LAST-MODIFIED:20100912T034418Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ENCYSIVE PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20070615
DTSTAMP:20171003T193837Z
UID:pcnq77vu9es81uhep50qua9e78@google.com
CREATED:20100912T034418Z
DESCRIPTION:20061228 The FDA has designated the review as a Class 2 resubmi
 ssion and issued a new Prescription Drug User Fee Act (PDUFA) target action
  date of June 15\, 2007.
LAST-MODIFIED:20100912T034418Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ENCYSIVE PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20070721
DTSTAMP:20171003T193837Z
UID:d50fe0t6ut6pgdkhjo5jhi0itg@google.com
CREATED:20100912T034358Z
DESCRIPTION:20070212 DOR has filed an NDA with the FDA for the treatment of
  GI GVHD\, and has received a PDUFA date of July 21\, 2007.
LAST-MODIFIED:20100912T034358Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:DOR BIOPHARMA INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20071231
DTSTAMP:20171003T193837Z
UID:4nvje8rom8j85nvhioacaj518g@google.com
CREATED:20100912T034353Z
DESCRIPTION:20070426 The Prescription Drug User Fee Act (PDUFA) date for co
 mpletion of review by FDA is December 31\, 2007.
LAST-MODIFIED:20100912T034353Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:PCYC PHARMACYCLICS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20070815
DTSTAMP:20171003T193837Z
UID:vtse9ilo9iu73027p1lrh9deao@google.com
CREATED:20100912T034353Z
DESCRIPTION:20070502 First a New Drug Application for satraplatin was filed
  and accepted for priority review\, with a target decision date (PDUFA date
 ) of August 15\, 2007\, by the FDA.
LAST-MODIFIED:20100912T034353Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SPPI SPECTRUM PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20071018
DTSTAMP:20171003T193837Z
UID:plco9tba7cgkg0imv0u02u3a64@google.com
CREATED:20100912T034351Z
DESCRIPTION:20070503 During the quarter\, the company received notification
  of the acceptance of its Biologic Licensing Application by the FDA\, with 
 an anticipated response (PDUFA) date of October 18\, 2007.
LAST-MODIFIED:20100912T034351Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ZGEN ZYMOGENETICS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20080123
DTSTAMP:20171003T193837Z
UID:bfp5j97ibbnk2mamqhpao9hpt8@google.com
CREATED:20100912T034350Z
DESCRIPTION:20070508 The Company has been notified by the Agency that its N
 DA has been received\, and if accepted for filing\, the application would r
 eceive a Prescription Drug User Fee Act (PDUFA) target action date of Janua
 ry 23\, 2008.
LAST-MODIFIED:20100912T034350Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ADVANCIS PHARMACEUTICAL CORP PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20070729
DTSTAMP:20171003T193837Z
UID:sp7281tvu2jhdol8j7l5gg0tq0@google.com
CREATED:20100912T034347Z
DESCRIPTION:20070531 With a PDUFA action date of July 29\, 2007 from the U.
 S. Food and Drug Administration\, the Company\, currently expects the produ
 ct to be approved and launched during the second half of fiscal 2008.
LAST-MODIFIED:20100912T034347Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:KV KV PHARMACEUTICAL CO DE PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20080130
DTSTAMP:20171003T193837Z
UID:1ubvgp7uuj15n6dhbqq4halnl0@google.com
CREATED:20100912T034342Z
DESCRIPTION:20070723 The FDA has set a Prescription Drug User Fee Act (PDUF
 A) date of January 30\, 2008 to complete its review of the NDA\, and comple
 tion of the MAA review by the EMEA is expected to occur in 2008.
LAST-MODIFIED:20100912T034342Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:PGNX PROGENICS PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20070924
DTSTAMP:20171003T193837Z
UID:8hsmlq3plaudssdq1el0pbbmo8@google.com
CREATED:20100912T034342Z
DESCRIPTION:20070726 The PDUFA date for this application is September 24\, 
 2007.
LAST-MODIFIED:20100912T034342Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ANESIVA INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20070830
DTSTAMP:20171003T193837Z
UID:4b0njdftbrbc1s2j5l5ggc78gc@google.com
CREATED:20100912T034341Z
DESCRIPTION:20070802 Our next major milestone is the August 30\, 2007 PDUFA
  date for Somatuline Autogel\, followed by its U.S. launch subject to FDA a
 pproval\, " added Dr. Scarlett.
LAST-MODIFIED:20100912T034341Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:TERCICA INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20070522
DTSTAMP:20171003T193837Z
UID:ivu6a809siid8cbkc6lnqq4n10@google.com
CREATED:20100912T034340Z
DESCRIPTION:20070802 The Company was notified by the FDA that its NDA was a
 ccepted for filing on May 22\, 2007\, and that the application received a P
 rescription Drug User Fee Act (PDUFA) target action date of January 23\, 20
 08.
LAST-MODIFIED:20100912T034340Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:MiddleBrook Pharmaceuticals Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20071021
DTSTAMP:20171003T193837Z
UID:uj06t9aqm0lc8nk5krqh7vge64@google.com
CREATED:20100912T034340Z
DESCRIPTION:20070814 We will continue to work with the FDA to ensure that o
 rBec reaches patients as soon as possible as we work towards our new PDUFA 
 date of October 21\, 2007.
LAST-MODIFIED:20100912T034340Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:DOR BIOPHARMA INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20070821
DTSTAMP:20171003T193837Z
UID:rs9mctis5pb7ibhrbhmna2m97g@google.com
CREATED:20100912T034339Z
DESCRIPTION:20070822 Exhibit 99.1 For Immediate Release Contact at Neurocri
 ne Biosciences: Elizabeth Foster (858) 617-7600 NEUROCRINE ANNOUNCES PDUFA 
 ACTION DATE OF DECEMBER 12\, 2007 FOR INDIPLON CAPSULES San Diego\, CA\, Au
 gust 21\, 2007 Neurocrine Biosciences\, Inc. (NASDAQ:NBIX) announced today
LAST-MODIFIED:20100912T034339Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:NBIX NEUROCRINE BIOSCIENCES INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20080210
DTSTAMP:20171003T193837Z
UID:2k9l2pg869r9c1smesqjv54h1g@google.com
CREATED:20100912T034337Z
DESCRIPTION:20070828 The FDA informed the Company that the response is cons
 idered a complete class 2 response with a Prescription Drug User Fee Act (P
 DUFA) goal date of February 10\, 2008.
LAST-MODIFIED:20100912T034337Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ADLR ADOLOR CORP PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20071212
DTSTAMP:20171003T193837Z
UID:c03vi0ofp6lc5cc34abgovgh40@google.com
CREATED:20100912T034335Z
DESCRIPTION:20071101 In anticipation of our PDUFA date on December 12\, 200
 7 we are currently engaged in pre-commercialization activities for indiplon
 .
LAST-MODIFIED:20100912T034335Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:NBIX NEUROCRINE BIOSCIENCES INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20080428
DTSTAMP:20171003T193837Z
UID:9u26llthhr50rtcpbpug98l3p0@google.com
CREATED:20100912T034335Z
DESCRIPTION:20071101 The Prescriptions Drug User Fee Act action date ( PDUF
 A date ) is April 28\, 2008. Shire is expecting a decision from the FDA on 
 the approvability of VYVANSE intermediate strength products in the pediatri
 c indication by the PDUFA date\, December 15\, 2007.
LAST-MODIFIED:20100912T034335Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SHPGY Shire plc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20071129
DTSTAMP:20171003T193837Z
UID:u5tda69ravp8l38p5knmb7vk60@google.com
CREATED:20100912T034334Z
DESCRIPTION:20071102 The original action date under the Prescription Drug U
 ser Fee Act (PDUFA) for the BLA was November 29\, 2007. The FDA considers t
 his additional information to be a major amendment to the rilonacept BLA\, 
 allowing the extension of the action date under PDUFA regulations.
LAST-MODIFIED:20100912T034334Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:REGN REGENERON PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20071105
DTSTAMP:20171003T193837Z
UID:jovse2th7ihli3qa4f2uj4dr5k@google.com
CREATED:20100912T034333Z
DESCRIPTION:20071105 EXHIBIT 99.1 SCIELE REPORTS THAT FDA EXTENDS PDUFA DAT
 E ON NEW SULAR FORMULATION TO JANUARY 2\, 2008 ATLANTA (November 5\, 2007) 
 Sciele Pharma\, Inc. (NASDAQ:SCRX) today announced that the U.S. Food & Dru
 g Administration (FDA) has extended to January 2\, 2008\, the Prescription
LAST-MODIFIED:20100912T034333Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SCIELE PHARMA INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20071222
DTSTAMP:20171003T193837Z
UID:9kh82k9ggc000cvhst3c8bmnkc@google.com
CREATED:20100912T034332Z
DESCRIPTION:20071106 The PDUFA action date for Luvox CR is December 22\, 20
 07.
LAST-MODIFIED:20100912T034332Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:JAZZ JAZZ PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20071106
DTSTAMP:20171003T193837Z
UID:h6b2632i0o2l6gh198nt4novts@google.com
CREATED:20100912T034332Z
DESCRIPTION:20071107 On November 6\, 2007\, the Company announced that the 
 FDA has requested that the Company pay a second PDUFA user fee and has offi
 cially notified the Company that the FDA Metabolism and Endocrinology Produ
 cts Division will undertake a formal review of the diabetes data as a separ
 ate NDA filing.
LAST-MODIFIED:20100912T034332Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:CV THERAPEUTICS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20080727
DTSTAMP:20171003T193837Z
UID:f7bajb5ofuatvqo762ttj9ajjo@google.com
CREATED:20100912T034255Z
DESCRIPTION:20071207 The Prescription Drug User Fee Act (PDUFA) action date
  for the sNDAs and the NDA is July 27\, 2008.
LAST-MODIFIED:20100912T034255Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:CV THERAPEUTICS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20080229
DTSTAMP:20171003T193837Z
UID:29s9c2bkci748iqgk51sdruffg@google.com
CREATED:20100912T034253Z
DESCRIPTION:20080131 The FDA has notified Solvay Pharmaceuticals that the A
 gency considers this a complete\, class 1 response and the PDUFA action dat
 e is February 29\, 2008.
LAST-MODIFIED:20100912T034253Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:JAZZ JAZZ PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20080727
DTSTAMP:20171003T193837Z
UID:n3883gualn7d1t19ftlp87gm18@google.com
CREATED:20100912T034252Z
DESCRIPTION:20080214 Under the Prescription Drug User Fee Act (PDUFA) of 19
 92\, Vanda expects a PDUFA action on or about July 27\, 2008.
LAST-MODIFIED:20100912T034252Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:VNDA Vanda Pharmaceuticals Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20080415
DTSTAMP:20171003T193837Z
UID:5od09cc7eh0dm2nq95snf9vs3o@google.com
CREATED:20100912T034251Z
DESCRIPTION:20080221 The previous PDUFA date was April 15\, 2008.
LAST-MODIFIED:20100912T034251Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SCIELE PHARMA INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20080415
DTSTAMP:20171003T193837Z
UID:4c9ko1djhljkv34jubn2mdq82o@google.com
CREATED:20100912T034250Z
DESCRIPTION:20080226 We believe that the submission of this additional data
  will not result in any change to the April 15\, 2008 PDUFA date\; however\
 , the FDA could decide to extend the date.
LAST-MODIFIED:20100912T034250Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:POZN POZEN INC NC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20080721
DTSTAMP:20171003T193837Z
UID:k5i297opuififrrb31ah2idnp4@google.com
CREATED:20100912T034249Z
DESCRIPTION:20080305 The FDA assigned a Prescription Drug User Fee Act (PDU
 FA) target date of July 21\, 2008.
LAST-MODIFIED:20100912T034249Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:THRX THERAVANCE INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20080430
DTSTAMP:20171003T193837Z
UID:p7l7ce0kb83oh72s36coqed7r4@google.com
CREATED:20100912T034249Z
DESCRIPTION:20080401 This application has a Prescription Drug User Fee Act 
 (PDUFA) date of April 30\, 2008.
LAST-MODIFIED:20100912T034249Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:PGNX PROGENICS PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20080421
DTSTAMP:20171003T193837Z
UID:9jeqnvd2ooqimoaej281n5no4s@google.com
CREATED:20100912T034247Z
DESCRIPTION:20080430 On April 21\, 2008\, the FDA accepted Addrenex Pharmac
 euticals 505(b)(2) New Drug Application (NDA) for CloniBID to treat hyperte
 nsion\, and assigned a Prescription Drug User Fee Act (PDUFA) date of Decem
 ber 19\, 2008. The FDA has assigned a PDUFA date of July 15\, 2008\, for th
 e LARx NDA.
LAST-MODIFIED:20100912T034247Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SCIELE PHARMA INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20080501
DTSTAMP:20171003T193837Z
UID:hiobrliv4m9sjq5usqrtj10de8@google.com
CREATED:20100912T034246Z
DESCRIPTION:20080502 The Approvable Letter was received in the evening of M
 ay 1\, 2008\, the PDUFA date that had been established for Surfaxin.
LAST-MODIFIED:20100912T034246Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:DSCO DISCOVERY LABORATORIES INC DE PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20080516
DTSTAMP:20171003T193837Z
UID:2nn7ojl4vkt14id1mbrruioag4@google.com
CREATED:20100912T034245Z
DESCRIPTION:20080506 The FDA has granted a May 16\, 2008 PDUFA date for bal
 salazide tablet and an October 31\, 2008 PDUFA date for granulated mesalami
 ne. Additionally\, the FDA has granted a November 30\, 2008 PDUFA date for 
 metoclopramide-ZYDIS\, licensed from Wilmington Pharmaceuticals.
LAST-MODIFIED:20100912T034245Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SLXP SALIX PHARMACEUTICALS LTD PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20080602
DTSTAMP:20171003T193837Z
UID:4rs133ejh6pvrro30m61tt69mk@google.com
CREATED:20100912T034243Z
DESCRIPTION:20080513 More importantly\, we are now within 30 days of our Ak
 ten PDUFA date of June 2\, 2008.
LAST-MODIFIED:20100912T034243Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AKRX AKORN INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20080627
DTSTAMP:20171003T193837Z
UID:ioqqjf419n682gdi9tu20kcfvo@google.com
CREATED:20100912T034242Z
DESCRIPTION:20080606 The Company will finalize the requirements and initiat
 e the study following the receipt of formal communication from the FDA whic
 h the Company expects to receive by the original June 27\, 2008 PDUFA date.
LAST-MODIFIED:20100912T034242Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:INDEVUS PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20081201
DTSTAMP:20171003T193837Z
UID:23td7e06h9qt168dmjulv3jc7o@google.com
CREATED:20100912T034242Z
DESCRIPTION:20080613 Pursuant to PDUFA guidelines\, Somaxon expects that th
 e FDA will complete its review and provide an action letter to the company 
 with respect to the NDA by December 1\, 2008.
LAST-MODIFIED:20100912T034242Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SOMX Somaxon Pharmaceuticals Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20080831
DTSTAMP:20171003T193837Z
UID:5t2o4o7h72qv5qgo2lrk5eur50@google.com
CREATED:20100912T034239Z
DESCRIPTION:20080728 We are hopeful that Bioral Amphotericin B will be the 
 first product of several in our pipeline using the Bioral drug delivery tec
 hnology. The company s lead product\, BEMA Fentanyl\, is currently under re
 view at the FDA with a PDUFA date of August 31\, 2008.
LAST-MODIFIED:20100912T034239Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:BDSI BIODELIVERY SCIENCES INTERNATIONAL INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20080619
DTSTAMP:20171003T193837Z
UID:c4ej9nej0843qr3rncljcn3330@google.com
CREATED:20100912T034238Z
DESCRIPTION:20080731 The original PDUFA date of June 19\, 2008 has been ext
 ended to September 19\, 2008.
LAST-MODIFIED:20100912T034238Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:LGND LIGAND PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20081231
DTSTAMP:20171003T193837Z
UID:l73j2krvuu448ogu1ob7shn398@google.com
CREATED:20100912T034237Z
DESCRIPTION:20080807 EPIX met all pre-specified endpoints prospectively agr
 eed to with the FDA. In June\, EPIX resubmitted its NDA to the FDA\, and in
  July\, the FDA issued a PDUFA goal date of December 31\, 2008.
LAST-MODIFIED:20100912T034237Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:EPIX Pharmaceuticals Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20090228
DTSTAMP:20171003T193837Z
UID:4mvshje0rmgc1fe7ql9sg9cjfg@google.com
CREATED:20100912T034235Z
DESCRIPTION:20080811 Announced FDA acceptance of NDA\, with expected target
  action date under the Prescription Drug User Fee Act (PDUFA) of February 2
 8\, 2009. Amended intellectual property agreements to shift a portion of th
 e payments due in 2008 to beyond the PDUFA date in 2009.
LAST-MODIFIED:20100912T034235Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ACUSPHERE INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20080918
DTSTAMP:20171003T193837Z
UID:fakp71qgenb2q24kcdbv4n3140@google.com
CREATED:20100912T034234Z
DESCRIPTION:20080919 Exhibit 99.1 NovaDel Pharma Announces PDUFA Deadline E
 xtension on Zolpimist Flemington\, NJ\, September 18\, 2008 - NovaDel Pharm
 a Inc. (AMX: NVD) today announced that the U.S. Food and Drug Administratio
 n (FDA) has requested an extension of up to 3 months on the Prescription Dr
 ug User Fee
LAST-MODIFIED:20100912T034234Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:NOVADEL PHARMA INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20090531
DTSTAMP:20171003T193837Z
UID:v44nj7o1ao75c6td5vnqlf7bak@google.com
CREATED:20100912T034233Z
DESCRIPTION:20080925 The New Drug Application (NDA) for Gencaro has been ac
 cepted for review by the U.S. Food and Drug Administration (FDA) with a PDU
 FA date of May 31\, 2009.
LAST-MODIFIED:20100912T034233Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:NUVELO INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20081027
DTSTAMP:20171003T193837Z
UID:de6hvd8m6oua23gothsf9ncvig@google.com
CREATED:20100912T034232Z
DESCRIPTION:20081021 The company is revising 2008 revenue and earnings guid
 ance to reflect the impact of its recent announcement that the U.S. Food an
 d Drug Administration will not complete its review of the alogliptin NDA by
  the PDUFA date of October 27\, 2008\, and the effect of current business c
 onditions.
LAST-MODIFIED:20100912T034232Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:PPDI PHARMACEUTICAL PRODUCT DEVELOPMENT INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20081203
DTSTAMP:20171003T193837Z
UID:spmn9v35shp3v7pc8d7ot5r53k@google.com
CREATED:20100912T034231Z
DESCRIPTION:20081106 FDA has assigned a Prescription Drug User Fee Act (PDU
 FA) goal date of December 3\, 2008 to this application.
LAST-MODIFIED:20100912T034231Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:GENTA INC DE PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20090417
DTSTAMP:20171003T193837Z
UID:k845g10edt5sffaa8sahvtcm3g@google.com
CREATED:20100912T034229Z
DESCRIPTION:20081110 The FDA has designated the Complete Response as a Clas
 s 2 resubmission and has established April 17\, 2009 as its target action d
 ate under the Prescription Drug User Fee Act (PDUFA) to complete its review
  and potentially grant marketing approval for Surfaxin.
LAST-MODIFIED:20100912T034229Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:DSCO DISCOVERY LABORATORIES INC DE PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20081208
DTSTAMP:20171003T193837Z
UID:3pnmlbf6kuphmitghtem86a7ls@google.com
CREATED:20100912T034228Z
DESCRIPTION:20081120 The target PDUFA date for oritavancin is December 8\, 
 2008.
LAST-MODIFIED:20100912T034228Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:Targanta Therapeutics Corp PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20090228
DTSTAMP:20171003T193837Z
UID:dtqv0fb8e0tdvvn6348hltso3c@google.com
CREATED:20100912T034227Z
DESCRIPTION:20081124 The FDA indicated that the review would be extended fo
 r up to three additional months\, resulting in a new PDUFA date of February
  28\, 2009.
LAST-MODIFIED:20100912T034227Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SOMX Somaxon Pharmaceuticals Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20081018
DTSTAMP:20171003T193837Z
UID:bmpcunr246upejb5dcpq5hqdmo@google.com
CREATED:20100912T034208Z
DESCRIPTION:20081208 The Prescription Drug User Fee Act (PDUFA) date was Oc
 tober 18\, 2008.
LAST-MODIFIED:20100912T034208Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:CYPB CYPRESS BIOSCIENCE INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20090402
DTSTAMP:20171003T193837Z
UID:mh58v6a0kn39qr65rnm1f3arjc@google.com
CREATED:20100912T034207Z
DESCRIPTION:20081219 A Prescription Drug User Fee Act (PDUFA) target date o
 f April 2\, 2009 has been established by the FDA for a decision regarding t
 he ZEVALIN sBLA.
LAST-MODIFIED:20100912T034207Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SPPI SPECTRUM PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20090402
DTSTAMP:20171003T193837Z
UID:7pg6kmrs607ar7ntpcsvg75jj4@google.com
CREATED:20100912T034206Z
DESCRIPTION:20081219 A Prescription Drug User Fee Act (PDUFA) target date o
 f April 2\, 2009 has been established by the FDA for a decision regarding t
 he Zevalin sBLA.
LAST-MODIFIED:20100912T034206Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:CTIC CELL THERAPEUTICS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20090730
DTSTAMP:20171003T193837Z
UID:ilei2q6pq6rp7neoa6j228qf94@google.com
CREATED:20100912T034206Z
DESCRIPTION:20090106 The related Prescription Drug User Fee Act (PDUFA) dat
 e is scheduled for July 30\, 2009.
LAST-MODIFIED:20100912T034206Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:NOVACEA INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20090125
DTSTAMP:20171003T193837Z
UID:f7g2jfh4ikfo8e2pmcf9685r9o@google.com
CREATED:20100912T034205Z
DESCRIPTION:20090126 The Company previously announced that the PDUFA date f
 or the NDA (which is the date by which the FDA is scheduled to issue a deci
 sion on whether to approve the application) was expected to be January 25\,
  2009.
LAST-MODIFIED:20100912T034205Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:KV KV PHARMACEUTICAL CO DE PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20090531
DTSTAMP:20171003T193837Z
UID:g19ve1qq8s5bahpc7noe5r39dk@google.com
CREATED:20100912T034204Z
DESCRIPTION:20090128 The New Drug Application for approval of Gencaro for t
 he indication of chronic heart failure\, including the proposed brand name\
 , is currently under review by the U.S. Food and Drug Administration with a
  Prescription Drug User Fee Act (PDUFA) date of May 31\, 2009.
LAST-MODIFIED:20100912T034204Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ABIO ARCA biopharma Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20090531
DTSTAMP:20171003T193837Z
UID:p0cp06l3dvo460umapvu4lgrck@google.com
CREATED:20100912T034202Z
DESCRIPTION:20090217 The Company has engaged in discussions to reduce\, def
 er or eliminate costs to ensure that it can fund its operations beyond the 
 anticipated PDUFA date of May 31\, 2009.
LAST-MODIFIED:20100912T034202Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ACUSPHERE INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20090730
DTSTAMP:20171003T193837Z
UID:ha8fkut5u3j0gntb2v829h1k78@google.com
CREATED:20100912T034202Z
DESCRIPTION:20090219 In order to allow the agency time to consider these am
 endments\, the FDA has notified the Company that the pegloticase BLA priori
 ty review PDUFA action date has been extended by three months to July 30\, 
 2009.
LAST-MODIFIED:20100912T034202Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SVNT SAVIENT PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20090731
DTSTAMP:20171003T193837Z
UID:ebiavv2135p2qba7bp76002fb4@google.com
CREATED:20100912T034201Z
DESCRIPTION:20090227 In November\, 2008\, the FDA filed the Company s NDA f
 or cethromycin and established a target Prescription Drug User Fee Act (PDU
 FA) action date for the cethromycin NDA of July 31\, 2009.
LAST-MODIFIED:20100912T034201Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:Advanced Life Sciences Holdings Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20090630
DTSTAMP:20171003T193837Z
UID:h1nnn3at9sl4kg17e634sf3ou8@google.com
CREATED:20100912T034159Z
DESCRIPTION:20090303 The user fee goal date under the Prescription Drug Use
 r Fee Act (PDUFA) is June 30\, 2009. A Priority review classification by th
 e FDA determines an NDA's review timeline under PDUFA and is not intended t
 o predict a drug's market acceptance or sales potential.
LAST-MODIFIED:20100912T034159Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ACUR ACURA PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20090430
DTSTAMP:20171003T193837Z
UID:0ugquft35rlv7gggm0mflp17a8@google.com
CREATED:20100912T034158Z
DESCRIPTION:20090303 Under the Prescription Drug User Fee Act (PDUFA) regul
 ations\, the FDA extended the review period by three months beyond the orig
 inal April 30\, 2009 PDUFA action date.
LAST-MODIFIED:20100912T034158Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SVNT SAVIENT PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20090305
DTSTAMP:20171003T193837Z
UID:gan2li76k8btisdjiolgn4mmvc@google.com
CREATED:20100912T034157Z
DESCRIPTION:20090306 Exhibit 99.1 FDA Provides PDUFA Target Agency Action D
 ate For GTx s Toremifene 80 mg NDA MEMPHIS\, Tenn. (BUSINESS WIRE) March 5\
 , 2009 GTx\, Inc. (Nasdaq: GTXI)\, today announced that the United States F
 ood and Drug Administration will target a Prescription Drug User Fee Act ag
 ency action date of
LAST-MODIFIED:20100912T034157Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:GTXI GTX INC DE PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20090325
DTSTAMP:20171003T193837Z
UID:02u2q8fl54i1pmmgj93cj97dts@google.com
CREATED:20100912T034157Z
DESCRIPTION:20090319 Therefore\, the corrected PDUFA date is March 25\, 200
 9.
LAST-MODIFIED:20100912T034157Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:DYAX DYAX CORP PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20090702
DTSTAMP:20171003T193837Z
UID:4ek02juqn22i2odi58vr0blfnk@google.com
CREATED:20100912T034156Z
DESCRIPTION:20090319 A Prescription Drug User Fee Act (PDUFA) target date o
 f July 2\, 2009 has been established by the FDA for a decision regarding th
 e ZEVALIN sBLA.
LAST-MODIFIED:20100912T034156Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SPPI SPECTRUM PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20090730
DTSTAMP:20171003T193837Z
UID:krngt0lbplpnoe2r0rhns0tk04@google.com
CREATED:20100912T034154Z
DESCRIPTION:20090323 Following the 2008 Intermezzo NDA submission\, the FDA
  assigned a July 30\, 2009 PDUFA review date.
LAST-MODIFIED:20100912T034154Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:TSPT Transcept Pharmaceuticals Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20090430
DTSTAMP:20171003T193837Z
UID:4aecouc8rj5s2rpv56qnuiqb1o@google.com
CREATED:20100912T034147Z
DESCRIPTION:20090428 In a notice received today\, the FDA extended the Pres
 cription Drug User Fee Act (PDUFA) date from April 30\, 2009\, to July 30\,
  2009.
LAST-MODIFIED:20100912T034147Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:UTHR UNITED THERAPEUTICS CORP PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20091204
DTSTAMP:20171003T193837Z
UID:cug93ba5eac8e7qbu4a7i6hpjo@google.com
CREATED:20100912T034147Z
DESCRIPTION:20090506 Pursuant to Prescription Drug User Fee Act (PDUFA) gui
 delines\, Santarus expects the FDA will complete its review or otherwise re
 spond to the NDA by December 4\, 2009.
LAST-MODIFIED:20100912T034147Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SNTS SANTARUS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20090828
DTSTAMP:20171003T193837Z
UID:bpg8rsclh2gkeduttod1kkpvho@google.com
CREATED:20100912T034146Z
DESCRIPTION:20090506 The FDA has provided a Prescription Drug User Fee Act 
 (PDUFA) goal date of August 28\, 2009 for completion of its review of the X
 IAFLEX BLA.
LAST-MODIFIED:20100912T034146Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:AUXL AUXILIUM PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20090505
DTSTAMP:20171003T193837Z
UID:csvmc5djjfor259lh74i5h3ens@google.com
CREATED:20100912T034145Z
DESCRIPTION:20090506 On May 5\, 2009\, the FDA accepted the Fampridine-SR N
 DA for filing and assigned it Priority Review with a Prescription Drug User
  Fee Act (PDUFA) date of October 22\, 2009.
LAST-MODIFIED:20100912T034145Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ACOR ACORDA THERAPEUTICS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20090828
DTSTAMP:20171003T193837Z
UID:5g9ej98r0h1rdqlilumfpqp52g@google.com
CREATED:20100912T034145Z
DESCRIPTION:20090511 The Prescription Drug User Fee Act (PDUFA) date has be
 en set for August 28\, 2009.
LAST-MODIFIED:20100912T034145Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:BSTC BIOSPECIFICS TECHNOLOGIES CORP PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20091212
DTSTAMP:20171003T193837Z
UID:rm1uuo0q5h32dg7sr98rok1494@google.com
CREATED:20100912T034142Z
DESCRIPTION:20090515 We have also learned that our end-user fee date or PDU
 FA date is December 12\, 2009 which is less than seven months away.
LAST-MODIFIED:20100912T034142Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:VION PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20090816
DTSTAMP:20171003T193837Z
UID:dlb09c0kqjrce0jaerr9dp6c9o@google.com
CREATED:20100912T034141Z
DESCRIPTION:20090522 In December 2008\, the NDA was accepted by the FDA for
  review\, resulting in a Prescription Drug User Fee Act (PDUFA) date of Aug
 ust 16\, 2009.
LAST-MODIFIED:20100912T034141Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:NGSX NeurogesX Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20090924
DTSTAMP:20171003T193837Z
UID:u6gjtmbsq847epk6tp899vlsq0@google.com
CREATED:20100912T034140Z
DESCRIPTION:20090526 The Company also announced that the FDA has granted th
 e NDA priority review status and established a Prescription Drug User Fee A
 ct (PDUFA) date of September 24\, 2009 for a decision regarding approval of
  the NDA.
LAST-MODIFIED:20100912T034140Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ALTH ALLOS THERAPEUTICS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20090801
DTSTAMP:20171003T193837Z
UID:c498o0old174fdm58glvi2kilc@google.com
CREATED:20100912T034139Z
DESCRIPTION:20090608 The Company submitted amendments to the BLA to the FDA
  in January 2009 and the FDA extended the review period by three months\, r
 evising the PDUFA date to August 1\, 2009.
LAST-MODIFIED:20100912T034139Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SVNT SAVIENT PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20090222
DTSTAMP:20171003T193837Z
UID:tcgsittco604pfnf32l2216c0s@google.com
CREATED:20100912T034136Z
DESCRIPTION:20090623 On February 22\, 2009\, Acurox was granted a priority 
 review classification by the FDA with a Prescription Drug User Fee Act ( PD
 UFA ) date of June 30\, 2009. Based on this review letter\, we do not belie
 ve Acurox Tablets will receive NDA approval on the PDUFA date.
LAST-MODIFIED:20100912T034136Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ACUR ACURA PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20090630
DTSTAMP:20171003T193837Z
UID:lcd8gab3vgrr7og3s10f618ico@google.com
CREATED:20100912T034134Z
DESCRIPTION:20090623 Based upon the proximity of this communication to the 
 June 30\, 2009 Prescription Drug User Fee Act (PDUFA) date for the NDA\, ma
 nagement believes that the Company is unlikely to receive regulatory approv
 al of the NDA on that date.
LAST-MODIFIED:20100912T034134Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:KG KING PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20090916
DTSTAMP:20171003T193837Z
UID:lo7safnjpm8o9jogchj8qpcllg@google.com
CREATED:20100912T034130Z
DESCRIPTION:20090723 The FDA assigned a Prescription Drug User Fee Act (PDU
 FA) goal date of September 16\, 2009. The FDA has established a standard 10
 -month review for this NDA\, with a PDUFA goal date of November 26\, 2009.
LAST-MODIFIED:20100912T034130Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:THRX THERAVANCE INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20080930
DTSTAMP:20171003T193837Z
UID:spgigml4pd8jm3uusdm3n2kbkc@google.com
CREATED:20100912T034110Z
DESCRIPTION:20090804 On September 30\, 2008 we submitted a new drug applica
 tion for Intermezzo to the FDA and the agency has established October 30\, 
 2009 has the PDUFA date for the review of this NDA.
LAST-MODIFIED:20100912T034110Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:TSPT Transcept Pharmaceuticals Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20100207
DTSTAMP:20171003T193837Z
UID:0bgb9uaiqs3u7t3sbs3br83d28@google.com
CREATED:20100912T034109Z
DESCRIPTION:20090804 Pursuant to Prescription Drug User Fee Act (PDUFA)\, S
 trativa expects the FDA will complete its review by February 7\, 2010. Purs
 uant to PDUFA\, BioAlliance expects the FDA will complete its review by sec
 ond quarter 2010.
LAST-MODIFIED:20100912T034109Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:PAR PHARMACEUTICAL COMPANIES INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20090727
DTSTAMP:20171003T193837Z
UID:p65h7doasg72hv7q1no6jbq8ok@google.com
CREATED:20100912T034109Z
DESCRIPTION:20090805 The Prescription Drug User Fee Act date ( PDUFA ) for 
 INTUNIV was July 27\, 2009. Shire and the FDA were not able to reach agreem
 ent on final product labeling in time to meet the PDUFA date.
LAST-MODIFIED:20100912T034109Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SHPGY Shire plc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20100318
DTSTAMP:20171003T193837Z
UID:e76590ob3an046kr4jl8249oso@google.com
CREATED:20100912T034108Z
DESCRIPTION:20090805 Based on the Prescription Drug User Fee Act (PDUFA)\, 
 the FDA has issued an action date of March 18\, 2010. The NDA for APF530 wa
 s submitted in May 2009 and accepted for review in July 2009\, at which tim
 e the FDA set a Prescription Drug User Fee Act (PDUFA) date of March 18\, 2
 010.
LAST-MODIFIED:20100912T034108Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:APPA AP PHARMA INC DE PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20091116
DTSTAMP:20171003T193837Z
UID:hfv0mjjsgejngtn6a8ffooais8@google.com
CREATED:20100912T034107Z
DESCRIPTION:20090807 On the US regulatory front\, as I mentioned\, we recei
 ved notification of an extension of our PDUFA date to November 16\, 2009. W
 e have previously discussed that we anticipated a potential extension in ou
 r PDUFA date.
LAST-MODIFIED:20100912T034107Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:NGSX NeurogesX Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20091122
DTSTAMP:20171003T193837Z
UID:n3o47ne1tgtb82n6fv4v9p0dqg@google.com
CREATED:20100912T034107Z
DESCRIPTION:20090810 Neuromed has filed a New Drug Application with the FDA
  for Exalgo\, which has a November 22\, 2009 PDUFA review date.
LAST-MODIFIED:20100912T034107Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:COMBINATORX INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20091030
DTSTAMP:20171003T193837Z
UID:ovo5nkq8cbs5qal0485ahulnv8@google.com
CREATED:20100912T034106Z
DESCRIPTION:20090810 The agency has targeted a Prescription Drug User Fee A
 ct (PDUFA) agency action date of October 30\, 2009. The FDA has informed us
  that it has targeted October 30\, 2009 as the Prescription Drug User Fee A
 ct\, or PDUFA\, date by which it will respond to our toremifene 80 mg NDA.
LAST-MODIFIED:20100912T034106Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:GTXI GTX INC DE PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20091008
DTSTAMP:20171003T193837Z
UID:m55qb3orcmf310smcs3jiiiae4@google.com
CREATED:20100912T034106Z
DESCRIPTION:20090813 FUSILEV October 8\, 2009 PDUFA action date for advance
 d metastatic colorectal cancer.
LAST-MODIFIED:20100912T034106Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SPPI SPECTRUM PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20091030
DTSTAMP:20171003T193837Z
UID:gb9e927rumoc44pmvnjirah3f4@google.com
CREATED:20100912T034105Z
DESCRIPTION:20090819 The U.S. Food and Drug Administration (FDA) has establ
 ished October 30\, 2009 as its target date under PDUFA to take action on it
 s review of the New Drug Application (NDA).
LAST-MODIFIED:20100912T034105Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:TSPT Transcept Pharmaceuticals Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20090904
DTSTAMP:20171003T193837Z
UID:41l1k67baf2lq1jk512mjqai94@google.com
CREATED:20100912T034104Z
DESCRIPTION:20090824 A Prescription Drug User Fee Act (PDUFA) date will be 
 established by the FDA regarding the review of the pixantrone NDA by Septem
 ber 4\, 2009.
LAST-MODIFIED:20100912T034104Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:CTIC CELL THERAPEUTICS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20091224
DTSTAMP:20171003T193837Z
UID:0abvtbjangsp5fv12tcnntrfqo@google.com
CREATED:20100912T034104Z
DESCRIPTION:20090825 Based on this classification\, the FDA has issued an a
 ction date of December 24\, 2009 under the Prescription Drug User Fee Act (
 PDUFA).
LAST-MODIFIED:20100912T034104Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SLXP SALIX PHARMACEUTICALS LTD PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20090227
DTSTAMP:20171003T193837Z
UID:aeni30bsnfe1eaabsh51aohbr8@google.com
CREATED:20100912T034101Z
DESCRIPTION:20090917 Auxilium filed its BLA for XIAFLEX for the treatment o
 f Dupuytren's disease on February 27\, 2009 and received a target date unde
 r the Prescription Drug User Fee Act (PDUFA) date of August 28\, 2009\, whi
 ch has not been updated.
LAST-MODIFIED:20100912T034101Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:BSTC BIOSPECIFICS TECHNOLOGIES CORP PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20090905
DTSTAMP:20171003T193837Z
UID:iv810copqtj94bav7d6cka5cfs@google.com
CREATED:20100912T034059Z
DESCRIPTION:20090930 Furthermore\, on September 5\, 2009\, the Company anno
 unced that the FDA had notified the Company that a Prescription Drug User F
 ee Act (PDUFA) action date of April 23\, 2010 under standard review has bee
 n established regarding the pixantrone NDA.
LAST-MODIFIED:20100912T034059Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:CTIC CELL THERAPEUTICS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20091022
DTSTAMP:20171003T193837Z
UID:585264iehem2plidhtp56p3thc@google.com
CREATED:20100912T034058Z
DESCRIPTION:20091022 The original Prescription Drug User Fee Act (PDUFA) da
 te for this priority review application was October 22\, 2009.
LAST-MODIFIED:20100912T034058Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ACOR ACORDA THERAPEUTICS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20091126
DTSTAMP:20171003T193837Z
UID:5a9vbgquectqmr5p181iph5tuo@google.com
CREATED:20100912T034057Z
DESCRIPTION:20091027 The New Drug Application (NDA) for telavancin for the 
 treatment of nosocomial pneumonia (NP) is currently under review by the FDA
 \, with a Prescription Drug User Fee Act (PDUFA) date of November 26\, 2009
 .
LAST-MODIFIED:20100912T034057Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:THRX THERAVANCE INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20091201
DTSTAMP:20171003T193837Z
UID:5iange6h4q6que834ro4hhp1ng@google.com
CREATED:20100912T034056Z
DESCRIPTION:20091028 The FDA accepted the submission and assigned Dyax s BL
 A a new Prescription Drug User Fee Act (PDUFA) action date of December 1\, 
 2009.
LAST-MODIFIED:20100912T034056Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:DYAX DYAX CORP PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20100122
DTSTAMP:20171003T193837Z
UID:cgsvhlulsf4cv94qaqm8rfesm0@google.com
CREATED:20100912T034056Z
DESCRIPTION:20091103 On October 22\, the FDA notified the Company that the 
 October 22 Prescription Drug User Fee Act (PDUFA) goal date for the Famprid
 ine-SR New Drug Application (NDA) was being extended to January 22\, 2010.
LAST-MODIFIED:20100912T034056Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ACOR ACORDA THERAPEUTICS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20100228
DTSTAMP:20171003T193837Z
UID:uo1p38mbjgnlpadgp6ltjndrf4@google.com
CREATED:20100912T034054Z
DESCRIPTION:20091104 The FDA has issued an action date for the NDA of Febru
 ary 28\, 2010 under the Prescription Drug User Fee Act (PDUFA).
LAST-MODIFIED:20100912T034055Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:SHPGY Shire plc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20091109
DTSTAMP:20171003T193837Z
UID:qs8377qtd7s627mlrcvaab98ak@google.com
CREATED:20100912T034053Z
DESCRIPTION:20091109 The original PDUFA date for this NDA review was Novemb
 er 9\, 2009. The FDA has the option to extend the PDUFA goal date when a sp
 onsor submits a major amendment that provides a substantial amount of new d
 ata not previously reviewed by the FDA.
LAST-MODIFIED:20100912T034053Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:XNPT XENOPORT INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20100212
DTSTAMP:20171003T193837Z
UID:diag4tm9gggd96mdrg2ij2gijk@google.com
CREATED:20100912T034052Z
DESCRIPTION:20091113 The extended PDUFA goal date is February 12\, 2010. Th
 e FDA has the option to extend the PDUFA goal date when a sponsor submits a
  major amendment to an NDA within three months of the PDUFA goal date to pr
 ovide time to complete the review.
LAST-MODIFIED:20100912T034052Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:CADX CADENCE PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20091117
DTSTAMP:20171003T193837Z
UID:i2n59tjngo4o3shukvpng9b1lg@google.com
CREATED:20100912T034051Z
DESCRIPTION:20091117 Exhibit 99.2 NeurogesX\, Inc. PDUFA Announcement Confe
 rence Call November 17\, 2009 Operator: Greetings ladies and gentlemen and 
 welcome to the NeurogesX Inc. conference call.
LAST-MODIFIED:20100912T034051Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:NGSX NeurogesX Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20100501
DTSTAMP:20171003T193837Z
UID:kk3kp2guc4gd2qs4in1o8qkiso@google.com
CREATED:20100912T034050Z
DESCRIPTION:20091123 The FDA has assigned a Prescription Drug User Fee Act 
 (PDUFA) date of May 1\, 2010\, by which time it will respond to the amended
  BLA.
LAST-MODIFIED:20100912T034050Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:DNDN DENDREON CORP PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20100222
DTSTAMP:20171003T193837Z
UID:jp867qudlj4ruu544533j91kkk@google.com
CREATED:20100912T034046Z
DESCRIPTION:20091221 Escrow shares will be released in whole or in part to 
 former Neuromed stockholders based upon the outcome and timing of the FDA s
  review of the NDA product candidate Exalgo\, which has a February 22\, 201
 0 PDUFA review date.
LAST-MODIFIED:20100912T034046Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:COMBINATORX INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20100410
DTSTAMP:20171003T193837Z
UID:jcp7ojp0r91uvj5q5gbj6coja8@google.com
CREATED:20100912T034040Z
DESCRIPTION:20100115 The FDA has completed clinical trial site inspections 
 and manufacturing inspections\, has communicated with Kreussler regarding t
 he final steps needed in the approval process\, such as the package insert 
 review\, and has set a PDUFA target date of April 10\, 2010\, to complete t
 he NDA review.
LAST-MODIFIED:20100912T034040Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:BIOFORM MEDICAL INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20100118
DTSTAMP:20171003T193837Z
UID:81nj15m0e94bhp7eivvua80p3c@google.com
CREATED:20100912T034040Z
DESCRIPTION:20100119 The original Prescription Drug User Fee Act (PDUFA) da
 te was January 18\, 2010.
LAST-MODIFIED:20100912T034040Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:OSI PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20100423
DTSTAMP:20171003T193837Z
UID:5ucb7182t65cm4kldri7nfh9os@google.com
CREATED:20100912T034038Z
DESCRIPTION:20100211 The FDA established Prescription Drug User Fee Act (PD
 UFA) date of April 23\, 2010. Initiated a Marketing Authorization Applicati
 on ( MAA ) for pixantrone in Europe in 2009 and received Orphan Drug Design
 ation by the European Medicines Agency.
LAST-MODIFIED:20100912T034038Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:CTIC CELL THERAPEUTICS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20100216
DTSTAMP:20171003T193837Z
UID:ceqvpu84ac1c2nr5us155q9l3g@google.com
CREATED:20100912T034036Z
DESCRIPTION:20100216 On February 16\, 2010\, CombinatoRx\, Incorporated ("C
 ombinatoRx") issued a press release announcing that the FDA has extended th
 e PDUFA date for EXAGLO TM until March 1\, 2010 due to federal government c
 losings.
LAST-MODIFIED:20100912T034036Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:COMBINATORX INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20091222
DTSTAMP:20171003T193837Z
UID:eus2nc103opqco39k65r4v6uio@google.com
CREATED:20100912T033905Z
DESCRIPTION:20100224 We submitted the lorcaserin NDA on December 22\, 2009\
 , and expect to learn the Prescription Drug User Fee Act\, or PDUFA\, date 
 in the next few weeks. The PDUFA date is the target date for the FDA to com
 plete its review of an NDA.
LAST-MODIFIED:20100912T033905Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:ARNA ARENA PHARMACEUTICALS INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20101004
DTSTAMP:20171003T193837Z
UID:i3dnmpimub1vo7945iofojftnk@google.com
CREATED:20100912T033904Z
DESCRIPTION:20100302 In February 2010\, HGS received confirmation that the 
 BLA submission was accepted by the FDA for filing with a Prescription Drug 
 User Fee Act (PDUFA) target date of October 4\, 2010.
LAST-MODIFIED:20100912T033904Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:HGSI HUMAN GENOME SCIENCES INC PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20101003
DTSTAMP:20171003T193837Z
UID:8l2eo1iilcd6bc1d75fgm53n1k@google.com
CREATED:20100912T033901Z
DESCRIPTION:20100315 Dyloject has received an FDA PDUFA date of October 3\,
  2010.
LAST-MODIFIED:20100912T033901Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:Myriad Pharmaceuticals Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20101030
DTSTAMP:20171003T193837Z
UID:240vjreskir3bh32oe6honvvog@google.com
CREATED:20100912T033840Z
DESCRIPTION:20100825 The warrants will be exercisable beginning on the orig
 inal date of issuance and will expire on the date that is 12 months after t
 he 21 st day following the PDUFA date. Biodel expects the PDUFA date to be 
 October 30\, 2010.
LAST-MODIFIED:20100912T033840Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:BIOD Biodel Inc PDUFA
TRANSP:TRANSPARENT
CATEGORIES:http://schemas.google.com/g/2005#event
END:VEVENT
END:VCALENDAR
